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Abstract 
In this dissertation, new antimicrobial functions stemming from synthetic polymer 
structures and properties were explored to address antibiotic resistance and tolerance in 
bacterial infections. Amphiphilic antimicrobial polymers that mimic host defense peptides have 
been explored as alternative antibiotics which could bypass existing antibiotic resistance and 
have a low risk of resistance development. However, their antimicrobial activity and selectivity 
need to be improved toward clinical use. This dissertation explored the use of macromolecules 
with multiple polymer chains, while the previous studies have been limited primarily to tuning 
monomer compositions. Since antimicrobial peptides act by collective action of multiple 
peptide chains, it was hypothesized that macromolecules presenting multiple antimicrobial 
polymer chains will show improved antimicrobial activity and selectivity towards bacteria as 
compared to the previously studied linear structures. Initially, we attempted to synthesize 
hyperbranched amphiphilic methacrylate copolymers through free radical polymerization with 
a crosslinking monomer (Chapter 2). However, these structures resulted in only lightly 
crosslinked polymers with high molecular weight, having comparable antimicrobial activity to 
linear polymers and increased hemolytic activity. To address the lack of target architecture, we 
also synthesized 4-armed star-shaped copolymers by atom transfer radical polymerization 
(Chapter 3). 4-armed star-shaped copolymers did not show any improved antimicrobial activity 
as compared to linear polymers, while they significantly increased the hemolytic activity, 
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resulting in low selectivity. We propose future work explore architecture with additional 
polymer arms, which may better mimic the membrane disruptive behavior of multiple polymers 
on bacterial membranes. 
The challenge of bacterial biofilm stem from both the difficulty to prevent their 
formation and the difficulty to treat by traditional antibiotics, as summarized in Chapter 1. 
Previous anti-biofilm coatings suffer from short lifetimes, and their applications are limited to 
surfaces. In this dissertation, we explored a new approach to biofilm prevention based on the 
hypothesis that changing planktonic bacteria behavior to result in sub-optimal biofilm 
formation (Chapter 4). Incubation of Pseudomonas aeruginosa planktonic bacteria with a 
cationic polymer resulted in the aggregation of planktonic bacteria, and a reduction in biofilm 
development. We propose that cationic polymers may sequester planktonic bacteria away from 
surfaces, thereby preventing their attachment and suppressing biofilm formation. In attempts 
to address the antibiotic tolerance in biofilms due to low metabolic activity in bacteria, we 
hypothesized treatment of cationic polymers may increase the antibiotic susceptibility of 
embedded bacteria while the polymers are not killing bacteria by disrupting the bacterial 
membrane (Chapter 5). The polymer increased the metabolic activity of bacteria in biofilm and 
membrane potential of planktonic bacteria. These suggest that the bacteria are awaken, and 
antibiotic tobramycin uptake might be enhanced due to increased membrane potential. 
However, treatment with a cationic polymer did not increase the sensitivity of P. aeruginosa 
biofilms to tobramycin. While this approach does not increase biofilm sensitivity to antibiotics, 
it may provide the foundation for future approaches with adjuvant materials for combination 
therapies.  
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Chapter 1 Introduction and Background 
Motivation 
Infectious diseases accounts for over 25% of worldwide mortality, cause primarily by 
bacteria and viruses.1-2 In order to combat future bacterial infections, it is necessary to develop 
new strategies for antimicrobial treatment, including improvements to efficacy of current 
antibiotics and the development of new antimicrobial materials. Since the discovery of 
penicillin in 19283, antibiotics have been a potent tool to combat bacterial infections.  Over 270 
antibiotic drugs were introduced between then and the 1970s, but between 1987 and 2000, no 
new classes of antibiotics had been developed, despite the increasing rate of antibiotic 
resistance development to existing antibiotics. Antibiotic classes are distinguished by the 
mechanisms in which the agent acts against bacteria, such as the specific site it targets within 
the cell. The number of new antibiotics coming to market has been decreasing each year, and 
new antibiotics are modifications of previously used antibiotics4, as in the new antibiotics were 
defined as antibiotic classes with the same mechanisms which bacteria were developing 
resistances to. The high cost of antibiotic development is economically unattractive to 
pharmaceutical companies, despite a new growing need, as the time they have to recover 
investment is significantly reduced with new antibiotic resistance development.5 Over 
prescription of existing antibiotics has led to the recent surge in number of antibiotic resistant 
bacteria, especially multidrug resistant (MDR) species.  Since 2000, two new classes of 
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antibiotics have been approved by the FDA (oxazolidinoes6 in 2000 and cyclic lipopeptides7 in 
2003), introducing two new mechanisms of antibiotic activity which had previously not been 
targeted, and should therefore be effective against multi-drug resistant bacteria. However, the 
development of new traditional antibiotics for the market is not a viable long-term solution to 
the antibiotic resistance problem, as antibiotic lifetimes are only 5-15 years.8-11  
Objectives 
With growing concerns over the increase in the number of antibiotic resistant infections, 
the objective of this dissertation is to find materials that can subvert antibiotic resistance 
mechanisms. This could help to improve a drug’s market longevity and economically incentivize 
new drug development.  One objective of this study is to develop new antimicrobial compounds 
that won’t contribute to antibiotic resistance development, which have low toxicity to human 
cells and ideally low manufacturing cost. These materials could theoretically also be able to 
overcome existing mechanisms of resistance, given they should subvert traditional 
antimicrobial pathways that lead to the development of antibiotic resistance. Secondly, it is 
ideal to address the antibiotic challenge of tolerant bacterial biofilms, which are associated with 
chronic infections. Development of new synthetic compounds that are able to effectively kill 
biofilm bacteria and/or modulate biofilm behavior such as slower biofilm formation, easier 
removal or enhanced susceptibility to existing antibiotics, would significantly contribute to the 
challenge of antibiotic tolerance, as biofilms contribute to the likelihood of antibiotic resistant 
mutation. These two objectives are not mutually exclusive; the convergence of these two 
strategies could allow for an enhanced bacterial infection treatment of a broad range of 
bacteria, including current antibiotic resistant strains. 
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Background: Antibiotic Resistance/Tolerance in Bacteria 
Bacteria have existed for 3.5 billion years12, and have accomplished this by the ability to 
respond to environmental threats. One of these survival responses is the development of 
antibiotic resistance, which can be imparted by genetic mutation (genotype) and/or bacteria 
characteristics and behavior (phenotype). 
Mutations in the bacteria’s DNA can imparts antibiotic resistance, termed acquired 
resistance, and consequently the division and propagation of the mutated bacteria imparts 
resistance to the subsequent generations. This survival response allows specific bacteria to 
survive antibiotic exposure when others have died, and thus leads to exclusively selection of 
antibiotic resistant populations rather than resistance development in all population. There are 
three major resistance mechanisms: modification of antibiotic molecule, change in the 
antibiotic target site, and drug uptake/efflux.13 In an example of enzymatic degradation of 
antibacterial agents, bacteria resistant to β-lactam antibiotics (such as amoxicillin) mutated to 
produce an enzyme (β-lactamase) that to breaks open the 4-atom β-lactam ring structure, 
which renders the antibiotic ineffective.14 Quinolone drugs are prone to resistance 
development by bacteria alterations to their antimicrobial target sites, where normally 
bacterial enzyme DNA gyrase is responsible for replication and repair of bacterial DNA, but can 
be trapped as a part of a quinoline-enzyme-DNA complex, leading to cell death. Amino acid 
substitutions in DNA gyrase result in poor quinolone-enzyme binding by reducing drug affinity, 
causing the antibiotic resistance.15 Mutations can also affect the permeability of the bacterial 
membrane. For example, porin are protein channels that act as pores in the bacterial 
membrane, allowing the passive diffusion of molecules into the cell, such as nutrients and 
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antibiotics.16 Mutations such as reducing the number or size of porins can effectively restrict 
antibiotic access into the bacteria.17 Mutations which cause porins smaller than antibiotics size 
prevent access to inner cell targets, while decreasing the number of porins reduces the overall 
diffusion of antibiotics into the cell.17 The specific mutation is related to the antibiotic mode of 
action, as surviving bacteria are those that can best prevent antibiotic exposure. However, it 
has also been noted that the presence of antibiotics at low concentrations can act as a trigger 
for the development of adaptive antibiotic resistance in some bacteria, affecting signaling 
pathways typically used in cell-cell communication.18-20 MDR develops when bacteria have 
multiple resistance mechanisms encoded on their chromosomes.21 The genetic codes of a 
bacteria populations are continually changing to subvert conventional antibiotics.  
An important bacteria behavior is the formation of biofilms, three-dimensional 
structures of bacteria encased in self-produced extracellular polymeric substance (EPS).22 
Biofilms protect the encased bacteria from the surrounding environment, including antibiotics, 
making them difficult to treat and consequently account for 65-80% of bacterial infections.23-24 
Biofilms are intrinsically antibiotic tolerance, conveying inherent properties to the bacteria that 
helps limit antimicrobial effectiveness. While antibiotic resistance is exclusively conferred by 
genetics, antibiotic tolerance in biofilms is a due to a combination of protective mechanisms 
provided by the biofilm structure.  As in, a dispersal of the biofilm structure would restore 
antibiotic sensitivity to planktonic bacteria. The exact mechanisms of biofilm antibiotic 
tolerance are still being explored, but several factors have been widely discussed including high 
cell density25, slower growth rate26, and low antibiotic penetration27. Many antibiotics target 
cell division and replication, such as preventing DNA separation or the formation of cell walls, 
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and thus have significantly reduced efficacy against non-dividing cells present in biofilms.26 
Even those antibiotics that do possess activity against dormant cells have reduced efficacy due 
to slow metabolic processes.28-29 Antibiotics must also penetrate through the EPS in order to 
access embedded bacteria, and the limited diffusion of antibiotics may result in concentrations 
lower than effective concentrations. The biofilm matrix is composed of proteins, extracellular 
DNA, and polysaccharides, which combined are known as the extracellular polymeric substance 
(EPS).30 Components of the EPS matrix can restrict the penetration of oppositely charged 
antibiotics, such as matrix eDNA blocking cationic tobramycin.31-32 The exposure of bacteria to 
antibiotics at sub-lethal concentrations may result in resistance development in bacteria, 
known as adaptive resistance. As such, the tolerant nature of the biofilm itself contribute to its 
antibiotic resistance and antibiotic resistance development. Different bacteria within the 
biofilm may  be  resistant by different mechanisms33, including enzymatic degradation of 
antibacterial agents, alteration of antimicrobial targets, or changes in membrane 
permeability.34-35  The collective consequence is antibiotic tolerance 100 to 1000-fold larger 
than exponential planktonic (individual) bacteria.36-39  
While all antibiotic resistance/tolerance mechanisms are survival responses, the manner 
in which the bacteria behave as antibiotic resistant have different sources but are intrinsically 
entangled. For example, bacteria within biofilms may be exposed to sub-lethal antibiotic 
concentrations due to diffusion40, which contributes to the likelihood of mutation, especially 
because biofilm bacteria exhibit hypermutability26. Therefore, it is optimal to combat both 
sources of antibiotic resistance/tolerance (planktonic mutations and biofilms). 
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Antimicrobial Macromolecules as Alternative Antibiotics 
Antimicrobials that don’t contribute to traditional antibiotic resistance development are 
highly desirable targets for future drug development. Intrinsically antimicrobial 
macromolecules are a class of materials that are promising for such an application. A natural 
part of the innate immune system consists of these antimicrobial macromolecules (host 
defense peptides), and synthetic polymer mimics of these compounds can be designed to 
maintain excellent biological performance at a lower cost. 
Host Defense Peptides and Synthetic Antimicrobial Peptides 
Innate immune systems are found in all classes of plants and animals and are able to 
recognize and attack pathogens based on generic characteristics, such as differences in cell 
membrane charge. Host-defense antimicrobial peptides (AMPs) are a class of small proteins 
(10-50 amino residues) in the innate immune system that have broad spectrum bacterial 
activity, including against antibiotic resistant bacteria.41 In literature, “HDPs” have been used 
when the function of peptides in the immune system, and “AMPs” have been used when the 
antimicrobial activity of peptides is the primary focus of study.  AMPs are found in all known 
species of life42, with over 2600 natural peptides known.43 No common sequence has been 
found to exists between the diversity of HDPs, but all contain the same essential features that 
allow for antibacterial behavior. HDPs are characterized by cationic and hydrophobic amino 
acid residues, and the segregation of these functions by the formation of a secondary structure 
(i.e. α-helix, β-sheet) upon binding to cell membranes.41, 44 These antimicrobial peptides have 
been identified in as a part of human saliva, sweat, seminal plasma, amniotic fluid, white blood 
cells, and skin.43  
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The antimicrobial mechanism of HDPs has been the topic of significant research.44-48 
Magainin-2 (Figure 1.1) was one of the first purified HDP derived from the skin of the African 
clawed frog Xenopus laevis49,  and the magainin class of antimicrobial peptides were the subject 
of early mechanism research.50 While previous research had established the affinity of α-helical 
antimicrobial peptides to bind with lipid bilayers membranes51, Matsuzki et al. observed 
magainin-1 would form amphiphilic α -helix structures in the presence of acidic lipid bilayer 
vesicles, and would induced concentration dependent leakage, indicating membrane 
disruption.50 Due to the concentration dependent behavior, they suggested membrane 
disruption was linked to peptide-membrane binding.50  As bacterial cell membranes are rich in 
anionic lipids, AMPs bind to bacterial cell membranes by electrostatic interactions between the 
cationic groups of AMPs and the anionic membrane surface of bacteria.  On the other hand, 
mammalian cell membranes are comprised mostly of zwitterionic lipids and cholesterols and 
are comparatively less anionic as compared to the bacterial cell membrane (Figure 1.2). 
Therefore, AMPs preferentially bind to bacterial cell membranes over human cell membranes, 
resulting in selective activity against bacteria over human cells.  
 
 
Figure 1.1. Structure of Magainin-2, depicted in the characteristic α-helix secondary structure. The α-helix structure is facially 
amphiphilic, where hydrophobic groups (green) are segregated to one side and cationic groups (blue) are located on the 
opposite.52 Magainin-2 sequence:  GIGKFLHSAKKFGKAFVGEIMNS. Reprinted with permission; Copyright 2013 American 
Chemical Society.52 
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Figure 1.2. Schematic of bacterial and mammalian cell membranes that govern bacteria-selective membrane binding of HDPs 
(Magainin shown).52 Cationic, amphiphilic HDPs bind to bacterial membranes by electrostatic and hydrophobic interactions, as 
compared to only hydrophobic binding to mammalian membranes. 
Since then, several models of membrane disruption have been proposed to explain 
AMP’s antimicrobial mode of action, where the mechanism can vary between the multitude of 
AMPs (Figure 1.3). Regardless of the mechanism of AMP-membrane incorporation, the end 
result is compromising the barrier function of cell membranes and increasing the membrane 
permeability, allowing the outflow of cellular components, and ultimately cell death. In the 
“barrel-stave” a critical density of HDPs causes self-aggregation within the membrane, resulting 
in the formation of ion channel-like transmembrane pores lined by HDPs, without any re-
orientation of the lipid bilayer. 46, 53-56  In the “toroidal pore” model, the insertion of HDPs in the 
membrane induces induced curvature strain along the lipid monolayers, resulting in of the 
reorientation of the lipids into pores lined by HDPs.46, 55 Lastly, the “carpet” model describes the 
accumulation of HDPs along the membrane surface, disrupt lipid bilayer structures non-
specifically.46, 53-55  Because the bacterial membranes are an essential component of the cells 
and common structures to all bacteria, the mode of action of AMPs can result in broad-
spectrum antimicrobial activity and decreased potential for resistance.  
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Figure 1.3. Proposed mechanisms of membrane disruption by antimicrobial peptides: (1) Barrel-stave, (2) Toroidal pore, and (3) 
Carpet models. Reprinted with permission; Copyright 2013 American Chemical Society.52 
During the study of HDPs as potential therapeutics, researchers uncovered that the 
sequence of amino acids was not critical for antimicrobial behavior, but rather the 
physiochemical properties that provided the antimicrobial mode of action. This was supported 
by the results using AMP enantiomers; D-enantiomers of magainin exhibited comparable 
behavior to natural magainin.  In addition, no common sequences had been discovered in 
natural HDPs. These results reveal that AMP mode of action was not dependent on specific 
protein-protein interactions, which require specific peptide configurations and sequences.57 
These results also suggested that the cationic amphiphilic structure of α-helices which were 
responsible for the mode of action were key to antimicrobial behavior. This discovery led to 
further studies that utilized synthetic peptides and peptidomimetics including beta-peptides58 
and peptoids59 that mimic the facially amphiphilic helical structure. These synthetic peptides 
mimic both the charge distribution and secondary structure of known HDPs, with alterations to 
amino acid sequences and/or length to improve antimicrobial efficacy and reduce toxicity to 
mammalian cells.60-62 Many synthetic AMPs have demonstrated promising antibiotic 
candidates, with several in clinical-efficacy trials, but to date no AMPs have achieved FDA 
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approval.63-64 A common issue is that AMPs often fail to meet the requirement to provide 
superior behavior to traditional antibiotics for the intended use. The implementation of AMPs 
has been hampered in clinical application primarily due to the susceptibility to proteolytic 
degradation in physiological fluids. Practically, the high cost of design and manufacturing results 
in AMPs being a prohibitively expensive pharmaceutical therapeutic.63-65 
Synthetic Antimicrobial Polymers as AMP Mimetics 
The discovery that AMP activity does not necessarily require peptide structures 
prompted research into synthetic antimicrobial polymers as AMP mimetics. It has been 
postulated that by replacing amino acids with randomly distributed cationic and hydrophobic 
segments and enabling the segregation of cationic and hydrophobic charge when interacting 
with a bacterial membrane, synthetic antimicrobial polymers maintain the same mode of action 
as AMPs, without the need for any ordered sequences necessary to generate secondary 
structures. Therefore, the essential minimum requirements for synthetic antimicrobial 
polymers is a distribution of hydrophobic and cationic functionality, whereas AMP also require 
amino acid chemistry and the specific ordering of amino acids to generate secondary 
structures. Synthetic polymers are cost-effective, as the peptide synthesis is labor and cost-
intensive. Synthetic polymers also resist enzymatic degradation. These properties of polymers 
meet the major challenges to clinical translation of AMPs.66-68 Additionally, polymers can be 
designed with a diversity of chemistries and structural properties, which can be tailored to the 
desired application. In chapters 2 and 3 we design a star-shaped polymer architecture to 
improve antimicrobial functions, which are not readily accessible by peptides. A large body of 
antimicrobial polymers have since been designed using a diversity of strategies to explore the 
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AMP mimetic ability of varying polymer designs, some of which will be discussed in the 
following sections.  
Polymethacrylate: Polymer Design and Design Rules 
One research area of focus has been the design of antimicrobial polymethacrylate 
copolymers composed of a statistical or random distribution of hydrophobic and cationic 
ammonium side chains as the representative polymer is depicted in Figure 1.4. Upon bacterial 
membrane binding, these copolymers  can spontaneously adopt an amphiphilic conformation 
capable of membrane disruption (Figure 1.4), and ultimately bacterial cell death.69-79 The 
advantage to antimicrobial polymethacrylates is that the chemistries for preparation, 
modifications, and manufacture of methacrylate polymers have been well-established. This is 
advantageous for the exploration of tunable polymer parameters including polymer size, 
hydrophobic/cationic balance, chemical functionalities of cationic and hydrophobic groups, and 
polymer shapes and architectures.68 Previous work has explored many of these properties, with 
a focus on modification of polymer chemistry to achieve desirable biological properties (high 
antimicrobial activity, low toxicity).  
 
Figure 1.4. Representative Structure of antimicrobial polymethacrylate with random distribution of cationic (red) and 
hydrophobic (blue) monomer segments to result in a flexible amphiphilic structure. Cationic and hydrophobic groups segregate 
to opposite sides upon binding to bacterial membranes.80   
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In order to most closely mimic natural AMPs, polymers with low molecular weights were 
desired (2,500 —10,000 g/mol). This design was supported by findings that higher molecular 
weight amphiphilic polymethacrylate exhibited greater hemolytic activity against human red 
blood cells in addition to greater antimicrobial activity.69, 81 Therefore, low molecular weight 
polymers offer the platform with the greatest opportunity to minimize mammalian cell toxicity, 
and therefore to improve selective activity towards bacterial cells while maintaining sufficient 
antimicrobial behavior. Free radical polymerization is a cost-effective, facile method for 
synthesis of polymers, a desirable approach when considering scalability for mass production of 
alternative antibiotic. By targeting low molecular weight polymers, free radical polymerization 
with chain transfer agents can be utilized without significant concern for characteristically 
broad molecular weight distributions (Đ>1.5). This is because low molecular weight polymers 
give a small range of molecular weight variations (a few hundreds to thousands), resulting in Đ= 
1.3-1.5 when sufficiently high concentrations of CTA (10-15 mol%) are used. 
Polymer optimization is primarily governed by controlling amphiphilic balance between 
cationic and hydrophobic group, and therefore the main stream strategy has been optimization 
in monomer compositions and chemical identities of these groups 73. Learning from the 
antimicrobial mechanism of AMPs, we hypothesized that the cationic functionality and 
hydrophobicity are the minimal, but essential requirements for potent antimicrobial activity 
and selectivity. Therefore, a library of polymethacrylate derivatives with cationic and 
hydrophobic side chains have been previously explored to identify the structural properties 
optimal for high antimicrobial activity and low toxicity. 
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Previously, the effect of cationic and hydrophobic balance of copolymers on their 
antimicrobial and hemolytic activities has been examined using copolymers with different 
binary compositions of monomers with cationic and hydrophobic side chains. The result 
indicated that random copolymers with many cationic side chains showed low antimicrobial 
activity and low hemolytic activity. Increasing the hydrophobic monomers increased both the 
antimicrobial and hemolytic activities of copolymers, indicating that the hydrophobicity of 
polymers is a driving force for their activities. However, highly hydrophobic polymers showed 
high hemolytic activity. The result suggested that the cationic and hydrophobic functionalities 
should be balanced to maximize the antimicrobial activity and minimize the hemolytic activity. 
The cationic charge of copolymers promotes the selective binding of polymers to anionic 
bacterial cell membranes through electrostatic attractions over human cell membranes, but 
without hydrophobic groups, the copolymers cannot disrupt bacterial cell membranes, thus 
resulting in low antimicrobial activity. However, excess hydrophobicity of polymers in turn 
results in non-specific hydrophobic interaction with human cell membranes, causing high 
hemolytic activity.69-70, 81 Therefore, the design rule here is that the cationic functionality of 
copolymers needs to be maximized for selectivity, and the hydrophobicity should be maximized 
to achieve high antimicrobial activity. The main challenge of the field has been to identify the 
balance of cationic functionality and hydrophobicity for potent antimicrobial activity and low 
hemolytic activity.  
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Figure 1.5. Amphiphilic balance of copolymers and biological activities. Optimized ratio of cationic and hydrophobic groups is 
critical for potent antimicrobial, non-hemolytic polymers. Copyright © 2010 by Springer. Adapted by permission of Springer 73. 
In addition to monomer composition, tuning the hydrophobicity of monomers by alkyl 
length is another strategy previously to control the amphiphilic balance of copolymers. 
Copolymers with methyl, ethyl, butyl, or hexyl side chains have been prepared. In general, the 
antimicrobial activity increased (the MIC values decreased) as the mole percentage of alkyl 
monomers and reached the maximum activity (MIC values leveled off) at high mole 
percentages of alkyl monomers (Figure 1.6). The copolymers with shorter hydrophobic alkyl 
chain lengths required higher mole percentages to reach the maximum antimicrobial activity,68-
69, 81 while the MIC values at high mole percentages of alkyl monomers are same for all 
polymers with different alkyl monomers (Figure 1.6). However, the copolymers with shorter 
hydrophobic alkyl chain lengths were much less hemolytic, resulting in higher selectivity (Figure 
1.6).68-69, 81 Therefore, the chemical identity of hydrophobic side chains is also effective in 
tuning the antimicrobial activity and selectivity.  
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Figure 1.6. Antimicrobial and hemolytic activities of cationic amphiphilic methacrylate copolymers. Chemical structure of 
methacrylate copolymers with R= methyl, ethyl, butyl, or hexyl as hydrophobic side chains. Hydrophobic composition 
dependence. The average molecular weights of copolymers are in the range of 1,600-2,000. The data are adapted from 
references.68 
Polymer length, or molecular weight, is one tunable parameter beyond amphiphilic 
balance that has been explored. Controlling polymer length controls the average number of 
biologically active groups per chain. As the molecular weight of random methacrylate copolymers 
containing butyl side chains increases, the MIC values against E. coli decrease (Figure 6C) when 
compared for the copolymers with the same mole percentage of butyl side chains.69, 81 On the 
other hand, with increasing molecular weight, the HC50 values decreases, indicating the 
copolymers became hemolytic (Figure 6C).69, 81 The increased antimicrobial and hemolytic 
activities are likely because a longer polymer chain provides more contact points with the 
bacteria and human cells. Accordingly, the molecular weight of polymers should be small to 
minimize the hemolytic activity, but large enough to warrant the antimicrobial action by the 
amphiphilic polymer structures. As the copolymers with 2,000-3,000 have been investigated, 
these copolymers showed potent antimicrobial activity and selectivity. These MWs are 
comparable to those of natural AMPs, which may suggest that such MW range may be optimal 
for membrane disruption mechanisms.   
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Figure 1.7. Molecular weight dependence for the copolymers with butyl side chains (R = C4). The data are adapted from 
references.69, 81 
The chemical identity of the ammonium group is another parameter to control 
antimicrobial polymer activity. The primary ammonium groups have been selected for intimal 
study to mimic the lysine amino acid of AMPs.   The copolymers with primary, tertiary, or 
quaternary ammonium groups have been prepared and their antimicrobial and hemolytic 
activities have been investigated 71, 74. As the electrostatic interaction between the cationic 
charge of polymers and anionic bacterial membranes is responsible for polymer binding to 
bacteria for antimicrobial activity and selectivity, it was hypothesized that a permanent cationic 
charge such as found on quaternary ammonium would result in greater bacteria binding affinity 
and higher selectivity, resulting in the potent, selective antimicrobial activity. Primary and 
tertiary ammonium groups are pH-dependent owing to the equilibrium between deprotonated 
(neutral) and protonated (cationic). On the other hand, quaternary ammonium groups provide 
cationic charge regardless of the environmental pH. The copolymers with primary ammonium 
groups showed the higher antimicrobial activity against E. coli (MIC = 16 μg/mL) compared to 
counterpart polymers with either tertiary (MIC = 260 μg/mL) or quaternary ammonium (MIC 
>1,300 μg/mL) groups.71  The copolymer with primary ammonium groups also showed stronger 
binding to a lipid bilayer that those with ternary or quaternary ammonium groups.74 It has been 
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proposed that the primary ammonium groups are capable of forming a complex with the 
phosphate groups by electrostatic binding coupled with hydrogen bounding, increasing the 
affinity of polymers to bacterial lipid membranes 74, while the quaternary ammonium groups 
cannot form hydrogen bonds with lipid heads. Therefore, primary ammonium groups offer an 
advantage in polymer design based on improved membrane disrupting ability at physiological 
pH. 
Polymer Architectures and Macromolecules  
While we have been focused on linear polymers, which are intended to mimic AMPs, 
but other shapes and structures of macromolecules have also been explored by other 
laboratories, such as dendrimers and branched polymers. Synthetic antimicrobial peptides with 
short sequence (4-8 amino acids) dendrimer structures showed an increase in antimicrobial 
activity and lower toxicity to mammalian cells when branched to 4 arms, but only a marginal 
increase when the number of arms was further increased to 8, thought the authors fail to 
provide discussion on the mechanism of structure-property relationships.82 Further exploration 
of star-shaped structures with multiple α -helical peptide arms by Wiradharma et al. also show 
an increase in antimicrobial activity and reduced hemolysis as compared to linear structures, 
leading to greater cell selectivity, which is hypothesized to be due to an increase in structure 
flexibility at the branching point.83 The branched architectural design has been applied to 
synthetic antimicrobial polymers as well, though few studies have examined the comparative 
membrane activity of branched versus linear structures to provide a foundation for branching 
as a tunable factor. When utilized as coatings, Tiller and co-workers observed  poly(4-vinyl-N-
alkylpyridinium) 3-arm star polymers exhibited similar antimicrobial activity to linear 
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counterparts.84 A study of 4-arm methacrylate-based star polymers showed good antimicrobial 
activity and low cytotoxicity when quaternized, but a lack of linear comparative provide no 
knowledge of structure-property relationship.85 A study of branched polyethyleneimines 
examined the dependence of membrane disruption on amphiphilic balance, arm length, 
hydrophobic group identity and cationic group identity, but challenges with high polymer 
dispersity in branched polymer synthesis prevented conclusions regarding the role of 
architecture.86 Based on the state of the field, there is a need for further studies on branched 
antimicrobial polymer architectures to determine foundational knowledge necessary to apply 
architecture as a tunable parameter for antimicrobial efficacy and cell selectivity. 
Anti-Biofilm Approaches 
Biofilms are a major concern in the healthcare industry, as they are often the cause of 
chronic infection. The development of biofilms is natural bacterial behavior, imparting 
antibiotic tolerance to the bacteria within, thus making treatment of biofilm associated 
infections very difficult. Due to their difficulty to treat, both methods that prevent of biofilm 
formation (prevention) and increase antibiotic effectiveness against existing biofilms 
(treatment) have been explored. For example of prevention, because medical devices are 
common biofilm colonization sites, researchers developed surfaces with hydrophilic coatings 
for physical repulsion or antimicrobial-releasing coatings which kill bacteria being attached.87-88 
In addition to surface coatings, another example is small molecules or polymers which can 
block adhesin or receptors to interfere with the adherence of bacteria to a surface. Examples of 
these will be discussed in detail later in this section. Approaches to improving biofilm treatment 
efficiency include targeting signaling pathways involved in biofilm tolerance.89 For example, 
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quorum sensing signaling pathways involved in antibiotic tolerance can be interpreted by 
inhibitor molecules.90-91  Because the biofilm matrix is known to block the antibiotic penetration 
into biofilms, enzymes have been used to degrade the biofilm matrix similar to biofilm 
dispersal. have been shown to enhance antibiotic efficacy by improving antibiotic 
penetration.92-95 The challenge to these current approaches are three-fold: 1) coating 
chemistries may not be compatible to all abiotic surfaces; (2)  many coatings suffer 
accumulation of cells and proteins when exposed to physiological conditions, reducing their 
activities; 3) biological agents such as adhesin are bacteria specific, but not effective in biofilm 
prevention against a diversity of bacteria.  
Biofilm Formation Process and Properties 
Bacterial biofilms form in several steps, beginning with the preparation of a surface for 
bacterial attachment through the adsorption of a conditioning film (or layer) of proteins and 
carbohydrates.96  The conditioning layer creates hydrophobic surface which is favorable for 
bacteria attachment97, increase surface roughness which promotes bacteria adhesion98, and 
provides new functional groups at the surface which promote cell adhesion.99 These changes to 
the materials surface enable initial attachment of planktonic bacteria to a surface, first by 
reversible, physical attachment caused by Brownian motion, and then by irreversible biological 
attachment, caused by the binding of cellular appendages called adhesin with complimentary 
receptors in the conditioning layer.100 The subsequent proliferation of the attached bacteria 
and the production of extracellular polymeric substances (EPS) results in the formation of a 
three-dimensional community of bacteria (Figure 1.8). Medical implants are especially 
susceptible to biofilm colonization. Opportunistic bacteria can be introduced at the surgical site, 
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and damage to epithelial and mucosal barriers impairs host defense mechanisms which would 
otherwise defend against such bacteria.101 Protein adsorption occurs quickly (seconds) on both 
hydrophilic and hydrophobic implant surfaces, which promotes cell adhesion but also 
consequentially bacteria attachment and subsequent biofilm fouling.88, 102-103  Signals used in 
cell-cell communication, such as quorum sensing, indicate to the cells when critical density has 
occurred at a surface, at which point specific sets of gene expression are promote, enabling 
cells to develop into mature biofilms.104 Mature biofilms are characterized by bacterial cells 
encased in self-produced extracellular polymeric substance, consisting of polysaccharides, 
extracellular DNA, and proteins.105 The EPS matrix has multiple functions, including structurally 
maintaining cells in close proximity necessary for cell-cell communication, retaining 
components from dead cells which assists in conferring mutated antibiotic resistances, and 
protecting the cells from hostile environments.  Once biofilms are established, they are difficult 
to remove by medicinal treatments or mechanical removal. The EPS  matrix provides biofilms 
with viscoelastic properties, including elastic tension and viscous damping106, and grow more 
tightly adhered and stronger under shear stress.107 Treatment by medicinal means are 
challenged by features such as high cell density25, slower growth rate26, and low antibiotic 
penetration27.  Once a biofilm has reached maturation, the cycle begins again as pieces of the 
biofilm structure disperse, attach to new surfaces, and result in secondary colonization sites. 
The seeding of new biofilms by existing dispersing biofilms promotes biological diversity and 
bacterial survival and can contribute to infection recurrence.108 
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Figure 1.8. Biofilm formation occurs when planktonic bacteria produce a conditioning layer on a material surface (1), and 
subsequently attach to the surface (2). The attached bacteria grow and divide to form thick layers of bacteria (3). When 
sufficient bacteria are present, bacteria produce an extracellular polymeric substance (EPS) (4) that helps protect them against 
the surrounding environment. Portions of the biofilm can detach from the biofilm (5) and consequently form subsequent 
biofilms. 
Approaches to Biofilm Mitigation  
Engineered Surfaces 
Difficulty in eradicating established biofilms has resulted in research strategies that aim 
to modify material surfaces to prevent initial reversible bacteria attachment before biofilm 
formation can occur. Polymer coatings make up a significant amount of this work in three main 
categories of functions: (1) non-bacterial adhesion, (2) antimicrobial releasing, and (3) contact-
killing .109-110 In all cases, polymers are physically adsorbed or chemically (covalently)-bound 
onto surfaces. Non-bacterial adhesion surfaces repel bacteria by manipulating the 
physicochemical interactions of bacteria with surfaces. As bacteria prefer to bind on 
hydrophobic and charged surfaces, coatings composed of hydrophilic nonionic or charge-
neutral polymers can prevent bacterial attachment effectively, such as polyethylene glycol and 
zwitterionic polymers.111-113 In addition to the physicochemical properties of polymers, high-
density polymer brushes are also proven effective in preventing bacterial attachment. 
Antimicrobial-releasing surfaces contain antimicrobial agents such as metal ions or antibiotics, 
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which diffuse into the surrounding area, killing planktonic bacteria prior to surface contact or 
adherent bacteria.114-116 As the objective is to kill bacteria near the implant surface that 
threaten to attach, the greatest killing potential is near the materials surface, and becomes 
diluted as it diffuses into the surrounding area. Contact-killing surfaces do not release any agent 
into the surrounding solution, but rather have antimicrobial agents immobilized at the 
materials surface. One example is surfaces coated with cationic antimicrobial polymers which 
compromise the bacteria membrane on contact.117-118 Surfaces may be utilize multiple 
approaches for best effect, such as creating a surface that both releases antimicrobial agents 
and is anti-adhesion, such as through topological nano-patterning which disrupts bacteria 
surface recognitions.119-121 However, while some recent approaches show promising results, in 
practice all modified surfaces suffer from a short lifetime due to protein and cell accumulations 
once exposed to physiological conditions.122-123 Polymer regenerative surfaces for non-bacterial 
adhesion are of recent interest in the field, however most are only capable of one-time surface 
regeneration, and the efficacy of the renewed surface is low compared to the original surface 
for those that can achieve multiple cycles.124-127  
Anti-adhesion Agents (interrupt biological attachment) 
Non-surface approaches have relied on the interruption of the irreversible biological 
attachment mechanisms, such as the interaction of specific bacteria proteins (adhesins) with 
complementary surface receptors found on host cells or the conditioning layer on material 
surfaces. Several strategies have been employed to prevent adhesin-receptor binding, either by 
targeting the adhesin (bacteria) or receptor (biological surface).  Inhibition of adhesin 
biosynthesis128-130 in bacteria or receptor glycoslation131 target the formation of the 
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adhesin/receptor. The use of adhesin128, 132-133 or receptor analogs 134-136 block the 
adhesin/receptor site, preventing the complimentary interaction from occurring. Dendrimers 
have been of particular interest for use as scaffolds to present receptor analogs due to their 
multivalent nature, and have been used to inhibit bacterial cellular uptake to host cells by 
preventing binding of virulence factors AB5 toxins.137-138 However, bacteria can subvert these 
agents through mutation/adaptation, such as expressing a variety of adhesins that bind to 
different receptors, and a single adhesin variety capable of binding to multiple receptors.128, 139 
The prevention of biofilms continues to be a major scientific challenge: a single attached 
bacteria can theoretically result in a bacterial biofilm.  
Increasing Biofilm Susceptibility  
Given the challenges in the prevention of biofilm formation, several studies have instead 
focused on the development of approaches to improve treatment methods for bacterial 
biofilms, specifically through increasing biofilm antibiotic susceptibility. Biofilms are resistant to 
antibiotics for a multitude of reasons, including high cell density26, low antibiotic penetration27, 
and slower growth rate26. The dormancy of biofilm bacteria is a major challenge, as it restricts 
antibiotic uptake and the availability of antibiotic target sites.140 Research has often targeted 
persisters, a sub-population of the dormant bacteria phenotype that are able to survive 
antibiotic threats that would otherwise kill the bacteria population, but whose tolerance is not 
due to resistant mutation.141-142 By making biofilms more susceptible, conventional antibiotic 
treatment will be able to effectively eradicate biofilms, preventing resistance development in 
bacteria 143-144 and improving the treatment outcomes, reducing hospitalization time145-147.  
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Many efforts have been made to understand antibiotic tolerance in biofilms, and a 
variety of different approaches have been studied to increase their antibiotic susceptibility. 
Quorum sensing inhibitors increased the efficacy of tobramycin against in P. aeruginosa in 
biofilms, but had no effect on planktonic cells, suggesting blocking quorum sensing may 
interrupt the regulation of characteristic biofilm gene expression involved in antibiotic 
tolerance.90 Harrison et al. noted that E. coli lacking a nonessential protein transport pathway 
resulted in disorganized biofilms, and had increased sensitivity to antimicrobials when grown in 
nutrient-limited conditions.148 Alginate in mucoid strains of P. aeruginosa biofilms have been 
suggested to impart antibiotic tolerance, and the co-administration of aminoglycosides with 
alginate lyase helped degrade alginate the biofilm, and enhanced the antibiotics 
effectiveness.92 Approaches used to targeted persisters, a metabolically inactive sub-population 
(<1%) of dormant cells in biofilms142, 149, may also be applicable to sensitize the slow-growing 
dormant cell majority through activity stimulation. Choudhary et al. found that exposure to 
host defense factors increases the sensitivity of persister cells in P. aeruginosa biofilms to 
antibiotics by upregulating genes associated with motility consequentially increasing bacterial 
activity as cells move away from host cytokines.150 Biofilms grown in the presence of mannitol 
had increased susceptibility to tobramycin, reverting persister cells in biofilms to antibiotic 
susceptible phenotype by inducing a metabolic pathways and generating a PMF (proton motive 
force).151 It is important to note that while studies that utilize mutant bacteria, such as those 
lacking specific signaling pathways, are useful in understanding the nature of the biofilm 
tolerance, they do not offer a tangible approach to treatment of clinical infections. Instead, it is 
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best understood that these approaches rely on modulating the natural behavior of bacteria in 
order to generate sub-optimal biofilms.  
Thesis Objectives 
The purpose of this dissertation is to develop new antimicrobial functions stemmed 
from synthetic polymer structures and properties that can be used for directly treat bacterial 
infections (antimicrobial) or indirectly act as biofilm suppressants and antibiotic adjuvant. This 
dissertation will introduce a new polymer architecture, specifically macromolecules with 
multiple polymer chains, designed to control the antimicrobial activity and hemolytic behavior. 
The findings of this dissertation will contribute fundamental knowledge necessary to develop 
high efficacy, low toxicity amphiphilic polymers to treat bacterial infections. This dissertation 
also introduces a new materials approach to modulate bacteria activity to prevent biofilm 
formation and potentially improve antibiotic efficacy. The findings of these studies provide new 
insight into the interaction of synthetic polymers with bacterial membranes, and the knowledge 
can be used to develop new antimicrobial and anti-biofilm strategies. 
Approach 1: Multi-Armed Amphiphilic Polymers for Direct Bacteria Killing 
In chapters 2 and 3, amphiphilic polymethacrylate derivates will be explored for their 
antimicrobial and hemolytic activities. The central hypothesis is that branched and multi-armed 
macromolecules presenting multiple antimicrobial polymer chains will show improved 
antimicrobial activity and selectivity towards bacteria as compared to the previously studied 
linear structures. In chapter 2, hyperbranched copolymers will be synthesized to examine the 
effect of branched structures and sizes on their antimicrobial and hemolytic activities. In 
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chapter 3, 4-armed star polymers will be synthesized, and the effect of star structure on 
antimicrobial and hemolytic activities will be examined. The goal of these chapters is to identify 
if macromolecules presenting multiple polymer chains can effectively be used to improve 
antimicrobial activity and improve selectivity compared to linear polymers, which could be used 
as a new tunable parameter for future polymer designs.  
Approach 2: Biofilm Formation and Treatment Modulating Polymers  
In chapters 4 and 5, cationic polymers will be explored for their ability to target bacteria 
behavior to modify biofilm formation and antibiotic susceptibility. In chapter 4, interactions 
between cationic poly[(3-methacryloylamino)propyl] trimethylammonium chloride and 
planktonic bacteria are investigated to change planktonic bacteria behavior during biofilm 
formation, which may result in downstream sub-optimal biofilm formation. In chapter 5, 
cationic poly[(3-methacryloylamino)propyl] trimethylammonium chloride was used to  treat 
existing biofilms to determine if the polymer could increase antibiotic susceptibility of bacteria. 
The goal of these chapters is to identify new routes in which synthetic polymers can modify the 
behavior of bacteria to prevent biofilm formation and to improve biofilm treatments.
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Chapter 2 Antimicrobial and Hemolytic Activities of Crosslinked Amphiphilic 
Methacrylate Polymers 
Introduction 
The number of antibiotic-resistance bacterial infections, including multidrug resistant 
infections, has been rapidly increasing over the past several decades. Conventional antibiotic 
treatment may no longer be a viable option. However, the number of new synthetic antibiotics 
entering the market decreased.4 There is an urgent need for new antimicrobials that are 
effective in eradicating drug-resistant bacteria. To that end, the therapeutic potential of 
membrane-active antimicrobial polymers has been explored as new antimicrobial agents, which 
mimic the behavior of host-defense antimicrobial peptides (AMPs) found in the innate immune 
system.66-68 The major barrier to antimicrobial polymers as antibiotic therapeutics is insufficient 
antimicrobial activity and poor selectivity.152-153 Antimicrobial peptides typically require higher 
concentrations (µM) than traditional antibiotics (nM) in laboratory tests.74-75, 78 The MIC values 
of antimicrobial peptide magainin-2, bee venom lytic peptide melittin, antibiotic ciprofloxacin 
and norfloxacin are listed in Table 2.1, which were determined in our laboratory for references. 
Many antibiotics are enzyme and DNA inhibitors, which act by binding a specific active site of 
proteins within the bacteria. Antibiotic resistance requires large quantities of antibiotics beyond 
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clinically useful concentrations to eliminate resistant bacteria. For example, our laboratory 
previously demonstrated that MIC of norfloxacin against E. coli increased 500 time greater than 
the initial MIC as the bacteria were passaged 21 times.75 Such large doses of antibiotics may 
cause systemic toxicity, and it would be difficult to solubilize for clinical use.  On the other hand, 
AMPs act by disrupting the bacterial cell membrane. While AMPs have reduced potency (lower 
MIC) as compared to antibiotics, they have a higher killing rate, broad-spectrum activity and a 
reduced likelihood of resistance development, which is highly desirable.154  
Table 2.1. Antimicrobial activity of antimicrobial peptides (magainin-2, melittin) as compared to traditional antibiotics 
(ciprofloxacin, norfloxacin).74-75, 78 
 MIC against E. coli 
µg/mL µM 
Antimicrobial 
Peptides 
Magainin-2 125 51 
Melittin 12.5 4.4 
Traditional 
Antibiotics 
Ciprofloxacin 0.01 0.02 
Norfloxacin 0.06 0.2 
 
 Cationic random amphiphilic polymers have been one design platform to explore 
structural factors to mimic AMPs, including monomer compositions and molecular sizes.155-165 
Traditionally, cationic and hydrophobic balance of polymers has been the major tunable factor 
to control their antimicrobial activity and cell selectivity to bacteria over mammalian cells, as 
the cationic functionality imparts the binding to anionic bacterial cell membranes and the 
insertion of hydrophobicity cause membrane disruption, resulting in bacterial cell death. The 
optimal balance has been achieved by tuning the composition of cationic and hydrophobic 
monomers during polymerization. This strategy has been extensively studied to improve the 
activities of polymers; however, it appears that there is a limit in the improvement. While the 
previous work has been focused on the monomer composition of polymer chains to mimic the 
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amphiphilic properties of AMPs, there may be the clue to improve the polymer activity in the 
mechanism of AMPs. When AMPs are bound to bacterial cell membranes, multiple AMPs are 
assembled to form pores in cell membranes or accumulated to non-specifically disrupt 
membrane structures. It has been reported that 4-11 peptide chains are necessary for pore 
formation, depending on AMPs.166-167 Therefore, AMP activity should be thought of as the 
collective action of the peptides. Here we hypothesize that macromolecules presenting multiple 
antimicrobial polymer chains will show improved antimicrobial activity and selectivity. Because 
no need for assembly or accumulation of polymer chains for pore formation or membrane 
disruption, the low concertation of macromolecules would effectively kill bacteria.  
Antimicrobial macromolecules with multiple polymer chains have not been extensively 
studied. A study conducted by Tiller and co-workers found that poly(4-vinyl-N-alkylpyridinium) 
3-arm star polymers (10,000-85,000 g/mol) exhibited similar antimicrobial activity to linear 
counterparts when used as coatings84, but the solution conformation of polymers prior to 
binding is proposed to affect antimicrobial properties and cell selectivity.168  Liu and co-workers 
studied methacrylate-based 4-arm star polymers (16,000-28,000 g/mol) with good 
antimicrobial activity and low cytotoxicity when quaternized85, but this does not provide 
essential knowledge of the advantages or disadvantages of branched or star-shaped 
architecture  as compared to traditional linear antimicrobial polymer architecture.  
To test the hypothesis, we investigated a synthetic approach to macromolecules which 
can present multiple antimicrobial polymer chains, and their antimicrobial and hemolytic 
activities. In this study, we further hypothesize that a hyperbranched polymer structure will 
provide a simple model scaffold to present multiple polymer chains in one (macro)molecule. 
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The purpose of this study is to study the synthesis of hyper-branched crosslinked polymers 
using free-radical polymerization with a chain transfer agent and examine the effect of 
structures and monomer compositions on their antimicrobial and hemolytic activities. In this 
study, we attempted to prepare hyper-branched polymers with different molecular sizes, 
degree of branching, and polymer densities by altering the concentrations of di-functional 
monomer (crosslinker) and chain transfer agent. The composition of cationic and hydrophobic 
monomers was also altered to tune the inherent antimicrobial activity of polymer chains.  
Methods 
Materials 
Azobisisobutyronitrile (AIBN, Sigma Aldrich), methyl 3-mercaptopropionate (MMP, 
Acros Organic), dimethylformamide (DMF, Fisher Chemicals), acetonitrile (MeCN, Fisher 
Chemicals), dichloromethane (Fisher Chemicals), hexane (Fisher Chemicals), trifluoracetic acid 
(TFA, Fisher Chemicals), methanol (MeOH, Fisher Chemicals), ethanolamine (Acros Organic), 
tetrahydrofuran (THF, Fisher Chemicals), di-tert-butyldicarbonate (Acros Organic), ethyl acetate 
(Fisher Chemicals), and ethyl ether (Fisher Chemicals) were used as received. Methacryloyl 
chloride was purchased from Acros Organic and distilled prior to each use. Sodium hydroxide 
pellets (NaOH, Fisher Chemicals) was used to prepare solutions of desired molar 
concentrations. Sodium bicarbonate (Fisher Chemicals) and sodium chloride (NaCl, Fisher 
Chemicals) were used to prepare saturated solutions. Ethylene glycol dimethacrylate (EGDMA, 
Electron Microscopy Sciences) and ethylmethacrylate (EMA, Aldrich) were passed through a 
column of aluminum oxide (50-200 µm) to remove inhibitors prior to polymer synthesis.  
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Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923) were used as 
model bacteria evaluate antimicrobial activity. Human red blood cells (RBCs) (leukocytes 
reduced adenine saline added) were obtained from the American Red Cross Blood Services 
Southeastern Michigan Region and used prior to the out date indicated on each unit. Mueller 
Hinton Broth (MHB, BD and Company ©) and phosphate buffered saline (PBS, pH=7.4, Gibco®) 
were prepared according to manufacturer instructions and sterilized prior to use.  
Synthesis of N-boc-protected aminoethyl methacrylate (boc-AEMA) 
A solution of ethanolamine (255 mmol, 15.8 mL) in a biphasic mixture of THF (180 mL) 
and NaOH (aq) (1 M, 300 mL) was added dropwise to a solution of di-tert-butyldicarbonate (255 
mmol, 55.7 g) in 120 mL THF. The solution was stirred at room temperature overnight. The 
solution was evaporated under reduced pressure, and the resulting solid dissolved in ethyl 
acetate. The desired N-boc-protected alcohol was extracted in ethyl acetate by washing with 
water (3x), followed by saturated NaCO3H (aq) and saturated NaCl (aq) to remove residual 
monomer. Residual water was removed by magnesium sulfate, and ethyl acetate removed by 
evaporation under reduced pressure.  The resulting oily product was dried under vacuum. A 
solution of N-boc-protected alcohol (67.1 mmol, 10.8 g) and trimethylamine (162 mmol, 16.4 
mL) in dichloromethane (150 mL) was bubbled with nitrogen for 10 minutes in a 0 °C ice bath. 
Freshly distilled methacryloyl chloride (67 mmol, 6.60 mL) was diluted with dichloromethane 
(15.0 mL), bubbled with nitrogen for 5 minutes, and added dropwise to the solution of N-boc-
protected alcohol. The solution was stirred 16h in a 0 °C ice bath. The solution was filtered, and 
the filtrate concentrated by evaporated under reduced pressure. The resulting product was 
extracted in ethyl acetate by washing with water (3x), followed by saturated NaCO3H (aq) and 
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saturated NaCl (aq). Ethyl acetate was evaporated under reduced pressure, and the solid 
dissolved in minimal dichloromethane (~2 mL). Hexane was added to the solution (~10 mL), and 
the product recrystallized at room temperature, followed by 0 °C and -18 °C to maximize 
recovery of N-boc-protected aminoethyl methacrylate (boc-AEMA). The solid was isolated at 
each temperature, crushed and dried under vacuum overnight before confirmed high purity by 
1H NMR. 
Preparation of methacrylate polymers (20% monomer (wt) /solvent (v)) : Series a, b, c 
Boc-AEMA (0.10 g, 0.44 mmol), ethyl methacrylate (EMA, varied), ethylene glycol 
dimethacrylate (EGDMA, varied), AIBN (14.5 mg, 0.09 mmol) and MMP (varied) were dissolved 
in a DMF/MeCN solution (1/4, v/v, 5 mL). Series b and c were designed with 30 or 50 mol% of 
EMA, relative to total monomer concentration (Boc-AEMA+EMA). The length and density of 
polymer arms were controlled by the amount of EGDMA and MMP, which was varied 0, 1, 5, or 
10% relative to monomer concentration. The solutions were sealed by rubber septum, bubbled 
with nitrogen for 10 minutes, and reacted overnight at 60 °C with stirring. Having observed 
challenges synthesizing polymers with high EGDMA content without the formation of gels, a 
series of polymers was also generated at 5% monomer (w)/solvent (v), termed Series d. 
1H-NMR (CDCl3) was taken of crude solution to determine the conversion rates from 
monomer to polymer. The solutions were concentrated by evaporated under reduced pressure 
and re-dissolved in dichloromethane (~0.5 mL). The solution was then precipitated twice in 
hexanes to remove unreacted monomers and reagents, resulting in fine white particulates 
which were dried under high vacuum.  
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Removal of the boc protecting group to achieve a primary amine was achieved by 
reacting polymers with trifluoracetic acid (TFA) for 20 minutes. A small amount of MMP was 
included to quench the formation of the carbo cation. TFA is harmful, and exposure to TFA 
should be limited. TFA was removed by blowing with nitrogen gas. The polymer residue was 
dissolved in methanol (~0.5 mL) and the solution precipitated twice in diethyl ether, resulting in 
white particulates. The precipitate was dried under high vacuum and subsequently dissolved in 
water and lyophilized. The degree of polymerization and molar composition of monomers were 
determined by 1H-NMR (D2O), through comparing integration of peaks from side chains to that 
of the end group (MMP) of polymer chain (see Supporting Information for 1H NMR spectra). 
Series a was designed as MA homopolymer (100% cationic monomers). Series b was 
designed as 70% MA-30% EMA (70% cationic-30% hydrophobic monomers), and Series c as 50% 
MA-50% EMA (50% cationic-50% hydrophobic monomers). Series d revisited a 70% MA-30% 
EMA polymer design. 
Characterization of methacrylate polymers 
Gel permeation chromatography (GPC) analysis was performed using a Waters 1515 
HPLC instrument equipped with Waters Styragel (7.8 × 300 mm) HR 0.5, HR 1, and HR 4 
columns in sequence and detected by a differential refractometer (RI). Calibration curves were 
based on narrow dispersity polystyrene standards between 1,050-1,000,000 g/mol (Polymer 
Laboratories Ltd. And Polysciences, Inc.). Boc-protected polymers were characterized by gel 
permeation chromatography (GPC) to determine number average molecular weight (Mn) and 
weight-average molecular weight (Mw), and calculated dispersity (Đ).  
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Antimicrobial Activity 
The minimum inhibitory concentration (MIC) of polymers against E. coli (ATCC 25922) 
and S. aureus (ATCC 25923) was determined in a standard microbroth dilution assay according 
to the Clinical and Laboratory Standards Institute guidelines with suggested modifications by R. 
E.W Hancock Laboratory (University of British Columbia, British Columbia, Canada)169 and 
Giacometti et al.170 Bacteria was grown overnight (~18 hours) in MHB at 37 °C with orbital 
shaking (180 rpm), and used as an inoculum by diluting overnight culture in MHB to a 
concentration of OD600=0.1. The inoculated solution was then grown at 37 °C to the exponential 
phase (OD600= 0.5-0.7, 2 hours). Final dilution to OD600= 0.001, ~2 x 105 CFU/mL, was made with 
MHB. Bacterial suspension (OD600= 0.001, 90 µL/well) was transferred to a 96-well sterile 
round-bottom polypropylene plate. Polymers were dissolved in 0.01% acetic acid to achieve 
stock concentrations of 20 mg/mL. Serial 2-fold dilutions of polymers were prepared from stock 
solutions in PBS and transferred to the 96-well sterile round-bottom polypropylene plate for a 
final concentration of 7.8-1,000 µg/mL (10 µL/well). PBS was used as a solvent control in place 
of polymer. Plates were sealed with parafilm and incubated for 18 hours at 37 °C without 
shaking. MIC was defined as the lowest concentration of polymers to completely inhibit 
bacterial growth, as indicated by lack visual of turbidity. Assays were repeated a minimum of 
three times in triplicate on different days.  
Hemolytic Activity 
Hemolysis, the lysis of human red blood cells (RBCs), was used to assess the toxicity of 
polymers to human cells. A 10% solution of human RBCs in PBS was centrifuged at 2000 rpm for 
5 minutes and washed with PBS x2 to remove initial hemoglobin. The number of RBCs in the 
 35 
resulting solution was determined by counting chamber, and the solution diluted in PBS to give 
a final concentration go 3.33 x 108 cells/mL. After serial dilutions, polymers (10 µL) were 
transferred to a 96-well sterile round-bottom polypropylene plate, followed by the RBC 
suspension (90 µL). Plates were incubated 37 °C with orbital shaking (180 rpm) for 1 hour. 
Triton X-100 (0.1% v/v in water) was used as the positive lysis control and PBS used as a 
negative control. Following incubation, the plate was centrifuged at 2000 rpm for 5 minutes. 
The supernatant (5 µL) from each well diluted in PBS (100 µL) with thorough mixing in a 96-well 
flat-bottomed polystyrene plate. The absorbance of released hemoglobin (415 nm) was 
measured using a Varioskan Flash microplate reader (Thermo Fisher). The percentage hemolysis 
was determined relative to Triton X-100 (100%) and PBS negative control (0%). The polymer 
concentration causing 50% hemoglobin release (HC50) was determined, and the hemolysis (%) 
at the highest concentration of polymer (1000 µg/mL) was reported if below 50%. Assays were 
repeated a minimum of three times in triplicate. 
Results and Discussion 
Polymer Design and Synthesis 
In our polymer design, we attempted to synthesize hyperbranched polymers by free 
radical polymerization to form a branched macromolecular structure of antimicrobial polymer 
chains through the incorporation of crosslinker. We built on a previously well-explored platform 
of methacrylate random copolymers with cationic primary ammonium side chains and 
hydrophobic ethyl side chains. The polymer chain length was controlled by thiol chain transfer 
agent 3-MMP. We polymerized boc-protected aminoethyl methacrylate (boc-AEMA), ethyl 
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methacrylate (EMA), and ethylene glycol dimethacrylate (EGDMA) using AIBN as an initiator 
and MMP as a chain transfer agent, followed by deprotection of the boc-group using TFA to 
yield polymers with primary ammonium groups (Figure 2.1).  
 
  
Figure 2.1. Synthesis of amphiphilic methacrylate-based copolymers containing crosslinking agent EGDMA. Feed stock 
compositions were varied as described in methods, where the ratio of EGDMA (m) was proportional to Boc-AEMA and EMA 
(n+k), and ratio CTA was relative to total monomer concentration (n+m+k).  
Composition 
We synthesized hyperbranched polymers and related linear polymers with three 
monomer compositions: 100% boc-AEMA homopolymer (Series a), 70% boc-AEMA -30%EMA 
copolymer (Series b and d) and 50% boc-AEMA -50%EMA copolymer (Series c). Previously, the 
balance of cationic and hydrophobic properties had been used to control antimicrobial and 
hemolytic activities. The ultimate goal of this project is to exploit the macromolecular 
presentation of polymer chains to improve their antimicrobial activity. Therefore, it is 
important we examine the activity of linear polymers and how the activity of individual polymer 
chains reflected the activity of macromolecular (branched) structures.  Polymer composition 
was controlled by varying the feed composition of boc-AEMA and EMA. EGDMA was not 
factored into the calculation of monomer compositions due to an attempt to separate factors 
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controlling polymer architecture from factors controlling amphiphilic balance. The amount of 
EGDMA was 0,	1.0, 5.0, and 10 mol% of the total amount of boc-AEMA and EMA, and the 
amount of MMP was 0, 1.0, 5.0, and 10 mol% of the total amount of boc-AEMA and EMA and 
EGMDA.  
The final monomer compositions were calculated by comparing the integrated areas in 
the 1H-NMR spectra as shown in the Appendix A as percent AEMA, EMA, and EGDMA relative to 
total monomer amount. For example, series B polymers contained 63-75% AEMA, 24-32% EMA, 
and 0-11% EGDMA (Table 2.2). The final polymer composition, determined by 1H-NMR analysis, 
was in good agreement with the feed monomer compositions, Series a, c, and d can be found in 
Appendix A.
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Table 2.2. Comparison of monomer feed composition to polymer composition calculated by 1H-NMR for Series b.  
  Monomer Feed Composition (mol%) Polymer Composition, 1H-NMR (mol%) 
  Boc-AEMA EMA EGDMA AEMA EMA EGDMA 
Se
rie
s b
 
Pb17 70.0 30.0 0.0 68 32 0 
Pb18 69.3 29.7 1.0  Gel Gel  Gel 
Pb19 66.7 28.6 4.8  Gel Gel  Gel 
Pb20 63.6 27.3 9.1  Gel Gel  Gel 
Pb21 70.0 30.0 0.0 70 30 0 
Pb22 69.3 29.7 1.0 70 30 0.01 
Pb23 66.7 28.6 4.8  Gel Gel  Gel 
Pb24 63.6 27.3 9.1  Gel Gel  Gel 
Pb25 70.0 30.0 0.0 72 28 0 
Pb26 69.3 29.7 1.0 70 29 1 
Pb27 66.7 28.6 4.8 69 29 2 
Pb28 63.6 27.3 9.1 69 27 4 
Pb29 70.0 30.0 0.0 75 25 0 
Pb30 69.3 29.7 1.0 73 26 1 
Pb31 66.7 28.6 4.8 68 24 8 
Pb32 63.6 27.3 9.1 63 26 11 
 
Conversion/Yield 
Following polymerization, the conversion of monomers to boc-protected polymers was 
determined by comparing the integrated area of the methylene groups on monomer side 
chains signal (~4 ppm) to integrated area from the methylene on the monomer double bond 
signal (~6 ppm) in the 1H-NMR spectra. Monomer conversion was between 85-99% for all series 
of polymers ( 
Table 2.3, Appendix A). Boc-protected polymers were collected by precipitation with 
good yield (78-100%), though some polymers retained trace amounts of DMF (<5 mol%) which 
were calculated to not affect polymer yields (<0.2 wt.%). Deprotected polymers were recovered 
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with excellent yield based on the theoretical weight of the resultant polymers (89-100%), and 
contained no solvent traces following lyophilization. 
Table 2.3. Polymerization conversion and yield of Series b copolymer.  
      Boc-Protected Deprotected 
    State % Conversion % Yield % Yield 
Se
rie
s b
 
Pb17 
0% MMP 
 
 
0% EGDMA Liquid 98 100 100 
Pb18 1% EGDMA Gel  Gel Gel  Gel 
Pb19 5% EGDMA Gel  Gel Gel  Gel 
Pb20 10% EGDMA Gel  Gel Gel  Gel 
Pb21 
1% MMP 
 
 
0% EGDMA Liquid 98 78 100 
Pb22 1% EGDMA Liquid 97 100 89 
Pb23 5% EGDMA Gel  Gel Gel  Gel 
Pb24 10% EGDMA Gel  Gel Gel  Gel 
Pb25 
5% MMP 
 
 
0% EGDMA Liquid 98 100 100 
Pb26 1% EGDMA Liquid 97 100 92 
Pb27 5% EGDMA Liquid 97 100 89 
Pb28 10% EGDMA Liquid 98 100 95 
Pb29 
10 %MMP 
 
 
0% EGDMA Liquid 98 86 100 
Pb30 1% EGDMA Liquid 99 91 100 
Pb31 5% EGDMA Liquid 98 90 100 
Pb32 10% EGDMA Liquid 99 89 100 
Gelation 
Due to the presence of crosslinking monomers, the polymerization mixtures resulted in 
either a solution or solid gel. Gelation occurred in some polymers when MMP ≥1 mol% and 
EGDMA ≤1 mol% (Figure 2.2). Monomer composition effected the critical ratios EGDMA/MMP 
for gelation. While the total monomer concentration in solvent remained constant across these 
series, the increasing percentage of EMA resulted in increase of gelation EGDMA/MMP ratios, 
which may reflect the solubility of monomers and resultant polymers to solvent; EMA may be 
more soluble (miscible) as compared to boc-AEMA.  
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Figure 2.2. Phase diagrams of homo and copolymer series a, b, c, and d. Solution-gelation behavior is based on ratio of chain 
transfer agent (MMP) to crosslinking agent (EGDMA).  
Polymer Characterization 
Degree of Polymerization: Effect of CTA and Arm Length  
MMP, a chain transfer agent, was used to control the length of polymer chains by chain 
termination and re-initiation of polymerization.171 The degree of polymerization (DP) of the 
resultant polymer chains was determined by 1H-NMR analysis by comparing the integrated area 
of signals from the polymer side chain units to that from the end-group CTA (described in 
Appendix A). The DP of the polymers synthesized without MMP was not able to be determined 
from the 1H NMR spectra due to lack of the signal from the end groups. The degree of 
polymerization of polymers ranged from 12-80 repeat units (Table 2.4, Appendix A). The DPs of 
linear polymers without EGDMA was decreased as the mole percentage of MMP was increased 
from 1% to 10% as seen in Pb21 (DP= 82, 1% MMP), Pb25 (DP=33, 5% MMP) and Pb29 (DP=17, 
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10% MMP) (Figure 2.3). These results are consistent with the results from the previous 
reports.69, 81 For the polymers containing EGDMA, the apparent DP was calculated as the 
number of monomers (AEMA, EMA, and EGDMA) per one MMP. The calculated DP is apparent, 
as opposed to that for the linear polymers, because the polymer chains are cross-linked. The 
apparent DP provides the measure of polymer chains cross-linked in the branched structures.  
Increasing the amount of MMP from 1% to 10% resulted in a decrease in apparent DP, as can 
be seen in the examples with 1 mol% EGDMA feedstock Pb22 (DP=80, 1% MMP), Pb26 (DP=33, 
5% MMP) and Pb30 (DP=18, 10% MMP) (Figure 2.3). In branched polymers, the apparent DP is 
equal to the average length of polymer arms. However, we cannot determine the number of 
chains incorporated into the crosslinked macromolecule (true DP).  
Table 2.4. Calculation of absolute degree of polymerization (linear) and apparent degree of polymerization (crosslinked) by 1H 
NMR. 
  Absolute DP Apparent DP 
Se
rie
s b
 
Pb17 No CTA No CTA 
Pb21 82.465 Linear 
Pb22 Crosslinked 80.075 
Pb25 26.39 Linear 
Pb26 Crosslinked 33.28 
Pb27 Crosslinked 31.475 
Pb28 Crosslinked 18.72 
Pb29 17.265 Linear 
Pb30 Crosslinked 18.16 
Pb31 Crosslinked 17.015 
Pb32 Crosslinked 13.995 
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Figure 2.3. Effect of chain transfer agent (mol% MMP) on apparent DP.  
 
Molecular weight and Dispersity 
Apparent molecular weights of polymers were calculated based on apparent degree of 
polymerization (Table 2.4) and composition which are determined by 1H NMR analysis using the 
molecular weights of monomers (AEMA, EMA, and EGDMA), and MMP (Table 2.2). A sample 
calculation can be found in the Appendix A. Apparent molecular weight of polymers ranged 
from 2,000-16,000 g/mol (Table 2.5). However, these calculations are based on apparent DP, 
and it is not possible to determine the number of polymer chains incorporated into the 
crosslinked macromolecule.  
Mn, Mw and dispersity (Đ) of the boc-protected polymers were determined by GPC as 
relative to polystyrene standards. The Mn of boc-protected polymers ranged from 2,300-16,000 
g/mol (polystyrene standard), but Mw were significantly higher and ranged from 3,400-49,000 
g/mol (Table 2.5, Appendix A). For linear polymers, the highest Mn (15,872 g/mol) and Mw 
(49,002 g/mol) occurred in Pb17, which was synthesized in the absence of CTA. Additionally, 
Pb17 was also the linear polymer the highest Đ (3.09) (Table 2.5). Comparatively, polymers 
synthesized with MMP, such as Pb29 (10 mol% MMP), had reduced Mn (2,530 g/mol), Mw (3,461 
g/mol) and Đ (1.37). This suggests that the chain termination by CTA helps control molecular 
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weight and molecular weight dispersity, where increasing the mol% of CTA decreases Mn and 
decreases Đ (Figure 2.4a). This effect was also seen in crosslinked monomers.  A comparison of 
Pb22 (1 mol% MMP), Pb26 (5 mol% MMP), and Pb30 (10 mol% MMP) showed decreasing Mn at 
11,662 g/mol, 4,922 g/mol and 2,925 g/mol respectively (Figure 2.4b).  Increasing EGDMA 
content from 0 to 10 mol% shows both an increase in Mn and increase in Đ, seen in the case of 
Pb29 (0 mol%), Pb30 (1 mol%), Pb31 (5 mol%) and Pb32 (10 mol%) (Figure 2.4c). Evidence of 
greater dispersity can be observed by broadening of GPC column retention time (Figure 2.4d).  
Crosslinking polymer Đ was dependent on crosslinking monomer/CTA ratio, where the highest 
Đ occurred where crosslinking monomer content (mol%) was greater than CTA content (mol%). 
For example, Pb28 had the highest Đ (8.3) of Series b, which occurred at 10 mol% EGMDA and 5 
mol%.  This behavior is also evident in trend Series a and c (Pa12, Pc39, Pc44). 
Table 2.5. Molecular weight and dispersity characterization by 1H NMR and GPC of Series b copolymers. 
 
 
MW (g/mol) 
 (1H NMR) 
Mn (g/mol) 
(GPC) 
Mw (g/mol) 
(GPC) 
Đ 
(GPC) 
Se
rie
s b
 
Pb17 No DP 15872 49002 3.09 
Pb21 16174 8064 17804 2.21 
Pb22 15616 11662 33749 2.89 
Pb25 5238 3499 5238 1.50 
Pb26 6555 4922 9141 1.86 
Pb27 6046 8191 33631 4.11 
Pb28 3584 9415 78411 8.33 
Pb29 3487 2530 3461 1.37 
Pb30 3641 2925 4325 1.48 
Pb31 3470 3706 7040 1.90 
Pb32 2776 5649 19599 3.47 
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Figure 2.4. Polymer molecular weight and dispersity dependence on CTA and crosslinker content: (a) molecular weight 
dependence on MMP, (b) representative GPC spectrum of retention time variation by MMP content, (c) molecular weight and 
dispersity dependence on EGDMA, and (d) representative GPC spectrum of retention time variation by EGDMA content. 
Probing Polymer Architecture by EGDMA/Chain Ratio  
In order to gain insight on the polymer architecture in crosslinked polymers, a 
calculation of the number of crosslinkers per polymer chain (CTA end group). The number of 
EGDMA per polymer is indicative of the number of chains that are linked together through 
crosslinking (branches), and how structurally restricted the polymer is through multiple 
crosslinks between the same chains. The apparent DP was determined by 1H-NMR relative to 
the MMP end group, and mol% EGDMA was used to determine the number of EGDMA 
monomers per polymer chain (terminated in MMP).  The average number of crosslinks per CTA 
in the polymers synthesized at 20 wt% monomer/ v% solvent was typically between 0.2-1.7 
(Table 2.6, Appendix A). The low degree of branching suggests a structure that is not multi-
armed, but linear containing some crosslinking monomer. For gelled polymers, a theoretical 
calculation of crosslinks/CTA was carried out based on the EGDMA feed composition and 
degree of polymerization of comparable linear polymers. Gelled polymers Pb23 and Pb24 were 
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calculated to have crosslinker/CTA ratios of 4.1 and 8.2 respectively, indicating that polymers 
crosslinked into insoluble networks. The reduction of monomer content to 5 wt% in solvent (v) 
resolved the gelation and allowed a polymer to be synthesized with a crosslinker/CTA ratio of 
>2 (Pd50, 3.61).  
Table 2.6. Degree of polymerization and average crosslink density as determined by 1H-NMR for Series b copolymers. Average 
crosslink/CTA ratio denoted by * are theoretical calculations of gelled polymers based on linear comparable compositions. 
Denotations of N/A are indications of  
 
 
Apparent 
DP 
Average 
#Crosslinks/CTA Ratio 
Se
rie
s b
 
Pb17 No CTA No CTA 
Pb18 Gel No CTA 
Pb19 Gel No CTA 
Pb20 Gel No CTA 
Pb21 82 No EGDMA 
Pb22 80 0 
Pb23 Gel 4.1* 
Pb24 Gel 8.2* 
Pb25 26 No EGDMA 
Pb26 33 0.3 
Pb27 31 0.6 
Pb28 19 0.8 
Pb29 17 No EGDMA 
Pb30 18 0.2 
Pb31 17 0.4 
Pb32 14 1.5 
 
Antimicrobial Activity 
We next investigated the relationship between polymer structure and antimicrobial 
activity of polymers. The antimicrobial activity of the polymers was quantified as the lowest 
polymer concentration that completely inhibit bacterial growth, or the minimal inhibitory 
concentration (MIC), as the bacterial growth was determined by turbidity. The activity of 
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polymers against Gram-negative E. coli and Gram-positive S. aureus were used as model 
bacterium. Gram-positive bacteria possess a thicker peptidoglycan cell wall as compared to 
Gram-negative bacteria, while Gram-negative bacteria possess two (cytoplasmic and outer) 
membranes. These differences in the membrane structure can give rise to different behavior of 
membrane-active membranes, because the polymers need to penetrate these cell wall and 
membranes to reach the cytoplasmic membranes to exert antimicrobial effects. A list of MICs 
can be found in Table 2.7 and Appendix A.  
Effect of Polymer Composition 
Previous designs of amphiphilic random copolymers have utilized cationic/hydrophobic 
ratio to control antimicrobial behavior. Specifically, increased hydrophobic content has been 
linked to increased antimicrobial activity, though a saturation of hydrophobic groups can be 
reached. 70, 172-173 The insertion of hydrophobic polymer segments into the bacterial cell 
membrane causes membrane disruption and ultimately death, and thus greater hydrophobic 
composition imparts greater antimicrobial efficacy. Against E. coli, crosslinked and linear 
polymers had decreased MICs as mol% EMA increased. Linear polymer Pa1 (0% EMA) had an 
MIC of 208 (±72), which decreased to 63 µg/mL in Pb17 (32% EMA) and 31 µg/mL in Pc33 (47% 
EMA) (Figure 2.5a). Crosslinked polymers with 10% EGDMA showed a decrease from >1000 
µg/mL in Pa16 (0% EMA) to 63 µg/mL in Pb32 (26% EMA) and 12 µg/mL in Pc48 (42% EMA) 
(Figure 2.5a). Decreasing MIC values indicating increased antimicrobial efficacy with increasing 
hydrophobic content. However, MIC did not change significantly with hydrophobic content 
against S. aureus, as can be seen in Pa1 at 83 (±36) to Pc33 at 167 (±72), or Pa16 at 104 (±36) to 
Pc48 at 125 µg/mL (Figure 2.5b).  Lack of MIC change indicates hydrophobic compositional 
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changes did not affect antimicrobial efficacy against S. aureus. Previously S. aureus has been 
reported to be sensitive to the cationic charge density in copolymers, as opposed to 
hydrophobic density, due to differences in the outer bacterial membrane.72, 76 The lack of 
change in S. aureus antimicrobial activity with polymer composition suggests that cationic 
charge saturation occurs at 50 mol% MA. 
 
 
Figure 2.5. Hydrophobic content effect on antimicrobial activity of methacrylate random copolymers against (a) E. coli and b) S. 
aureus. Data points and error bars represent the average and s.d. from data in three independent experiments (n=3). 
Effect of EGDMA 
Crosslinked copolymers were designed with the intent to assess the effect of branched 
architecture on their antimicrobial activity as compared to linear architecture. While it is 
unlikely that crosslinked architecture was achieved by the incorporation of EGDMA due 
crosslink/chain ratios <2 (Table 2.6), EGDMA incorporation affected the antimicrobial behavior 
of the amphiphilic polymers, as seen as an example in Series b. Against E.coli, Pb29 (0% 
EGMDA)had an MIC of 417 (±144), which decreased to 250 µg/mL (Pb30, 1% EGDMA), 125 
(Pb32, 8% EGDMA) and 63 µg/mL in Pb32 (11 mol% EGDMA) (Figure 2.6a). However, MICs did 
not decrease with increasing EGDMA against S. aureus, as seen in the cases of Pb25-28 (125 
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µg/mL) (Figure 2.6b). There is therefore an apparent increase in antimicrobial activity against E. 
coli, but not S. aureus, due to EGDMA crosslinking. EGDMA incorporation may contribute to 
antimicrobial activity in several ways, such as increasing hydrophobic content, changes to 
molecular weight or dispersity, which will both be later discussed in detail. Series a lacked 
sufficient antimicrobial behavior to observe any such change, while the high hydrophobic 
content of Series c obscured any effect of EGDMA. 
 
 
Figure 2.6. EGDMA content effect on antimicrobial activity of methacrylate random copolymers against (a) E. coli and b) S. 
aureus. Data points and error bars represent the average and s.d. from data in three independent experiments (n=3).  
Effect of CTA, Molecular Weight and Dispersity 
Chain transfer agents were included in the polymer design to control the length of 
polymer arms, or the total degree of polymerization of the chain.  Length of polymer chains has 
previously been shown to be an important factor for antimicrobial behavior, specifically that 
increasing molecular weight in amphiphilic methacrylate copolymers enhances antimicrobial 
activity due to a total increase in the number of biologically active groups.69 In the case of linear 
and EGDMA containing copolymers, increasing MMP content decreased the MIC against E.coli 
(Figure 2.7). For example, the Pb30 (10 mol% MMP) showed an MIC of 250 µg/mL, but Pb22 
showed an MIC of 63 µg/mL (Figure 2.7a). Polymers synthesized with increasing amounts of 
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MMP resulted in shorter polymer chains with lower molecular weights. Note in this discussion, 
Mn determined by GPC will be used as comparative molecular weights, as absolute molecular 
weights cannot be determined by 1H NMR. MIC against E. coli decreased with increasing Mn for 
linear polymers, such as in Pb29 (2,530 g/mol) with an MIC of 417 (±144) µg/mL compared to 
Pb21 (8,064 g/mol) with an MIC of 63 µg/mL (Figure 2.7b). The same trend occurred for 
crosslinked polymers, where Pb30 (2,925 g/mol) with an MIC of 250 µg/mL decreases to 63 
µg/mL in Pb22 (11,662 g/mol) (Figure 2.7b). The MIC of Pb30 at Đ = 1.48 was 250 µg/mL, 
compared to Pb32 with Đ = 3.5 with an MIC of 63 µg/mL (Figure 2.7c). Beyond Đ ~2, MIC did not 
further decrease. This behavior suggests that while chain transfer agents have historically been 
used to control antimicrobial activity through molecular weight and dispersity in linear 
polymers, they are only effective in crosslinked polymers to the extent they can control 
dispersity. The inclusion of high molecular weight polymers in crosslinked systems may 
dominate the antimicrobial behavior or work synergistically with lower MW polymers. AMPs 
are monodispersed, and previous design platforms for amphiphilic methacrylate copolymers 
have attempted to mimic this through narrow molecular weight dispersity. However, the 
collective effect of multiple monodispersed polymers binding to the membrane may result in 
behavior that mimics a higher dispersity system. For instance, two AMPs overlapping at a 
bacterial membrane may have the apparent effect of a single AMPs with 2x their molecular 
weight. 
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Figure 2.7. Effect of polymer size on antimicrobial activity of methacrylate random copolymers against E. coli as a factor of (a) 
MMP mol% content, (b) molecular weight, (c) and polymer dispersity. Data points and error bars represent the average and s.d. 
from data in three independent experiments (n=3). 
Hemolytic Activity 
To investigate mammalian cell toxicity, the lysis of human red blood cells (hemolysis) by 
methacrylate polymers was assessed and quantified as the polymer concentration to induce 
50% hemoglobin release (HC50). For polymers which concentrations ≤1000 µg/mL did not 
achieve 50% hemolysis, the %hemolysis at 1000 µg/mL was recorded (Table 2.7).  
Effect of Polymer Composition 
One challenge with amphiphilic antimicrobial polymers is the toxicity to human cells due 
to non-specific hydrophobic interactions, disrupting mammalian cell membranes. Selecting a 
polymer composition that appropriately balances cationic and hydrophobic composition is 
necessary to achieve potent antimicrobial activity and low toxicity to mammalian cells. As the 
mole percentage of EMA was increased, the HC50 activity of linear and crosslinked polymers 
decreased (Figure 2.8a). For example, Pa1 (0% EMA) had at HC50 >1000 µg/mL, which 
decreased to 60 (±40) µg/mL in Pb17 (32% EMA), and further decreased to 6 µg/mL in Pc33 
(47% EMA). This indicates that increasing hydrophobic content results in increased hemolytic 
activity. Because increasing hydrophobic content increases both hemolytic and antimicrobial 
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activity, we sought to quantify the selectivity of polymers to bacterial cells over mammalian 
cells through a selectivity index (HC50/MIC against E.coli) (Table 2.7, Appendix A). Selective 
activity exists at ratios >1, though increases to selectivity by increasing ratio value are also of 
interest. The copolymers with the most potent antimicrobial activity (smallest MIC values) and 
largest SI are from Series b (~30% EMA), including Pb26, Pb21, and Pb25 (Table 2.7). Pb21 had an 
MIC of 63 µg/mL and an HC50 of 540 (±210) µg/mL, resulting in a selectivity index of 8.6.   Pb25 
had an MIC of 104 (±36) µg/mL and an HC50 of >1000 µg/mL (30% hemolysis at 1000 µg/mL), 
resulting in a selectivity index of 9.6. Pb26 had an MIC of 83 (±36) µg/mL and an HC50 of 600 
(±300) µg/mL, resulting in a selectivity index of 7.2. Pb21 and Pb25 are both linear polymers, 
while Pb26 contains 1% EGDMA. Pb25 and Pb26 have low Mn, 3,499 and 4,922 g/mol 
respectively, and low Đ, 1.5 and 1.86 respectively. Pb21 has a higher Mn of 8,064 g/mol, and a Đ 
of 2.2. Together, these properties suggest that selective polymers have 1) amphiphilic balance 
of approximately 30% hydrophobic-70% cationic side chains, 2) low molecular weights in the 
range of 3,000-8,000 g/mol, and 3) polymer dispersity of ≤ 2.2. This would also suggest that 
hyperbranching does not increase the selectivity of polymers compared to comparable linear 
polymers, as can be seen in the case of Pb25 and Pb26. 
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Figure 2.8. Hydrophobic content effect on RBC toxicity of methacrylate random copolymers. Data points and error bars 
represent the average and s.d. from data in three independent experiments (n=3). 
Table 2.7. Antimicrobial activity (MIC) and hemotoxicity (HC50) of Series b copolymers 
 
 
MIC (µg/mL) 
 
HC50 
(µg/mL) 
%Hemolysis 
at 1000 
µg/mL 
Selectivity Index 
(HC50/MIC E. 
coli) 
  E. coli S. aureus    
Se
rie
s b
 
Pb17 63 125 60 (±40) 72 (±5)% 0.95 
Pb21 63 125 540 (±210) 59 (±5)% 8.57 
Pb22 63 125 9 (±2) 91 (±7)% 0.14 
Pb25 104 (±36) 125 N/A 30 (±5)% 9.62 
Pb26 83 (±36) 125 600 (±300) 66 (±8)% 7.23 
Pb27 63 125 9 (±2) 82 (±5)% 0.14 
Pb28 63 125 13 (±6) 95 (±18)% 0.21 
Pb29 417 (±144) 250 N/A 22 (±7)% 2.40 
Pb30 250 167 (±72) N/A  19 (±9)% 4.00 
Pb31 125 167 (±72) 110 (±40) 64 (±10)% 0.88 
Pb32 63 208 (±72) 9 (±2) 90 (±5)% 0.14 
 
Effect of EGDMA  
The incorporation of EGDMA into methacrylate amphiphilic polymers has been shown 
capable of changing both antimicrobial and selectivity behavior, as earlier mentioned. 
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Increasing EGDMA content decreased HC50 values and the percentage hemolysis at 1000 
µg/mL. For example, Pb30 (1% EGDMA) has a HC50 >1000 µg/mL and 22 (±7)% hemolysis at 1000 
µg/mL, as compared to Pb32 which has a HC50 of 9 (±2) µg/mL and 90 (±5)% hemolysis at 1000 
µg/mL. This suggests that increasing EGDMA increases hemolytic activity. Due to the calculation 
of a low number of crosslinks per polymer chain (<2) discussed previously, it is unlikely that 
EGDMA results in changes to polymer architecture. However, the resulting increase to 
hemolysis with EGMDA incorporation may be due to contributions to total hydrophobic 
content, which is supported by the previous polymer composition section. To further 
investigate the effect of EGDMA on cell selectivity, selectivity indices were compared (Table 
2.7).  Increasing EGDMA content decreased SI, such as in the case of Pb25 (9.6, 0 mol% EGDMA) 
Pb26 (7.3, 1 mol% EGDMA), and Pb28 (0.2, 4 mol% EGDMA) This result suggest that EGDMA 
decrease the selectivity of polymers towards bacterial cells over mammalian cells. While 
antimicrobial activity of these polymers slightly increased (MIC decrease from 104 µg/mL to 63 
µg/mL), hemolytic activity increases significantly (HC50 >1000 µg/mL to 13 µg/mL).  Therefore, it 
is likely that a consequence of EGDMA incorporation on polymer structures may be responsible 
for increased selectivity discussed above, while EGDMA incorporation generally results in 
increasing toxicity.  
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Figure 2.9. EGDMA content effect on RBC toxicity shown as (a) HC50 or (b) hemolysis at 1000 µg/mL polymer, and (c) polymer 
selectivity. Data points and error bars represent the average and s.d. from data in three independent experiments (n=3). 
Effect of CTA, MW, Dispersity 
Chain transfer agents control the degree of polymerization, and consequentially 
molecular weight, which are a factor in hemolytic activity. High molecular weight polymers 
have previously been shown to have high hemolytic activity.69 The effect of CTA to control 
polymer chain length was utilized in this design. Increasing MMP content resulted in higher 
HC50 values, corresponding to decreased hemolytic activity. Additionally, increasing MMP 
increases the selectivity of polymers to bacterial cells over red blood cells, because of dramatic 
decreases in hemolytic activity rather compared to moderate decreases in antimicrobial 
activity. For example, the polymer Pb17 with 1% of MMP showed MIC of 63 µg/mL and HC50 of 
60 (±40) µg/mL, but the polymer Pb29 with 10% MMP showed MIC of 417 (±144) µg/mL and 
HC50 of >1000 µg/mL. As MMP content controls molecular weight, we would expect to find 
that hemolysis increases as molecular weight increases. However, at approximately the same 
molecular weight, linear polymer without EGDMA Pb21 (Mn = 8,064 g/mol) had an MIC of 63 
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µg/mL and HC50 of 540 (±210) µg/mL and hyperbranched polymer with 1% EGDMA Pb27 (8,191 
g/mol) showed MIC of 63 µg/mL and HC50 of 9 (±2) µg/mL.  This behavior may be attributed to 
greater polydispersity of Pb27, (Đ = 4.11) compared to linear Pb21 (Đ = 2.21) due to the larger 
population of high molecular weight polymers that are very hemolytic.   
  
Figure 2.10. Effect of polymer size on RBC toxicity: (a) HC50 dependence on mol% MMP, (b) cell selectivity dependence on mol% 
MMP, (c) HC50 dependence on molecular weight, and (d) HC50 dependence on dispersity. Data points and error bars represent 
the average and s.d. from data in three independent experiments (n=3). 
Discussion: Polymer Structure and Relationship with Antimicrobial and Hemolytic 
Activities 
In this study, we aimed to explore the effect of hyperbranched polymers on 
antimicrobial and hemolytic activity as compared to traditional linear antimicrobial 
counterparts. Antimicrobial and hemolytic assays suggest that the activity of polymers with 
hyperbranched architecture are not an improvement from linear architecture. Antimicrobial 
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activity is dominated by the degree of hydrophobicity from EMA composition, and possible 
contributions from EGDMA, and molecular weight (i.e. the total number of hydrophobic 
groups). The hemolytic activity of hyperbranched polymers is increased from linear polymers of 
similar molecular weight. We propose that the increased hemolytic activity of hyperbranched 
polymers is due increased dispersity, specifically the contribution of high molecular weight 
polymers that are highly hemolytic.69, 81  
The synthesis of hyperbranched polymers via free radical polymerization with 
crosslinking monomers was hypothesized to give rise to structures capable of mimicking the 
collective action of multiple AMP peptide chains at membrane surfaces. Based on the results of 
this study, we did not observe improved antimicrobial activity and selectivity in our 
hyperbranched polymers. We wonder if the resultant polymers are macromolecules which 
present multiple polymer chains as we initially designed. When we analyzed the data of 
polymer characterization, we found that, for the polymers which did not form gels during the 
polymerization, the number of crosslinkers in a polymer chain did not exceed 2. For example,  
Pb32 has DP of 14 determined by 1H NMR. Because EGDMA is 11 mol% relative to the total 
number of monomers (as determined by 1H NMR), one EGDMA molecule will be incorporated 
into every ~9 monomer units in a polymer chain.  Therefore, Pb30 (DP = 14) has 1.5 EGDMA 
molecules in a polymer chain. If polymers contain only 1 crosslink, they are architecturally 
linear polymers that are extended through the crosslinking monomer to a second linear 
polymer. Therefore, they can be thought of as a longer linear chain, with short portions of the 
backbone extending away from the main/longest polymer chain. If polymers contain 2 
crosslinks, they may suffer from restricted freedom of movement if both crosslinking 
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monomers associated in the same two chains, therefore having new architecture. However, in 
this study, the presence of 2 or more crosslinks resulted in polymer gelation, suggesting these 
conditions cannot be used to synthesize crosslinked polymers.  
This model would suggest that only two polymer chains are linked together on average, 
suggesting that the majority is linear polymers, and a small fraction of polymers containing a 
crosslinking monomer. Based on this, we propose that these polymers do not have 
appropriately high crosslinker concertation per “chain” (i.e. CTA) to mimic the collective 
behavior of multiple polymers for membrane activity. Therefore, while this study is able to 
deduce the effects of inclusion of a crosslinking monomer on biological activity, we do not feel 
it is able to conclude the effects of hyperbranched architecture on antimicrobial and hemolytic 
activity based on the polymer collective design. 
 
Figure 2.11. Theoretical structure of hyperbranched polymers by free radical polymerization with crosslinking monomers 
compared to the proposed structure of dilute crosslinked polymers that behavior as high molecular weight linear polymers. 
Conclusions 
In summary, amphiphilic primary ammonium copolymers composed of cationic 2-
aminoethyl methacrylate (AEMA), ethyl methacrylate (EMA), and ethylene glycol 
dimethacrylate (EGDMA), were synthesized by free radical polymerization and evaluated for 
their antimicrobial and hemotoxic activity. Despite the presence of crosslinking monomers, we 
propose that polymers were primarily linear in structure based on calculated crosslinker/CTA 
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ratios, likely due to combined effects of low concentration of crosslinking agents and low 
molecular weight/DP target to mimic natural AMPs.  While this approach is not an appropriate 
polymer model for the collective polymers responsible for membrane activity, these studies 
contributed and reinforced design factors for antimicrobial polymers. Antimicrobial and 
hemolytic activity both increased with percent hydrophobic composition and higher molecular 
weights. However, hemolytic activity is more sensitive to wider dispersity, suggesting 
mammalian cells may be more sensitive to high molecular weight polymers than bacterial cells.  
Additional research is necessary to determine polymer designs that appropriately mimic the 
behavior of multiples polymer on membranes in order to identify if multi-armed polymer 
architectures are a new tunable parameter for antimicrobial polymer designs.
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Chapter 3 4-Armed Star-shaped polymer Architecture for Antimicrobial and 
Hemolytic Activities  
Introduction 
The increasing number of antibiotic-resistant bacterium has stimulated research into 
the development of therapeutic alternatives for conventional antibiotics.174 While resistance 
has been increased at a growing rate175, new conventional antibiotics do not address the issue 
of antibiotic-resistance development. Instead, this approach attempts to replace drugs that 
have become obsolete with new drugs, effectively racing antibiotic development and antibiotic-
resistance. There is an emerging need for new antimicrobials that can overcome current 
resistance mechanisms and not contribute to the development of future resistances in bacteria. 
To that end, a recent approach has been the use of antimicrobial polymers which mimic host-
defense antimicrobial peptides found in the innate immune system.66-68 The barrier to clinical 
application of antimicrobial polymers has been the maintaining sufficient antimicrobial activity 
in the absence of mammalian cell toxicity.  
As previously discussed, cationic random amphiphilic polymers have been one such 
design platform to explore structural factors that mimic AMPs, including polymer composition 
and molecular sizes.155-165 Previous polymers have been primarily focused on tuning the balance 
of cationic and hydrophobic properties of the polymer in order to control selective membrane 
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activity. The cationic functionality of the polymer binds to the anionic bacterial cell membranes 
preferentially over more neutral mammalian membranes, followed by the insertion of 
hydrophobic groups into the lipid bi-layer to result in membrane disruption and ultimately 
cellular death. Achieving an optimal balance is often achieved by tuning polymer composition 
of cationic and hydrophobic monomers and has had good success in controlling polymer 
activities. However, we propose that further improvement of antimicrobial activity can be 
achieved by introducing multi-armed polymer architecture as a new tunable factor for polymer 
design. As we previously discussed in chapter 2, natural antimicrobial peptides are assembled 
to form pores on bacterial cell membranes or disrupt cell membrane structures. Therefore, we 
also hypothesize in this chapter that macromolecules presenting multiple antimicrobial polymer 
chains will show improved antimicrobial activity and selectivity. In the previous chapter, we 
attempted to synthesize hyperbranched polymers using crosslinking monomers by free radical 
polymerization but failed to achieve hyperbranched architecture. In this chapter, we will extend 
our approach to star-shaped polymers, which present a star-shaped structure with 4 polymer 
chains.  
To test the hypothesis, we investigated a star-shaped polymer architecture with 4 
polymer chains composed of cationic 2-aminoethyl methacrylate (AEMA) and ethyl 
methacrylate (EMA). The traditional antimicrobial polymer parameters of polymer composition 
and polymer size were explored within both architectures in order to examine each factors 
effect on antimicrobial and hemolytic activities. The ultimate goal of this study is to design 4-
armed polymers with increased antimicrobial activity due to the collective polymer effect, and 
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increased selectivity towards bacterial cells due to the high density of cationic charge, as 
compared to linear copolymer counterparts. 
Methods 
Materials 
Dichloromethane (DCM, Fisher Chemicals), hexane (Fisher Chemicals), trifluoracetic acid 
(TFA, Fisher Chemicals), methanol (MeOH, Fisher Chemicals), ethyl ether (Fisher Chemicals), 
copper (I) bromide (CuBr, Acros organics), 1,1,4,7,7-pentamethyldiethylenetriamine (PMDETA, 
Acros Organics), pentaerythritol tetrakis(2-bromoisobutyrate) (4f-BIB, Aldrich chemistry), and 
ethyl 2-bromo-2-methylpropionate (EBIB, Acros organics) were used as received. 
Tetrahydrofuran (THF, Fisher Chemicals) was dried over molecular sieves (3 Å). Ethyl 
methacrylate (EMA, Aldrich) was passed through a column of aluminum oxide (50-200 µm) to 
remove inhibitors prior to polymer synthesis. Boc-AEMA was synthesized as described in 
Chapter 2.   
Escherichia coli (E. coli ATCC 25922) and Staphylococcus aureus (S. aureus ATCC 25923) 
were used as model bacteria evaluate antimicrobial activity. Human red blood cells (RBCs) 
(leukocytes reduced adenine saline added) were obtained from the American Red Cross Blood 
Services Southeastern Michigan Region and used prior to the out date indicated on each unit. 
Mueller Hinton Broth (MHB, BD and Company ©) and phosphate buffered saline (PBS, pH=7.4, 
Gibco®) were prepared according to manufacturer instructions and sterilized prior to use.  
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Synthesis of Linear Methacrylate Copolymers by ATRP 
The synthesis of linear polymers via atom transfer radical polymerization (ATRP) was 
carried out following procedure modified from Dufresne.176 Monomers (Boc-AEMA and EMA, 
0.87 mmol, 20, 40 or 80 Eq) were dissolved in dry degassed THF (0.8 mL) with EBIB initiator (1 
Eq) in a N2 purged container. Concurrently, Cu(I)Br (1.1 Eq) and PMDETA (1.1 Eq) were dissolved 
in dry degassed THF (0.27 mL) in a second-round bottom flask, purged with N2. The 
monomer/initiator solution was transferred to CuBr/PMDETA solution via syringe under N2. 
Polymerization was carried out at 65 °C for 18 hours. The reaction was quenched by exposure 
to atmospheric oxygen, diluted with DCM (~2 mL) and passed through a neutral aluminum 
oxide column, followed by 8 mL of DCM to wash the column. Monomer conversion was 
confirmed by 1H NMR. Solvent was evaporated under reduced pressure, the polymer residue 
dissolved in DCM and precipitated twice in hexanes. Fine white particulates were dried under 
vacuum overnight. 1H NMR in CDCl3 was used to determine the degree of polymerization, 
composition and molecular weight of the boc-protected polymers. The degree of 
polymerization was determined by comparing integration of signal peaks from methylene in 
monomer side chains (~4 ppm) to that of the initiator methylene (~1.05 ppm) (1H NMR found in 
Appendix B). 
Removal of the boc protecting group to achieve a primary amine was performed by 
reacting polymers with trifluoracetic acid (TFA) for 20 minutes. A small amount of MMP was 
included to quench the formation of the carbo cations. TFA is harmful, and exposure to TFA 
should be limited. TFA was removed by blowing with nitrogen gas, which was subsequently 
passed through a NaOH solution. The polymer residue was dissolved in methanol (~0.5 mL) and 
 63 
the solution precipitated twice in diethyl ether, resulting in white particulates. The precipitate 
was dried under high vacuum and subsequently dissolved in water and lyophilized. 1H NMR in 
D2O was used to determine the monomer composition of final polymers. Overlapping peaks 
from both methyl and methylene signals of the initiator with monomer backbone and side 
chain peaks resulted in an inability to characterize degree of polymerization in the final 
polymer. 
Synthesis of 4-armed Methacrylate Copolymers by ATRP 
The synthesis of 4-armed methacrylate polymers via ATRP was carried out following 
procedure modified from Dufresne176, as described above with the replacement of EBIB 
initiator with 4f-BIB (1 eq). The concentration of Cu(I)Br (4.4 Eq) and PMDETA (4.4 Eq) were 
increased to reflect the number of active end groups, and the reaction time was decreased to 5 
hours. All other setup, reaction, and workup conditions remained the same as compared to 
linear polymer synthesis described above. 
Characterization of methacrylate polymers 
Gel permeation chromatography (GPC) analysis was performed using a Waters 1515 
HPLC instrument equipped with Waters Styragel (7.8 × 300 mm) HR 0.5, HR 1, and HR 4 
columns in sequence and detected by a differential refractometer (RI). Calibration curves were 
based on narrow dispersity polystyrene standards between 1,050-1,000,000 g/mol (Polymer 
Laboratories Ltd. And Polysciences, Inc.). Boc-protected polymers were characterized by gel 
permeation chromatography (GPC) to determine number average molecular weight (Mn) and 
weight-average molecular weight (Mw), and calculated dispersity (Đ).  
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Antimicrobial Activity 
The minimum inhibitory concentration (MIC) of polymers against E. coli (ATCC 25922) 
and S. aureus (ATCC 25923) was determined in a standard microbroth dilution assay according 
to the Clinical and Laboratory Standards Institute guidelines with suggested modifications by R. 
E.W Hancock Laboratory (University of British Columbia, British Columbia, Canada)169 and 
Giacometti et al.170 Bacteria was grown overnight (~18 hours) in MHB at 37 °C with orbital 
shaking (180 rpm), and used as an inoculum by diluting overnight culture in MHB to a 
concentration of OD600=0.1. The inoculated solution was then grown at 37 °C to the exponential 
phase (OD600= 0.5-0.7, 2 hours). Final dilution to OD600= 0.001, 2 x 105 CFU/mL, was made with 
MHB. Bacterial suspension (OD600= 0.001, 90 µL/well) was transferred to a 96-well sterile 
round-bottom polypropylene plate. Polymers were dissolved in 0.01% acetic acid to achieve 
stock concentrations of 20 mg/mL. Serial 2-fold dilutions of polymers were prepared from stock 
solutions in PBS and transferred to the 96-well sterile round-bottom polypropylene plate for a 
final concentration of 7.8-1,000 µg/mL (10 µL/well). PBS was used as a solvent control in place 
of polymer. Plates were sealed with parafilm and incubated for 18 hours at 37 °C without 
shaking. MIC was defined as the lowest concentration of polymers to completely inhibit 
bacterial growth, as indicated by lack visual of turbidity. Assays were repeated a minimum of 
three times in triplicate on different days.   
Hemolytic Activity 
Hemolysis, the lysis of human red blood cells (RBCs), was used to assess the toxicity of 
polymers to human cells. A 10% solution of human RBCs in PBS was centrifuged at 2000 rpm for 
5 minutes and washed with PBS x2 to remove initial hemoglobin. The number of RBCs in the 
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resulting solution was determined by counting chamber, and the solution diluted in PBS to give 
a final concentration go 3.33 x 108 cells/mL. After serial dilutions, polymers (10 µL) were 
transferred to a 96-well sterile round-bottom polypropylene plate, followed by the RBC 
suspension (90 µL). Plates were incubated 37 °C with orbital shaking (180 rpm) for 1 hour. 
Triton X-100 (0.1% v/v in water) was used as the positive lysis control and PBS used as a 
negative control. Following incubation, the plate was centrifuged at 2000 rpm for 5 minutes. 
The supernatant (5 µL) from each well diluted in PBS (100 µL) with thorough mixing in a 96-well 
flat-bottomed polystyrene plate. The absorbance of released hemoglobin (415 nm) was 
measured using a Varioskan Flash microplate reader (Thermo Fisher). The percentage hemolysis 
was determined relative to Triton X-100 (100%) and PBS negative control (0%). The polymer 
concentration causing 50% hemoglobin release (HC50) was determined, and the hemolysis (%) 
at the highest concentration of polymer (1000 µg/mL) was reported if below 50%. Assays were 
repeated a minimum of three times in triplicate. 
Results and Discussion 
Polymer Design and Synthesis 
In this study, we synthesized linear and 4-armed star-shaped polymers by atom transfer 
radical polymerization (ATRP). Polymer chain length was controlled by varying the feed mole 
ratio of monomers to initiator. For star-shaped polymers, boc-protected aminoethyl 
methacrylate (boc-AEMA) and ethyl methacrylate (EMA) are copolymerized using 
pentaerythritol tetrakis(2-bromoisobutyrate) as an initiator and CuBr/PMDTA catalyst/ligand,  
followed by deprotection of the boc-group using TFA to yield polymers with primary 
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ammonium groups (Figure 3.1). For linear polymers, ethyl 2-bromo-2-methylpropionate was 
used as an initiator.  
 
Figure 3.1. Synthesis scheme for linear and 4-armed methacrylate copolymers by ATRP. 
Conversion/Yield 
Following polymerization, the conversion of monomers to boc-protected polymers was 
determined by 1H NMR, and yield determined by weight. Polymer conversion was determined 
by the integration or absence of signal peaks from methylene on the unsaturated monomer 
double bond. Linear polymers were fully converted in the 18-hour reaction time, while star-
shaped polymers were fully converted in the 5-hour reaction time (Table 3.1). Boc-protected 
polymers were recovered by precipitation of DCM dissolved polymers in hexane with yields of 
62-87%. Previously linear amphiphilic methacrylate copolymers were recovered by 
precipitation DCM dissolved polymers in hexane at higher yields (80-100%, Chapter 2). The 
lower yield in this case, despite 100% conversion, is hypothesized to be due to interaction of 
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polymers with the aluminum oxide column used to remove the copper complex. Alternative 
copper complex removal methods could be used in attempts to increase yield, such as washing 
with H2O. Following deprotection, polymers were recovered with good yields of 85-94%.  
Table 3.1 Polymerization conversion and yield of boc-protected and deprotected linear and 4-armed methacrylate copolymer, 
determined by 1H NMR (conversion) and mass (yield). 
 
Monomer Feed 
Composition 
Target 
Total DP 
Conversion Boc-Protected 
Yield (%) 
Deprotected  
Yield (%) 
PL1 
100% Boc-AEMA 
20 100% 69 94 
PL2 40 100% 74 93 
PL3 80 100% 63 86 
PL4 70% Boc-AEMA-
30% EMA 
20 100% 71 89 
PL5 40 100% 66 91 
PL6 80 100% 67 86 
PL7 50% Boc-AEMA - 
50% EMA 
20 100% 70 92 
PL8 40 100% 62 89 
PL9 80 100% 71 90 
PS10 
100% Boc-AEMA 
20 100% 81 94 
PS11 40 100% 77 87 
PS12 80 100% 78 88 
PS13 70% Boc-AEMA-
30% EMA 
20 100% 73 86 
PS14 40 100% 72 90 
PS15 80 100% 75 90 
PS16 50% Boc-AEMA - 
50% EMA 
20 100% 77 90 
PS17 40 100% 87 89 
PS18 80 100% 74 88 
Composition 
Linear and 4-armed polymers were synthesized at three monomer compositions: 100 
mol% boc-AEMA, 70 mol% boc-AEMA-30 mol% EMA, and 50 mol% boc-AEMA-50 mol% EMA. 
Amphiphilic ratio, or the balance of cationic to hydrophobic groups, has previously been used 
to control antimicrobial and hemolytic activities. Since the goal of this project is to improve 
upon the linear architecture of antimicrobial polymers through the use of 4-armed star-shaped 
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architecture, it is important to examine how the inherent activity of each polymer chain is 
reflected in the activity of whole macromolecules (star-shaped polymers) through comparison 
of activity between the star-shaped polymers and linear (arm) polymers. Polymer composition 
was controlled by varying the monomer feed composition of boc-AEMA and EMA. The boc-
protected polymers were a good reflection of feed compositions (1H NMR found in Appendix B). 
For example, polymers designed with a monomer composition of 70% boc-AEMA resulted in 
74-78% boc-AEMA (linear) and 71-72% boc-AEMA (star-shaped) (Table 3.2). Following 
deprotection, the mole % of cationic monomer decreased slightly, suggesting preferential 
precipitation of hydrophobic polymers (1H NMR found in Appendix B). Polymers designed with 
70% boc-AEMA decreased to 69-71% boc-AEMA (linear) and 65-67% boc-AEMA (star-shaped) 
(Table 3.2). The ranges of monomer compositions were still considered is good reflection of 
molar monomer feed composition.
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Table 3.2. Monomer feed composition, boc-protected monomer composition, and deprotected monomer composition of linear 
and 4-armed methacrylate copolymers. 
  
Monomer Feed 
Composition (mol%) 
 Boc-Protected Polymers 
(mol%)  
 Deprotected Polymers 
(mol%) 
  Boc-AEMA EMA  Boc-AEMA EMA  AEMA EMA 
PL1 100 0  100 0 100 0 
PL2  100 0 100 0 
PL3  100 0 100 0 
PL4 70 30  74 26 69 31 
PL5  83 17 71 29 
PL6  78 22 70 30 
PL7 50 50  52 48 49 51 
PL8  59 41 51 49 
PL9  53 47 51 49 
PS10 100 0  100 0 100 0 
PS11  100 0 100 0 
PS12  100 0 100 0 
PS13 70 30  71 29 67 33 
PS14  70 30  65 35 
PS15  72 28 68 32 
PS16 50 50  51 49 43 57 
PS17  52 48 48 52 
PS18  54 46 49 51 
Polymer Characterization 
Degree of Polymerization, molecular weight and dispersity 
Monomer/initiator ratio was varied to synthesize polymers with target molecular sizes. 
In general, the monomer/initiator ratio is expected to be the degree of polymerization because 
of the nature of living polymerization. In 4-armed star-shaped polymers, the degree of 
polymerization was determined by comparing the integrated areas of signals from the initiator 
core to that of polymer side chains in 1H NMR spectra, providing the average degree of 
polymerization of total polymer arms.   
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In linear polymers, the DP of resultant polymers was not consistent with the target DP 
(Figure 3.2a); Polymers that targeted DP 20 resulted in DPs of 30-40, while polymers that 
targeted DP 80 resulted in DPs of 50-60 (Table 3.3). Target DP 40 polymers were closest to their 
goal with DPs of 37-53 (Table 3.3). On the other hand, the star-shaped polymers showed high 
DP than target DP (Table 3.3, Figure 3.2b). Molecular weights were calculated by DP and 
monomer composition (Table 3.2). Linear polymers were determined to be between 7,300-
14,400 g/mol (Table 3.2, Figure 3.2c), while star-shaped polymers were between 5,700-24,100 
g/mol (Table 3.2, Figure 3.2d), where the difference in MW was the factor of DP.  
Gel permeation chromatography was used to determine Mn, Mw and D of linear and 4-
armed copolymers. Linear polymers had Mn in the range of 5,000-10,300 g/mol and Mw in the 
range of 6,100-14,700 g/mol (Table 3.3). star-shaped polymers had Mn in the range of 5,000-
9,800 g/mol and Mw in the range of 6,900-14,800 g/mol (Table 3.3). Despite the controlled 
nature of ATRP, polymer dispersity (Đ) of the linear systems was larger than expected between 
1.23-1.43 (Table 3.3), with no apparent dependence on molecular weight of polymers (Figure 
3.3a). Star-shaped systems were slightly higher where Đ = 1.27-1.50 (Table 3.3, Figure 3.3b). 
The DP discrepancy and broad molecular distribution indicate that the polymerization was not 
controlled, and further optimization is necessary to obtain defined polymers.  
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Table 3.3. Size characterization of boc-protected linear and 4-armed methacrylate polymers by degree of polymerization, 
molecular weight, Mn, Mw, and Đ. 
  
DP 
(1H NMR) 
DP/Arm Molecular Weight 
(g/mol) (1H NMR) 
Mn (g/mol) 
(GPC) 
Mw (g/mol) 
(GPC) 
Đ 
(GPC) 
PL1 32 32 7,500 5,355 7,003 1.31 
PL2 37 37 8,642 7,342 9,749 1.33 
PL3 62 62 14,349 10,311 14,745 1.43 
PL4 30 30 6,153 5,248 6,577 1.25 
PL5 48 48 10,222 7,029 8,651 1.23 
PL6 60 60 12,386 10,269 13,889 1.35 
PL7 41 41 7,309 5,033 6,149 1.22 
PL8 53 53 9,814 6,138 7,967 1.30 
PL9 51 51 9,102 7,563 10,598 1.40 
PS10 29 7.3 7,353 5,000 6,922 1.38 
PS11 45 11.3 11,005 6,690 9,441 1.41 
PS12 91 22.8 21,506 9,335 13,588 1.46 
PS13 39 9.8  8,344 5,332 7,032 1.32 
PS14 62 15.5 12,763 7,394 10,564 1.43 
PS15 98 24.5 19,972 9,828 14,752 1.50 
PS16 29 7.2 5,713 6,421 9,308 1.45 
PS17 55 13.8 10,275 6,612 9,192 1.39 
PS18 133 33.3 24,111 9,490 12,084 1.27 
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Figure 3.2. Degree of polymerization and molecular weight evaluation. Comparison of theoretical DP based on polymer design 
and calculated DP by H NMR in linear (a) and 4-armed (b) polymers. Molecular weights determined by calculated DPs by H NMR 
in linear (c) and 4-armed (b) polymers. 
 
Figure 3.3. Polymer dispersity of (a) linear and (b) 4-armed star polymer systems. 
Antimicrobial Activity 
Next, we sought to investigate the relationship between polymer structure and 
antimicrobial efficacy. The antimicrobial activity of the polymers was quantified as the lowest 
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polymer concentration that completely inhibit bacterial growth, or the minimal inhibitory 
concentration (MIC), as the bacterial growth was determined by turbidity. The activity of 
polymers against Gram-negative E. coli and Gram-positive S. aureus were used as model 
bacterium. Gram-positive bacteria possess a thicker peptidoglycan cell wall as compared to 
Gram-negative bacteria, while Gram-negative bacteria possess two (cytoplasmic and outer) 
membranes. These differences in the membrane structure can give rise to different behavior of 
membrane-active membranes, because the polymers need to penetrate these cell wall and 
membranes to reach the cytoplasmic membranes to exert antimicrobial effects. 
Effect of Polymer Composition 
 Cationic/hydrophobic ratio has been a way for previous designs of amphiphilic random 
copolymers to control antimicrobial efficacy. Increasing hydrophobic ratio increases 
antimicrobial activity70, 172-173, as the hydrophobic segments inserts into the bacterial 
membrane to cause disruption and consequential cellular death. Against E. coli, increasing EMA 
content in linear and 4-armed polymers resulted in reduced MICs  . For example, PL1 (100% 
AEMA-0% EMA) had an MIC of >1000 µg/mL, which reduced to 63 µg/mL in PL4 (70% AEMA-
30% EMA), and further to 16 µg/mL in PL7 (50% AEMA-50% EMA) (Figure 3.4a). The same 
behavior is evident in PS10 (>1000 µg/mL), PS 13 (63 µg/mL), and PS 16 (16 µg/mL) (Figure 3.4a). 
Against S. aureus, increased EMA content slightly increased MICs in both linear and 4-armed 
polymers. PL2 had a MIC of 63 µg/mL which increased to 125 µg/mL PL5 and PL7 (Figure 3.4b). 
PS11 had an MIC of 63 µg/mL which increased to 250 µg/mL in PS17 (Figure 3.4b). S. aureus has 
previously been reported to be sensitive to cationic charge density in copolymers, as opposed 
to hydrophobic content, which is supported in this study. 
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Table 3.4. Antimicrobial activity of linear and star-shaped polymers as measured by MIC against E. coli and S. aureus. 
 MIC (µg/mL) 
 E. coli S. aureus 
PL1 >1000 63 
PL2 250 63 
PL3 250 83 (±36) 
PL4 63 125 
PL5 63 125 
PL6 52 (±18) 83 (±36) 
PL7 16 125 
PL8 16 125 
PL9 16 208 (±72) 
PS10 >1000 63 
PS11 >1000 63 
PS12 >1000 63 
PS13 63 63 
PS14 31 104 (±36) 
PS15 31 104 (±36) 
PS16 16 250 
PS17 16 250 
PS18 16 250 
 
  
Figure 3.4. Hydrophobic content effect on antimicrobial activity of linear and 4-armed star methacrylate random copolymers 
(target DP 20) against (a) E. coli and b) S. aureus. Data points and error bars represent the average and s.d. from data in three 
independent experiments (n=3). 
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Effect of Polymer Size 
Polymer size (i.e. degree of polymerization, molecular weight) has been previously 
shown to be an important factor in antimicrobial activity. Specifically, high molecular weight 
polymers have been shown to increase antimicrobial efficacy as compared to lower molecular 
weight polymers of similar composition, due to an increase in the total number of biologically 
active groups.69 In linear methacrylate random copolymers in the range of 6,000-12,400 g/mol, 
molecular weight did not significantly alter MIC behavior. This can be seen in PL4 (6,153 g/mol) 
had an MIC of 63 µg/mL as compared to PL6 (12,386 g/mol) which had an MIC of 52 (±18) 
(Figure 3.5a). In cationic homopolymer, there was a decrease in MIC from >1000 µg/mL in PL1 
(7,500 g/mol) to 250 µg/mL in PL2 (8,642 g/mol) and PL3 (14,349 g/mol) (Table 3.4). Polymers 
with 4-armed structure exhibited a decrease in MIC with increasing molecular weight, such as in 
the case of PS13 (8,344 g/mol) with an MIC of 63 µg/mL to PS15 (19,972 g/mol) with an MIC of 
31 µg/mL. These results indicate that increasing the number of active groups through increased 
molecular weight can help improve antimicrobial efficacy, though this approach appears 
minimally effective within the molecular weight ranges of 5,000-20,000 g/mol, which a 
maximum decrease of 1/2 MIC concentration. 
Polymer dispersity may also be a factor for consideration in antimicrobial activity, as it is 
related to molecular weight. While AMPs are monodispersed, polymer systems are the 
cumulative effect of polymers of a range of molecular weights on bacterial membranes. In 
linear polymers, within the range of Đ = 1.25-1.35, dispersity did not alter MIC values. This can 
be seen in PL4 (Đ = 1.25) had an MIC of 63 µg/mL as compared to PL6 (Đ = 1.35) which had an 
MIC of 52 (±18) (Figure 3.5b). In the case of 4-armed polymers, greater dispersity decreased 
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MICs. PS13 (Đ =1.32) had an MIC of 63 µg/mL which decreased in PS15 (Đ =1.5) to a MIC of 31 
µg/mL (Figure 3.5b). It is interesting to note that polymers with greater dispersity (PS15, PS14) 
also had higher molecular weights. However, polymers with low molecular weight with high 
dispersity, such as PS16 (5,713 g/mol, Đ =1.45) have similar activity to high molecular weight 
polymers with low dispersity, such as PS18 (24,111 g/mol, Đ =1.27). Akin to the previous 
discussion, while in some cases dispersity did increase antimicrobial activity, it was only 
increased by a factor of 2 (MIC). 
 
Figure 3.5. Effect of polymer size and dispersity on antimicrobial activity against E. coli of methacrylate random copolymers 
(70% AEMA-30% EMA) against E. coli as a factor of (a) molecular weight by 1H NMR and (b) polymer dispersity. Data points and 
error bars represent the average and s.d. from data in three independent experiments (n=3).  
Effect of 4-armed vs Linear Architecture 
The purpose of this study was to examine the antimicrobial efficacy of 4-armed 
polymers compared to linear polymers, with the goal of improving antimicrobial efficacy due to 
a collective action of multiple polymer chains on the bacterial membrane. The theory of this 
study is that 4-armed architecture can mimic the collection of multiple polymer chains (i.e. 4) 
Therefore, it is necessary to compare 4-armed polymers with arm lengths equal to the total DP 
of linear polymers.  The best comparison of antimicrobial activity can be seen in the case of 
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polymers designed at 70% AEMA-30% EMA, which demonstrates moderate antimicrobial 
activity.PS15 has a total DP of 98, where each arm has a DP of 24.5, with a composition of 68% 
AEMA-32% EMA (Table 3.2, Table 3.3).  There PS15 is a representation of the collection of 4 
polymers of DP 24.5. PL4, with a DP of 30 and a composition of 69% AEMA-31% EMA, is 
therefore an appropriate linear analog to discuss the impact of 4-armed architecture (Table 3.2, 
Table 3.3). PS15 has an MIC of 31 µg/mL, compared to PL4 with an MIC of 63 µg/mL against E. 
coli (Table 3.4). This increase in the activity is not significant considering that the MIC values 
were determined by 2-fold dilution. This indicates that the collection of multiple polymer chains 
into a macromolecule has no have any significant enhancement in their antimicrobial efficacy 
against E. coli compared to the linear polymer. In polymers with 100% AEMA composition, 4-
armed architecture does not affect MIC, such as in PL1 (DP 32) and PS12 (total DP 91, arm DP 
22.8) which both have an MIC of >1000 µg/mL against E. coli (Table 3.4). Polymers with 50% 
AEMA-50% EMA composition have an increased MIC against S. aureus in 4-armed polymers, 
where PS18 (DP 133, arm DP 33.3) has an MIC of 250 µg/mL compared to PL7 (DP 41) with an 
MIC of 125 µg/mL. (Table 3.4). However, the efficacy against E. coli is unaffected, where PS18 
and PL7 both have an MIC of 16 µg/mL (Table 3.4). For the activity of polymers against S. 
aureus, in similar to E. coli, these star-shaped polymers and linear analogues did not show any 
significant difference in the MIC values. These results suggest that the 4-arm star-shaped 
structure does not improve the activity of polymers.  
To further examine the effect of 4-armed architecture on their antimicrobial activity, , 
we compared the antimicrobial activity of linear and 4-armed polymers of comparable total DPs 
and molecular weight. If the MIC of these polymers is same, the antimicrobial activity of 
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polymers is determined by the polymer size, but not the shape. Within the composition of 70% 
AEMA-30% EMA, PL6 (12,385 g/mol) and PS14 (12,763 g/mol) have the similar molecular 
weights (Table 3.3).  PS14 has a lower MIC of 31 µg/mL as compared to PL6 which has an MIC of 
63 µg/mL against E. coli (Table 3.4). The increase in the activity is not significant.  PL8 (9,814 
g/mol) and PS17 (10,275 g/mol) which have similar molecular weights and compositions of 50% 
AEMA-50% EMA (Table 3.2, Table 3.3), have MICs of 16 µg/mL against E. coli (Table 3.4). For the 
activity of polymers against S. aureus, the star-shaped and linear copolymers did not show any 
difference in their activity. These results indicate that 4-armed star and linear architectures do 
not significantly affect the antimicrobial activity of polymers.  
Hemolytic Activity 
To investigate mammalian cell toxicity, the lysis of human red blood cells (hemolysis) by 
methacrylate polymers was assessed and quantified as the polymer concentration to induce 
50% hemoglobin release (HC50). For polymers which concentrations ≤1000 µg/mL did not 
achieve 50% hemolysis, the %hemolysis at 1000 µg/mL was recorded (Table 3.5). 
Effect of Polymer Composition 
Non-specific hydrophobic interactions with mammalian cells has been a major challenge 
for amphiphilic antimicrobial polymers. Therefore, selecting polymer compositions that balance 
cationic and hydrophobic functionalities is critical to achieve both potent antimicrobial activity 
and low mammalian cell toxicity. In both linear and 4-armed polymers, as EMA content 
increases, HC50 values decrease (Table 3.5), indicating greater toxicity with increasing 
hydrophobic content. PL2 had a HC50 value of >1000 µg/mL, which decreased to 414 (±16) 
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µg/mL in PL5 (70% AEMA-30% EMA), and further decreased to 4.5 (±0.4) µg/mL in PL8 (50% 
AEMA-50% EMA) (Figure 3.6). In 4-armed polymers, PB11 had HC50 value of >1000 µg/mL, which 
decreased to 2.8 (±0.4) µg/mL in PB14 (70% AEMA-30% EMA) and maintained comparable HC50 
value of 3.1 (±0.2) µg/mL in PB17 (Figure 3.6). This behavior may indicate a hydrophobic toxicity 
saturation in 4-armed polymers at 30% EMA. Linear polymers with compositions of 70% AEMA-
30% EMA demonstrate the best selectivity towards bacterial cells, specifically PL5 with a SI of 
6.57 (Table 3.5). However, 4-armed polymers have comparably low selectivity ratios in both 
30% EMA and 50% EMA compositions, due to the highly hemolytic nature of these polymers. 
PB18 demonstrate the best selectivity with an SI of 0.26 (Table 3.5), which as the SI <1, does not 
indicate selective behavior.
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Table 3.5. Hemolytic activity and selectivity of linear and 4-armed methacylrate copolymers.  
 
HC50 
(µg/mL) 
%Hemolysis at 
1000 µg/mL 
Selectivity Index (SI) 
(HC50/MIC E. coli) 
PL1 >1000 46 (±5) No HC50/No MIC 
PL2 >1000 29 (±6) No HC50 
PL3 >1000 44 (±7) No HC50 
PL4 369 (±56)  5.86 
PL5 414 (±16)  6.57 
PL6 71 (±23)  1.37 
PL7 6.9 (±0.5)  0.43 
PL8 4.5 (±0.4)  0.28 
PL9 2.9 (±0.2)  0.18 
PS10 >1000 15 (±2) No HC50/No MIC 
PS11 >1000 43 (±6) No HC50/No MIC 
PS12 551 (±18)  No MIC 
PS13 10 (±2)  0.16 
PS14 2.8 (±0.4)  0.09 
PS15 3.6 (±0.9)  0.12 
PS16 2.7 (±0.1)  0.17 
PS17 3.1 (±0.2)  0.19 
PS18 4.2 (±0.6)  0.26 
 
 
Figure 3.6. Hydrophobic content effect on RBC toxicity of methacrylate random copolymers. Data points and error bars 
represent the average and s.d. from data in three independent experiments (n=3). 
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Effect of Polymer Size 
 Molecular weight has been previously reported to affect hemolytic behavior, specifically 
where high molecular weight polymers have high hemolytic activity. 69 Linear polymers 
between 5,000-10,000 g/mol had similar hemolytic activity, as in the case of PL4 (6,153 g/mol) 
with an HC50 of 369 (±51) µg/mL and PL5 (10,222 g/mol) with an HC50 of 414 (±16) µg/mL 
(Figure 3.7a). Increasing molecular weight beyond 10,000 g/mol resulted in decreased HC50, 
such as in PL6 (12,386 g/mol) decreasing to 71 (±23) µg/mL (Figure 3.7a). 4-armed polymers 
also had a decrease in HC50 with increasing molecular weight, where PS13 (8,344 g/mol) had an 
HC50 of 10 (±2) µg/mL which decreased to 2.8 (±0.4) µg/mL in PS14 (12,763 g/mol) (Figure 3.7a). 
Alternatively, polymer dispersity may also contribute to hemolytic activity, because more 
disperse systems may contain only a small fraction of high molecular weight polymers that 
could significantly contribute to RBC membrane disruption. Indeed, as dispersity increases in 
linear polymers, HC50 decreases, such as in the case of PL5 (Đ = 1.23) at 414 (±16) µg/mL and PL6 
(Đ = 1.35) at 71 (±23) µg/mL. Increasing dispersity also contributes to hemolytic activity in 4-
armed polymers, where HC50 values decreased from 10 (±2) µg/mL in PS13 to 2.8 (0.4) µg/mL in 
PS14. Dispersity beyond 1.4 does not appear to significantly impact hemolytic activity, as seen in 
PS15.   
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Figure 3.7. Effect of polymer size on RBC toxicity: (a) HC50 dependence on molecular weight determined by 1H NMR and (b) HC50 
dependence on dispersity. Data points and error bars represent the average and s.d. from data in three independent 
experiments (n=3). 
Effect of 4-armed vs Linear Architecture 
While the goal of this study was to utilize 4-armed polymers to enhance antimicrobial 
activity as compared to linear polymers, the same collective chain mechanism which we 
proposed to act against bacterial membranes may also act against mammalian cell membranes. 
Therefore, it is necessary to compare 4-armed star polymers with comparable arm DPs to linear 
DPs to assess the collective action of multiple chains working together in a macromolecule. PL4 
(DP=30) has an HC50 of 369 (±56) µg/mL (Table 3.5). However, PS15 with arm DP = 24.5, which is 
close to PL4, has an HC50 of 3.6 (±0.9) (Table 3.5), indicating significant enhancement in 
hemolytic activity.  This enhancement of hemolytic activity by 4-armed architecture is apparent 
in all polymer compositions. PL1 (DP = 32) has an HC50 of >1000 µg/mL, which his reduced to 
551 (±18) µg/mL in PS12 (arm DP = 22.8), and PL7 (DP = 41) has an HC50 of 6.9 (±0.5) µg/mL 
which is reduced to 4.2 (±0.6) µg/mL in PS18 (arm DP = 33.3 (Table 3.5)). This increased in 
hemolytic activity causes decreased selectivity ratios. For example, PL4 has a selectivity of 5.86, 
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which is reduced to 0.12 in PS15 (Table 3.5). This suggests that 4-armed architecture is 
responsible for decreasing selectivity of polymers towards bacteria over mammalian cells.  
To verify that this effect was due to differences in polymer architecture and not 
differences in polymer size, polymers with comparable total DPs and molecular weights were 
compared. For example, PL6 has a molecular weight of 12,385 g/mol (D= 1.35) compared to 
PS14 with a molecular weight of 12,763 (D=1.43) (Table 3.5). However, PL6 has a HC50 of 71 
(±23) µg/mL, compared to PS14 with a 2.8 (±0.4) µg/mL HC50 (Table 3.5). This trend is also 
apparent in PL8 (9,814 g/mol) and PS17 (10,275 g/mol), where PL8 has a HC50 of 4.5 (±0.4) 
µg/mL and PS17 has an HC50 of 3.1 (±0.2) µg/mL. These results indicate that the increase in 
hemolytic behavior is not the result of increased molecular weight, but rather suggests that a 
macromolecule containing multiple polymer chains disrupts mammalian cell membranes more 
effectively than individual linear polymers of comparable properties (i.e. composition, size).  
Discussion: Membrane Sensitivity to 4-Armed Polymers 
In this study, we sought to improve antimicrobial properties of amphiphilic copolymers 
through 4-armed architecture that may mimic the collective activity of multiple polymers 
attached to a bacterial membrane. Additionally, we hypothesized that higher density of cationic 
charge on 4-armed polymers would result in improved selectivity. In this study, we saw a slight 
increase in antimicrobial efficacy in 4-armed polymers as compared to linear polymers, 
suggesting that 4-armed structure can simulate the effect of multiple polymers accumulated on 
the membrane surface necessary for disruption. However, we also found that 4-armed 
polymers were significantly more hemolytic than linear polymers, and less selective than linear 
polymers. This hemolytic activity was observed in polymers of comparable composition, 
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molecular weight and dispersity, which suggests that the differences in hemolytic activity is the 
result of architecture. Therefore, the result suggests that 4-armed star-shaped polymer 
structure is not effective in improving the antimicrobial activity and selectivity. Previous 
research on antimicrobial peptides has proposed that pore formation in membranes needs 4-11 
polymers to occur,166-167 where peptide chains are supposed to aligned in the pore structure. 
From our results, 4 polymer chains may not be sufficient to form pores in bacterial membranes. 
Further studies that explore the use of polymers with more arms and different design of 
polymer structures would be useful in improving the activity of polymers.  
Conclusions 
In summary, amphiphilic primary ammonium copolymers composed of cationic 2-
aminoethyl methacrylate (AEMA) and ethyl methacrylate (EMA) were synthesized by ATRP with 
linear or 4-armed initiators and evaluated for their antimicrobial and hemotoxic activity.  
Antimicrobial activity was a factor of polymer composition, size, and architecture (4-armed vs 
linear). Specifically, polymers with 4-armed architecture had decreased MICs by comparison to 
linear polymers against E. coli. However, 4-armed polymers were significantly more hemolytic 
than linear polymers of comparable designs, and therefore had reduced selectivity towards 
bacterial cells over mammalian cells. Further studies are necessary to evaluate this proposed 
mechanism but may provide useful experimental insight into the number of polymers necessary 
for bacterial membrane pore formation, and a new way to control amphiphilic polymer 
selectivity.  While this study indicates that linear polymers are preferable design to 4-armed 
polymers due to their hemolytic activity, the increase of antimicrobial activity by 4-armed 
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architecture does prove multi-armed polymers could provide a new tunable parameter for 
polymer design if mammalian cell toxicity is overcome.
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Chapter 4 Solution-Mediated Modulation of Bacterial Biofilm Formation by 
Synthetic Polymers 
Introduction 
Synthetic surfaces of medical devices and implants are susceptible to microbial 
colonization and biofilm formation177-181, which contribute to at least 60% of healthcare-
acquired infections.182 Biofilms are difficult to treat by antibiotics, due to reduced metabolic 
activity and poor antibiotic penetration, which can also results in sub-lethal exposure and 
contribute to resistance development.26, 183 Additionally, biofilms are physically robust, and 
difficult to remove mechanically. Specifically, Pseudomonas aeruginosa frequently develops 
into biofilms and consequently chronic infections of the respiratory system, especially in 
immunocompromised patients.184-186 The prevention of biofilm formation is a primary challenge 
in modern biomaterials science in order to prevent chronic infections. It is therefore critically 
important to better understand the factors that govern biofilm formation and growth in order 
to create effective solutions to biofilm colonization. 
The long-term goal of this study is to develop a new effective method to address the 
challenge of P. aeruginosa biofilm-associated infections. The main-stream approach in the 
general area of anti-biofilm materials is to modify device surfaces with antibacterial or anti-
fouling polymers, which kill bacteria on contact or effectively repel them.111-116, 119-121 However, 
while some recent approaches show promising results, it has been long-term scientific and 
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technical challenges to generate surface materials that can inherently overcome the 
sophisticated biological adhesion mechanisms of bacteria as well as meet requirements for use 
in products in terms of efficacy and manufacturing. In practice, once exposed to physiological 
conditions, modified surfaces suffer from a short lifetime due to protein and cell accumulations, 
while regenerative surfaces are of recent interest in the field.122-123 In addition, most 
approaches require surface chemistries on existing products, which are generally chemically 
inert, and some products are not tolerant to chemical exposures.  These problems lead us to 
explore a new bacterial target and an alternative approach to regulate biofilm formation.  To 
that end, we hypothesize that the surface properties of planktonic bacteria in solution can be 
targeted to modulate bacterial aggregation/adhesion and thus prevent biofilm formation. 
Traditionally, polymers have been modified by multiple ligands that bind to bacterial cell 
surfaces, which block adhesion of bacteria to host cell ligands.187-189 Instead, what if bacterial 
surfaces were modified by adhesion of polymers to change their physicochemical and/or 
solution properties such that the bacteria cannot effectively attach on material surfaces?  
In academic research and industrial settings, many applications of polymers have been 
reported for their physical and biological efficacies through the direct interactions between 
polymers and bacteria. For example, the bacterial surface modification by cationic polymers 
and subsequent aggregate formation or flocculation have been utilized to separate bacteria 
from solution for water purification and bioreactors.190-192 These polymers exploit the 
electrostatic interaction with negatively charged bacterial cell surfaces, which causes surface 
neutralization of bacterial surfaces, electrostatic patching and polymer bridging of bacterial 
cells, resulting in macroscopic aggregates or precipitates.193-195 However, it remains unclear if 
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such polymer-induced aggregates favor the formation of mature biofilms or rather prevent it, 
while it may be intuitive that they may pre-set bacterial assembly for mature biofilm structures. 
Similarly, previous studies used cationic polymers as a bacteria sequestrant, which causes 
clustering of bacteria in solution, triggering quorum sensing cell-cell communications.196-197 
While these studies elegantly demonstrate translation of polymer-mediated cell clustering to 
biological response of bacteria, it is not clear if bacteria clusters in solution would contribute to 
biofilm formation or not.155 There is a gap in our knowledge on how the polymer-bacteria 
interactions modulate biofilm formation. Such knowledge is critical to design and develop new 
anti-biofilm materials. 
The mechanism of biofilm formation consists of several stages, including bacterial 
attachment to the surface, micro-colony formation, the production of extracellular matrix, and 
ultimately the formation of a mature biofilm.198-199 The biofilm formation is orchestrated 
between bacteria on surfaces, involving changes in gene expression, spatial arrangement of 
bacteria and extracellular biopolymers, cell-cell communications, and timings of these 
events.200 This natural mechanism of biofilm formation has been evolutionarily optimized to 
construct robust biofilms. This led us to hypothesize that disrupting the natural behavior of 
planktonic bacteria may cause sub-optimal changes in the biofilm development process, leading 
to decreased biofilm accumulation. 
In this study, we take a step forward to understanding the polymer-bacteria interactions 
that govern biofilm formation toward the development of anti-biofilm polymers that exploit 
such interactions as our long-term goal. Specifically, because of its use in many applications 
already, this study is a first and important step to understand how cationic polymers induce 
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bacterial aggregates in solution and how the aggregates contribute to biofilm formation or 
prevention. Particularly, the purpose of this study is to provide foundational knowledge to 
guide future anti-biofilm approaches rather than elucidating the molecular mechanism of 
biofilm formation. Pseudomonas aeruginosa PAO1 was chosen as a model bacterium for this 
study because of its nature as an opportunistic pathogen, which frequently develop into 
biofilms and consequently chronic infections.184 We propose that cationic polymers used in this 
study result in concentration dependent suppression of biofilm development by planktonic 
bacteria sequestration.   
Methods 
Materials 
Tryptic Soy broth (TSB, Thermo Scientific Oxoid™), Mueller Hinton broth (MHB, BD and 
Company ©), and phosphate buffered saline (PBS, pH=7.4, Gibco®) were prepared according to 
manufacturer instructions and autoclave sterilized prior to use. SYTO 9 and propidium iodide 
(PI) nucleic acid stains (Molecular Probes, OR) were used as prescribed by the product manual 
at 1.5 µL/mL. Crystal violet (Sigma-Aldrich) was diluted in Millipore water to a working 
concentration of 0.01% (wt/vol). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolilum 
bromide, Thermo Scientific) was diluted in Millipore water to working concentration of 0.3% 
(wt/vol). 
Polyethylene glycol (PEG, average Mn = 6,000 g/mol) and polyethylenimine (branched, 
Mn= ~60,000 g/mol by GPC) were used as received from Acros Organics™. Poly[(3-
methacryloylamino)propyl] trimethylammonium chloride (P-1) and poly(2-acrylamido-2-
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methylpropane sulfonic acid) (P-2) were synthesized by RAFT polymerization using a modified 
literature procedure2 and characterized by 1H NMR and GPC (Appendix C). Stock solutions were 
prepared at 10 mg/mL in 0.01 % acetic acid). Further P-1 stock solutions were prepared by ten-
fold dilutions in PBS (1000, 100, 10 µg/mL). 
Pseudomonas aeruginosa (P. aeruginosa) PAO1 was received from Dr. Chuanwu Xi 
(Environmental Health Science, University of Michigan). P. aeruginosa cultures were prepared 
by suspension of a bacteria colony in TSB, collected from agar plate (<5 days old). Cultures were 
grown overnight (18 hours) at 37 °C at 180 rpm. Further preparations are as noted in 
subsequent methods. 
Antimicrobial Activity: MIC Assay 
The minimum inhibitory concentration (MIC) of polymers against P. aeruginosa (PAO1) 
was determined in a standard microbroth dilution assay according to the Clinical and 
Laboratory Standards Institute guidelines with suggested modifications by R. E.W Hancock 
Laboratory (University of British Columbia, British Columbia, Canada)169 and Giacometti et al.170 
P. aeruginosa was grown overnight (~18 hours) in TSB at 37 °C with orbital shaking (180 rpm), 
and used as an inoculum by diluting overnight culture in TSB to a concentration of OD600=0.1. 
The inoculated solution was then grown at 37 °C to the exponential phase (OD600= 0.5-0.7, 2 
hours). Final dilution to OD600= 0.001, ~4 x 106 CFU/mL, was made with TSB. Bacterial 
suspension (OD600= 0.001, 90 µL/well) was transferred to a 96-well sterile round-bottom 
polypropylene plate. Polymers were dissolved in 0.01% acetic acid to achieve stock 
concentrations of 20 mg/mL. Serial 2-fold dilutions of polymers were prepared from stock 
solutions in PBS and transferred to the 96-well sterile round-bottom polypropylene plate for a 
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final concentration of 7.8-1,000 µg/mL (10 µL/well). PBS was used as a solvent control in place 
of polymer. Plates were sealed with parafilm and incubated for 18 hours at 37 °C without 
shaking. MIC was defined as the lowest concentration of polymers to completely inhibit 
bacterial growth, as indicated by lack visual of turbidity. Assays were repeated a minimum of 
three times in triplicate on different days.  
Growth Curve Assay 
The effect of polymers on P. aeruginosa growth was assessed by optical density (OD600). 
Disposable polystyrene cuvettes were sterilized by soaking in 70% EtOH solution for 1 hour and 
air dried. P. aeruginosa overnight cultures were diluted in TSB to desired concentration of 
OD600= 0.001. A solution of bacterial suspension (OD600= 0.001, 900 µL) and stock polymer (PEG, 
P-1 or P-2, 100 µL) was prepared in cuvettes, and cuvettes secured with parafilm to prevent 
contamination. Final polymer concentrations were 1,000 µg/mL or 100 µg/mL after dilution in 
the bacteria suspension. Solutions were incubated at 37 °C with shaking (180 rpm) except when 
removed for time of measurement. The optical density (OD600) of dispersions were measured 
by optical density using a visible diode array spectrophotometer (WPA S800 Spectrawave, 
Biochrom). Measurements were taken at 2 and 4 hours, and then once an hour through 10 
hours, and a final point taken at 18 hours.  Triplicate measurements were carried out on 
separate days.  
Flocculation Assay 
The effect of polymers on bacteria aggregation and/or flocculation was assessed by 
optical density (OD600). Disposable polystyrene cuvettes were sterilized by soaking in 70% EtOH 
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solution for 1 hour and air dried. P. aeruginosa overnight cultures were diluted in TSB to 
desired concentration of OD600= 0.001. A solution of bacterial suspension (OD600= 0.001, 900 
µL) and stock polymer (PEG, P-1, P-2, or PEI 100 µL) was prepared in cuvettes, and cuvettes 
secured with parafilm to prevent contamination. Final polymer concentrations were 1,000 
µg/mL or 100 µg/mL after dilution in the bacteria suspension. In contrast to growth curve 
assays, bacterial suspensions were kept at room temperature in the absence of stirring, to allow 
for bacteria to aggregate and precipitate in the absence of external forces. The optical density 
(OD600) of dispersions were measured by optical density using a visible diode array 
spectrophotometer (WPA S800 Spectrawave, Biochrom). Measurements were taken at 0, 5 10 
minutes, and subsequently every 10 minutes for the first hour, and every 20 minutes during the 
second hour. To prevent agitation of the bacterial suspension, cuvettes remained in the 
spectrophotometer for the entirety of the measurement time. Triplicate measurements were 
carried out on separate days.  
Bacterial Aggregate Observation: Confocal Microscopy 
P. aeruginosa overnight cultures were diluted in TSB to desired concentration of 
OD600=1.0. Bacteria suspensions (OD600= 1.0, 900 µL) were combined with stock polymer 
solutions or PBS (100 µL) to achieve final polymer concentrations (1,000-1 µg/mL) in an 
Eppendorf tube. SYTO 9 (1.5 µL) was added and incubated with suspensions for 15 minutes at 
room temperature in the absence of light without shaking, simultaneously allowing time for 
polymer-bacteria interaction. An aliquot (5 µL) was collected from the bottom of Eppendorf 
tube and deposited on glass microscope slides and covered with glass coverslips, with the 
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manual removal of air bubbles. Bacteria was examined by inverted confocal microscope using a 
60x oil objective (Eclipse Ti-U, Nikon).  
Bacterial Attachment: Confocal Microscopy 
 P. aeruginosa overnight cultures were diluted in TSB to desired concentration of OD600= 
0.001. Bacterial suspensions (OD600= 0.001, 2.7 mL) were combined with stock polymer 
solutions or PBS (0.3 mL) to achieve final polymer concentrations (1,000-1 µg/mL). The 
prepared bacteria-polymer solutions were transferred to a clear cell culture dish (FD35-100, 
Fluorodish™) with glass window diameter of 23.5 mm, sealed with parafilm, and incubated for 
15 minutes at 37 °C in the absence of shaking. Following incubation, the culture medium was 
carefully removed from the wells by micropipette to avoid disrupting attached cells. Wells were 
washed twice with an excess volume of PBS. Bacterial cells were stained by SYTO 9 (3.34 mM) in 
0.85% NaCl solution for 15 minutes at room temperature in the absence of light without 
shaking. SYTO 9 solution was then removed by micropipette and cells washed once with 0.85% 
NaCl solution. Bacterial cells were examined by inverted confocal microscope (Eclipse Ti-U, 
Nikon) using a 60x oil objective. 
Bacterial Formation Over Time: Confocal Microscopy 
P. aeruginosa overnight cultures were diluted in TSB to desired concentration of OD600= 
0.001. Bacterial suspensions (OD600= 0.001, 2.7 mL) were combined with stock polymer 
solutions (10,000-10 µg/mL, 0.3 mL) or PBS (0.3 mL) to achieve desired polymer concentrations 
(1,000-1 µg/mL). The prepared bacteria-polymer solutions were transferred to a clear cell 
culture dish (FD35-100, Fluorodish™) with glass window diameter of 23.5 mm, sealed with 
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parafilm, and incubated for 4 hours at 37 °C in the absence of stirring. Following incubation, the 
culture medium was carefully removed from the wells by micropipette to avoid disrupting 
biofilms. Wells were washed twice with an excess of PBS. Biofilms were stained by SYTO 9 (3.34 
mM) and/or propidium iodide (20 mM) in 0.85% NaCl solution for 20 minutes at room 
temperature in the absence of light without shaking. SYTO 9-PI solution was then removed by 
micropipette and biofilms washed once with 0.85% NaCl solution. Biofilms were examined by 
inverted confocal microscope (Eclipse Ti-U, Nikon) using a 60x oil objective at of 2, 4, 8 and 24 
hours. 
Biofilm Formation and Polymer Exposure for Total Biomass, Direct Enumeration and Metabolic 
Activity 
Biofilm growth was performed with modifications to previous literature methods.201-202 
12 mm diameter borosilicate glass coverslips (Fisherbrand™) were sterilized in 70 vol% ethanol 
for a minimum of 1 hour and allowed to air dry. A thin strip of label tape was placed on the 
bottom wells of a sterile 12-well polystyrene plates (Corning® Costar®) to facilitate coverslip 
retrieval, and the plate sprayed with 70 vol% ethanol and allowed to dry completely. Coverslips 
were placed 1 per well, with the entire coverslip being flush with the well bottom. P. 
aeruginosa overnight cultures were diluted in TSB to desired concentration of OD600= 0.001 
Bacteria solution (900 µL) was added to each well to fully immerse the coverslip. Polymer stock 
solutions or PBS (100 µL) were then added to wells to achieve desired polymer concentrations 
(1,000-1 µg/mL).  TSB with PBS (100 µL) was also assayed along with the test samples to 
confirm no bacterial contamination. Plates were wrapped in parafilm and incubated for 24 
hours at 37 °C in the absence of shaking. 
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Evaluation of Total Biomass by Crystal Violet 
Biofilms were generated as described in the previous section. Following incubation, the 
supernatant was removed from the wells by micropipette. Wells were washed twice with 
excess PBS.  Crystal violet (CV, 0.01%, 1000 µL) solution was introduced to wells by 
micropipette and used to stain the biofilm for 15 minutes at room temperature without 
shaking. CV was removed from the wells by micropipette, and wells were rinsed twice with PBS, 
and the solution discarded. In order to maintain a consistent biofilm area, coverslips (with 
adhered biofilms) were removed and transferred to a new sterile 12-well plate using forceps, by 
holding a coverslip edge carefully as to not disrupt the biofilm. Ethanol (100%, 1000 µL) was 
used to extract CV from the biofilms for 10 minutes at room temperature and the biofilm 
manually disrupted by micropipette agitation of the solution and scraping. An aliquot of the 
solution (200 µL) was transferred to 96-well round-bottom plate, which was centrifuged at 
1000 rmp for 5 minutes in order to reduce the impact of cellular debris in solution. Aliquots (25 
µL) of solution were then transferred to untreated, sterile polystyrene 96-well flat-bottom plate 
containing ethanol (75 µL) to create 1:4 solutions and the OD595 was obtained on a Varioskan 
Flash microplate reader (Thermo Fisher). Experiments were carried out in duplicate on three 
separate days. Daily averages were calculated from duplicates and used to determine a grand 
average and standard error of the mean (n=3). 
Evaluation of Viable Bacteria by Direct Enumeration  
Biofilms were generated as described in the previous section. Following incubation, the 
supernatant was removed from the wells by micropipette. Wells were washed twice with PBS 
(1000 µL), and the solution discarded. Washed coverslips (with adhered biofilms) were 
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removed and transferred to 15 mL conical tubes containing PBS (3 mL) using forceps, by holding 
a coverslip edge carefully as to not disrupt the biofilm. Coverslips in PBS were sonicated for 10 
minutes to fully disrupt biofilms and dispersed bacteria in solution. 10-fold serial dilutions were 
performed in PBS, and an aliquot of samples (100 µL) was plated on TSB agar plates. The agar 
plates were incubated overnight (~18 hours) at 37 °C, and the number of viable colonies was 
counted. An appropriate dilution was selected from agar plate contained 30-300 colonies, the 
accepted range of countable colonies.203  Experiments were carried out in duplicate on three 
separate days. Daily averages were calculated from duplicates and used to determine a grand 
average and standard error of the mean (n=3).  
Evaluation of Metabolic Activity by MTT 
Biofilms were generated as described in the previous section. Following incubation, the 
supernatant was removed from the wells by micropipette. Wells were washed twice with PBS 
(1000 µL), and the solution discarded. To each well, a premixed solution of PBS (750 µL) and 
0.3% MMT (250 µL) were added and allowed to incubate for 2 hours at 37 °C in the absence of 
stirring. The solution was removed by micropipette and the wells washed with PBS, and the 
solution discarded. Washed coverslips were removed and transferred to a new 12-well plate 
using forceps, by holding a coverslip edge carefully as to not disrupt the biofilm. A solution of 
DMSO (750 µL) and glycine buffer solution (pH 10.5, 126 µL) was added to each well with 
coverslip and the biofilms manually disrupted by solution agitation and scraping and allowed to 
incubate at room temperature for 15 minutes. Aliquots (100 µL) of solution were then 
transferred to untreated, sterile polystyrene 96-well-plate containing ethanol (75 µL) to create 
1:4 solutions and the OD570 was obtained on a Varioskan Flash microplate reader (Thermo 
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Fisher). Experiments were carried out in duplicate on three separate days. Daily averages were 
calculated from duplicates and used to determine a grand average and standard error of the 
mean (n=3). 
Results 
Polymer Design, Synthesis and Characterization 
Cationic functionality on polymers have previously been utilized to facilitate 
electrostatic binding to anionic bacterial membrane. To test the hypothesis that cationic 
polymers are capable of modulating biofilm behavior through assembly disruption, model 
cationic polymer poly[(3-methacryloylamino)propyl] trimethylammonium chloride (P-1) was 
synthesized (Figure 4.1). P-1 design was chosen for this study because the quaternary 
ammonium groups provide permanent cationic charges, while some conventional cationic 
polymers such as poly(ethylene imine)s contain primary ammonium groups. In contrast to 
primary ammoniums, quaternary ammonium groups are pH-independent, which would 
minimize the effect of microenvironment pH in bacteria on the binding behavior of polymer 
chains onto the bacterial surface. As a control to assess the effects of a non-neutral polymer 
charge, poly(2-acrylamido-2-methylpropane sulfonic acid) (P-2) was synthesized, which 
contains sulfonate groups, which are negatively charged in a broad range of pH (Figure 4.1). 
Similar degrees of polymerization (~100) between P-1 and P-2 was selected to ensure 
comparable number of charges. 
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Figure 4.1. Synthesis scheme of (a) P-1 and (b) structures of P-2 and PEG. 
 P-1 and P-2 were synthesized by RAFT polymerization in order to achieve controlled 
molecular weight with narrow dispersity (Đ) (Figure 4.1).  1H NMR analysis confirmed the 
polymerization and removal of residual monomers (Appendix C). The degree of polymerization 
(DP) was determined by comparing of integral intensity ratio of peaks from the chain transfer 
agents (P-1: f; P-2: e) to methylene and methyl in the polymer side-chains (P-1: c+e; P-2: d) 
(Table 4.1). The number-average molecular weight (Mn) was calculated using DP and molecular 
weights of monomer and RAFT agent. GPC was used to determine Mn, molecular weight (Mw), 
and Đ, which were compared to Mn determined by 1H NMR.  The molecular weights of these 
polymers are ~20,000 g/mol, which is relatively smaller than conventional polymers used as 
flocculants. Lower molecular weight polymers (~20,000 g/mol) were utilized as an initial model 
for this study to focus on the charge effects on bacterial aggregation and biofilm formation 
rather than the effect of polymer sizes and a combined effect with polymer bridging204-205 in 
order to elucidate a simple rule in polymer-bacteria interactions for biofilm modulation.  
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Table 4.1. Polymer characterization of P-1 and P-2.  
 DP Mn (1H NMR) Mn (GPC) Mw (GPC) Đ 
P-1 116 25,900 19,600 20,580 1.05 
P-2 99 20,589 15,333 20,392 1.33 
Planktonic Bacteria-Polymer Interactions and Consequences 
Planktonic bacteria offer a favorable target for biofilm prevention. Once formed, 
biofilms are difficult to treat or remove, and thus prevention of biofilm formation from 
individual cells is highly desirable. Approaches that attempt to mitigate planktonic bacteria 
attachment through materials modification suffer both from short lifetimes, as well as limited 
applications to surfaces. Targeting planktonic bacteria offers the advantage that this approach 
is not reliant on a surface platform, and therefore could be applicable also to biotic surfaces 
such as biofilm related tissue infections. Additionally, the anionic surface of bacterial 
membranes is a universal target for a broad spectrum of bacteria. The interaction of planktonic 
bacteria with polymers, and their resulting consequences in solution, are hypothesized to affect 
the development of biofilms, as bacteria attachment is the first step to biofilm formation. 
Modulation of planktonic bacteria behavior could therefore effect biofilm development due to 
sub-optimal assembly.  
Biostatic, Biocidal and/or Antimicrobial Effect of Polymers 
Some cationic polymers have been reported to exert biocidal or biostatic behavior.206-208 
Biocidal behavior occur when bacteria are completely killed following exposure to material, 
while biostatic behavior occurs when bacterial growth is inhibited. Materials that eradicate only 
a portion of bacteria are considered biostatic. For the purposes of this chapter, antimicrobial 
activity will include both of these terms, where agents are biostatic at MIC concentration and 
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biocidal at higher concentrations. Typically, antimicrobial cationic polymers function act as 
biocidal agents through membrane disruption, where cationic segments adsorb onto the 
anionic bacteria surface and hydrophobic sections the polymer create catastrophic defects in 
the membrane which release essential cellular components and ions.  
Bacterial Growth Curve 
To determine if P-1 exhibited either biostatic or biocidal effects, the growth behavior of 
P. aeruginosa was observed during log phase growth by optical density (OD) at dilute 
(OD600=0.001) concentrations in TSB nutrient broth at 37 °C with stirring. In dilute bacteria 
concentrations, high P-1 concentrations (1000 µg/mL) resulted in an increase in optical density 
during the first 4 hours but did not subsequently change growth behavior (Figure 4.2). The high 
OD value is likely due to flocculation ability of highly cationic polymers, which is a physical 
aggregation of bacteria in solution resulting in greater light scattering from large aggregates 
and was further explored subsequently. Lower concentrations of P-1 did not induce noticeable 
changes in OD and likewise did not affect bacterial proliferation (Figure 4.2). Neither P-2 or PEG 
exhibited any changes to the bacterial growth behavior (Figure 4.2), suggesting no biostatic or 
biocidal activity. After 18 hours of growth, the optical density of bacteria was ~2.5 for all 
polymers, indicating polymers had no effect on the maximum load of stationary phase bacteria.
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Figure 4.2. Effect of polymers on planktonic P. aeruginosa growth behavior in Tryptic Soy broth (TSB) with stirring in the 
presence of P-1, P-2 or PEG at 1000 µg/mL. The data points and error bars represent the average and standard deviation from 
three independent experiments (n = 3). 
Minimum Inhibitory Concentration (MIC) 
The antimicrobial activity of P-1 was determined using the standard protocol as the 
minimum inhibitory concentration (MIC)169-170, which is the concentration of polymer necessary 
to inhibit growth of bacteria during long term incubation (~18 hours). The antimicrobial activity 
of polymers was evaluated against exponential phase P. aeruginosa (in TSB and MHB), as well 
as E. coli (in MHB) and S. aureus (in MHB), which are protocol standards. P-1, P-2 and PEG did 
not show any growth inhibition effect against P. aeruginosa in both TSB and MHB up to 1000 
µg/mL, the highest concentration tested. The MICs against E. coli and S. aureus were likewise 
>1000 µg/mL for all polymers. This suggests that no polymers may not bind to bacterial 
membranes, such as in the case of P-2 due to charge repulsion, or binding does not result in 
membrane disruption, such as in the case of PEG or P-1. Antimicrobial activity is derived from 
hydrophobic groups disrupting the bacterial membrane. It is important to note that MIC reflects 
inhibition of bacterial growth, or bacteriostatic activity, as opposed to a measure of killing 
capacity, or bactericidal activity. However, presence of bacterial growth indicates lack of 
bacteriostatic or bactericidal effect. 
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Bacterial Aggregation and Flocculation 
Charged polymers have been used to aggregate or flocculate charged molecules for 
applications such as waste water treatment or bioreactors.190-192 Cationic polymers have been 
previously used to induce bacterial aggregation and flocculation by interacting with bacterial 
surfaces which have high net negative charge.209 Electrostatic interactions between bacteria 
surfaces and polymers can result in surface neutralization, electrostatic patching and polymer 
bridging of bacterial cells, resulting in macroscopic aggregates or precipitates due to changes in 
repulsive and attractive forces.193-195 Bacteria aggregation is a simple way to observe a change 
exerted on bacteria behavior by a material through changing only physical properties. 
Interestingly, bacteria aggregation has been linked to consequential biological signaling, in 
which cationic polymers have been used to trigger cell-cell communications through bacteria 
clustering.196-197 
Bacterial Flocculation 
Optical density was used to evaluate the aggregation of diluted stationary phase 
bacteria when exposed polymers with various charges, specifically P-1 (linear cationic) in 
comparison to PEI (branched cationic), which is a known flocculant, in addition to P-2 (anionic) 
and PEG (neutral). As compared to the bacterial growth curves presented in Figure 4.2, bacteria 
(OD600=0.001) in TSB broth and polymers were combined and kept stationary at room 
temperature to allow bacteria to settle naturally. As aggregation is due to interactions between 
polymer chains and bacteria, changes in optical density were assessed at both dilute and 
concentrated bacteria suspensions, as behavior is likely dependent on the ratio of polymer 
chains to bacteria surfaces. At both dilute and high bacteria concentrations, PEI quickly and 
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effectively aggregates bacteria, evident by a sharp increase in OD, followed by a gradual 
reduction in OD as aggregates precipitate to the bottom of the solution (Figure 4.3). Likewise, 
P-1 (1000 µg/mL) also induced aggregation and a slow reduction in OD suggesting some 
aggregate settling (Figure 4.3). Lower concentration of P-1 (100 µg/mL) did not induce 
noticeable change in OD (Figure 4.3). As bacteria aggregation is due to the disruption of stable 
suspension dynamics, primarily electrostatic repulsive forces between negatively charged 
bacteria, the amount of cationic charge, such as polymer concentration or number of charged 
groups in the case of branched PEI, is responsible for the varying degrees of aggregation.  P-2 
and PEG failed to induce changes in optical density even in dilute bacteria solutions (Figure 4.3), 
results which are consistent with electrostatically driven aggregation. Control bacteria 
suspension, which replace polymer with PBS, show no spontaneous aggregation. However, P. 
aeruginosa has been reported to autoaggregate in liquid cultures, specifically at high bacteria 
concentrations, in which bacteria aggregates are incorporated into the bacteria suspension 
along with individual planktonic bacteria, which could not be detected through changes to 
optical density.210  
 
Figure 4.3. Effect of polymers on planktonic P. aeruginosa solution behavior. Representative data of optical density of P. 
aeruginosa in TSB incubated with P-1, P-2, PEG, or PEI at 1000 µg/mL, and PBS at room temperature without stirring. The 
polymers were added into the bacterial suspension at time 0.  
0 20 40 60 80 100 120
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Time (min)
O
D
60
0
Control (PBS)
P-1 (1000 µg/mL)
P-1 (100 µg/mL)
PEG (1000 µg/mL)
P-2 (1000 µg/mL)
PEI (1000 µg/mL)
 104 
Observation of Bacteria Aggregates 
The presence of aggregates in liquid cultures was confirmed by fluorescence 
microscopy. Higher bacteria density (OD600=1.0) was used to better visualize bacteria. In 
cultures of P. aeruginosa without any polymers, bacterial cells were observed in a diversity of 
aggregate sizes up to 50 µm diameter in addition to individual planktonic cells (Figure 4.4 
). This is consistent with previous reports of autoaggregation in nutrient deficient 
medium, such is the case of stationary phase bacteria.210 With the addition of PEG or P-2, the 
aggregates did not dissociate nor increase in size, indicating neutral or anionic charged 
polymers do not perturb bacteria surface charge (Figure 4.4). At higher concentrations of P-1 
(1000 and 100 µg/mL), large aggregates up to 200 µm diameter became evident in addition to 
smaller aggregates (20-50 µm) (Figure 4.4), suggesting cationic charged polymers are sufficient 
concentration can modulate the behavior of planktonic bacteria through charge. These results 
are consistent with optical density aggregation behavior, in which high concentrations of 
cationic polymer disrupt the normal state of planktonic bacteria through increased aggregation, 
such as by increasing the size of aggregates. While analysis of aggregate distribution in liquid 
cultures was considered, the size of both naturally occurring autoaggregates and cationic 
polymer induced aggregates are beyond the capabilities of dynamic light scattering (<10 µm) 
and should be an area of further study in the future.  At this time, it is not hypothesized that 
controlling the size or distribution of aggregates would affect resulting biofilm behavior. 
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Figure 4.4. Representative images depicting aggregates of 1.0 OD600 solutions following 15 min incubation with polymers 
solutions in PBS. 
Depending on size, aggregates may settle over time due to gravitational effects and 
alter the behavior of bacteria with surfaces. Computational models have suggested that the 
introduction of bacteria aggregates on a surface can result in changes to biofilm formation and 
behavior, due to increased access to nutrients compared to individual cells by height 
advantage.210-211 Biofilm formation begins with planktonic cells attaching to a surface, such as in 
a low bacteria concentration environment. Therefore, to assess if P-1 induced aggregates 
significantly affected bacterial attachment behavior, fluorescence microscopy was used to 
visualize glass surfaces after 4 hours of exposure to static dilute P. aeruginosa cultures. At dilute 
concentrations, large aggregates were not evident in the bacterial attachment layer, which was 
instead composed of a similar distribution of individual cells (Figure 4.5). While aggregates may 
have settled on the surface, washing may have removed them by sheer due to increased 
height, suggesting they only loosely attach to surfaces. This weak attachment of aggregates is 
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consistent with bacteria attachment behavior, during which bacteria first attach reversibly by 
non-specific forces, followed by ligand based irreversible attachment. In aggregates, only 
bacteria in contact with the surface would undergo irreversible attachment, in which case the 
bulk of aggregates may be easily removed.  
 
Figure 4.5. Representative images depicting bacterial attachment on surface of glass petri dish (1 hour) of 0.001 OD600 bacteria 
solution co-incubated with P-1. 
Polymer Co-incubation Effect on Mature Biofilms 
This work hypothesized that cationic polymers would bind to planktonic bacteria prior 
to their attachment and propagation into biofilms, and consequentially change their 
attachment behavior and subsequent biofilms formed. In order to evaluate the downstream 
effects of polymer interactions with planktonic bacteria, it was necessary to evaluate the 
properties of biofilms developed under co-incubation conditions. 
Total Biomass 
We evaluated the total biomass of P. aeruginosa biofilm as a measure of biofilm 
formation to determine if the polymers enhance or inhibit biofilm formation. Crystal violet (CV) 
staining has been an established method in biofilm microbiology to quantify the total biomass 
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of biofilms owing to electrostatic binding of cationic CV to the anionic biopolymers of 
extracellular matrix and bacterial membranes in the biofilm.212-213 The amount of CV adsorbed 
onto biofilms, extracted and characterized by absorbance reflects the total biomass of biofilms.  
P. aeruginosa was incubated with the polymers in a range of polymer concentrations for 
24 hours, sufficient time for polymers to interact with planktonic bacteria and a biofilm to 
develop during polymer-bacteria interactions. The total biomass in the presence of neutral PEG 
and anionic P-2 did not differ significantly from control biofilms (Figure 4.6). In the presence of 
P-1, total biomass by CV was decreased (Figure 4.6). This effect is concentration dependent, 
where biomass reduction is only evident at P-1 concentrations ≥ 100 µg/mL (Figure 4.6). The 
lack of change in biomass by PEG and P-2 suggest that the reduced biomass is the result of 
specifically cationic polymers. Furthermore, the concentration dependence suggests a total 
charge dependent effect. The change in total biomass may reflect several events: a lower 
quantity of biofilm development, polymers eradicated biofilms once developed a more fragile 
structure in biofilms causing removal during washing, and/or a change in biofilm properties 
reducing the binding efficiency of CV stain.
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Figure 4.6. Crystal violet evaluation of polymer-modulated biofilm formation. Total biomass dependence on polymer 
concentration after 24 hours of incubation in the presence of P-1, PEG, or P-2. PBS was used as a positive control. The 
experiment was performed in duplicate, and the absorbance was determined as the average of data for each experiment. The 
data points and error bars represent the average and s.d from data in three independent experiments (n = 3), with significance 
(**p< 0.01) indicated against control (PBS). 
Viable Bacteria 
Biofilms are heterogenous structures of extracellular matrix and microbial cells, both 
live and dead. When considering infection persistence, only live or viable cells are responsible. 
Therefore, to determine if polymers reduced the number of viable bacteria within biofilms, 
direct enumeration of colony forming units was conducted. P. aeruginosa was incubated with 
the polymers in a range of polymer concentrations for 24 hours, under which conditions 
biofilms were formed.  
In the absence of polymers, biofilms contained 5.4 (±2.5) x 108 CFU/cm2 viable bacteria.  
Incubation with PEG and P-2 did not significantly alter the viable bacteria load as compared to 
the control, with counts of 4.9 (±2.3) and 5.7 (±4.3) x 108 CFU/cm2 respectively (Figure 4.7). 
When biofilms were formed in the presence of 1000 µg/mL P-1, the number of viable bacteria 
was reduced to 7.7 (±5.5) 107 CFU/cm2 (Figure 4.7), which corresponds to an 86% reduction. As 
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P-1 concentration decreases however, the bacterial load approaches levels similar to the 
control. Therefore, reduction in viable bacteria is both a result of polymer charge and polymer 
concentration. These results support findings by CV that P-1 inhibits biofilm development, 
decreasing both biofilm matrix and viable cells. As P-1 has no antimicrobial activity, the 
reduction in viable cells is the result of inhibited biofilm growth. 
  
 
Figure 4.7. Viable bacteria evaluation of polymer-modulated biofilm formation. Viable bacteria dependence on polymer 
concentration after 24 hours of incubation in the presence of P-1, PEG, or P-2. PBS was used as a positive control. The 
experiment was performed in duplicate, and the absorbance was determined as the average of data for each experiment. The 
data points and error bars represent the average and s.d from data in three independent experiments (n = 3), with significance 
(**p< 0.01) indicated against control (PBS). 
Metabolic Activity 
Cellular activity for biofilm bacteria is reported lower as compared to planktonic 
bacteria and is a potential cause of poor antibiotic efficacy. Bacteria found in the interior of the 
biofilm have lower metabolic activity likely due to oxygen limitation28, and are considered to be 
in a dormant state. Structural changes to the biofilm may result in increased availability of 
oxygen and nutrients to interior bacteria, resulting in changes to metabolic activity caused by 
incorporation of charged or uncharged polymers into the biofilm matrix. Therefore, the 
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metabolic activity of biofilm bacteria was evaluated by MTT assay, a colorimetric assay in which 
MTT is converted to formazan by mitochondrial reductase, and the absorbance of formazan at 
570 nm is correlated to the amount of metabolic activity. MTT assays are also often used as 
indication of viable bacteria, assuming all bacteria in the study are at the same level of 
metabolic activity, where the amount of formazan converted correlates to the number of viable 
bacteria present. In this case, previous data indicates comparable number of viable bacteria, 
and therefore MTT assay will provide information regarding the metabolic activity of bacteria in 
the biofilm, and/or to corroborate the direct enumeration results. 
P. aeruginosa was incubated with the polymers in a range of polymer concentrations for 
24 hours and allowed to form biofilms, and biofilms were subsequently assessed by MTT assay. 
Biofilms grown in the presence of PEG and P-2 demonstrated similar metabolic activity to 
control biofilms (Figure 4.8), which supports direct enumeration, and indicates bacteria are at 
similar metabolic states. The reduction of metabolic activity at 1000 µg/mL P-1 (Figure 4.8) is 
consistent with the lower number in viable bacteria found by direct enumeration. As P-1 
concentration decrease, metabolic activity is recovered (Figure 4.8), supporting the finding of 
similar amounts of viable bacteria, and indicating similar metabolic activity. These findings 
corroborate direct enumeration studies indicating bacterial reduction only in the presence of 
high concentrations of P-1, indicating cationic charge and sufficient charge is necessary to 
reduce biofilm accumulation.  
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Figure 4.8. Metabolic activity of P. aeruginosa bacteria in biofilms measured by MTT colorimetric assay, through the reduction 
of MTT to formazan.  Metabolic activity dependence on polymer concentration after 24 hours of incubation in the presence of 
P-1, PEG, or P-2. PBS was used as a positive control. The experiment was performed in duplicate, and the absorbance was 
determined as the average of data for each experiment. The data points and error bars represent the average and s.d from data 
in three independent experiments (n = 3), with significance (**p< 0.01) indicated against control (PBS). 
Biofilm Formation Over Time 
Biofilm development begins from the attachment of planktonic bacteria to a surface, 
though previous research has reported bacteria aggregates may seed surfaces and change 
biofilm behaviors, such as early switching of bacteria biofilm phenotype that consequentially 
changes biofilm formation behavior.211, 214 Therefore, the accumulation and development of P. 
aeruginosa bacteria into biofilms was observed through confocal microscopy in the absence 
and presence of P-1 (1000 µg/mL). The formation of 3-dimensional structures can be seen 
observed in as little as 2 hours, originating from a layer of single cell attachments to the surface 
(Figure 4.9). After 4 hours, the biofilm has thickened with a dispersion of live bacteria 
throughout, which divide and more densely populate the biofilm after 8 hours (Figure 4.9). In 
the presence of P-1, biofilms appear to be initiated by single bacterium, or small clusters of 
bacteria (diameter<10 µm), but do not appear to include large aggregates that dominate the 
biofilm (Figure 4.9). After 4 hours, the biofilm thickens and becomes densely populated with 
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live bacteria after 8 hours, such as was seen in the case of control bacteria (Figure 4.9). Further 
studies that probe the comparative properties of biofilms as they develop, such as cellular 
density or surface roughness, should be aspects of future research to determine if incubation 
with P-1 results in changes to the biofilm structure during development, and if such changes are 
maintained at longer lifetimes. 
 
Figure 4.9. Representative three-dimensional renderings of P. aeruginosa biofilm development over 2, 4, and 8 hours in the 
absence (control) and presence of P-1 (1000 µg/mL). 
Proposed Polymer-Modulated Biofilm Formation Mechanism  
This study indicated that the co-incubation of cationic polymers results in the reduction 
of biofilm accumulation. As this reduction is not due to the biocidal or biostatic effects, we 
propose a new mechanism through the cationic polymer-bacteria interactions (Figure 4.10). 
The observed cellular aggregation of bacteria in the presence of cationic polymers results in 
bacteria sequestration in solution. The cationic polymers bind to the anionic surface of bacteria, 
which either results in surface charge neutralization which reduces repulsive activity between 
bacteria, or electrostatic bridging between cationic and anionic portions of adjacent bacteria. 
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This aggregation sequesters bacteria, reducing the number of planktonic bacteria that can 
attach to a surface to begin biofilm formation. Increasing the concentration of polymer more 
effectively result in sequestering the bacteria away from attaching surfaces. However, the 
polymer-bacteria interaction appears not to change the inherent ability of bacteria to attach to 
surface and form biofilms.  The bacteria eventually do attach divide and propagate as normal.  
The polymers can delay the biofilm formation. Studies that would further help elucidate the 
mechanism of action include identifying the relationship between polymer concentration, 
aggregate size and degree of biofilm suppression. Additionally, further studies that monitor the 
accumulation of biomass and viable bacteria over time both during early development (2-12 
hours), and beyond 24 hours would be useful to identify a point at which this approach no 
longer effectively combats biofilms, such as would be necessary for application in combination 
therapy studies. To the authors knowledge, no other studies have proposed a mechanism by 
which charged polymers are used to target bacteria surfaces for non-toxic prevention of biofilm 
formation. 
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Figure 4.10. Proposed mechanism for cationic polymer modulation of biofilm behavior through planktonic bacteria interactions. 
Cationic polymers are proposed to sequester bacteria in solution, preventing bacterial attachment to surfaces, and 
consequentially suppression biofilm accumulation.  
Conclusions 
In summary, cationic poly[(3-methacryloylamino)propyl] trimethylammonium chloride 
(P-1) is capable of modulating planktonic and biofilm bacteria behavior through electrostatic 
interactions. Specifically, P-1 has been shown to induce concentration dependent bacteria 
aggregation in solution, indicating changes to the physiochemical surface of bacterial 
membranes. Despite no direct antimicrobial action, P-1 suppressed biofilm accumulation of 
both matrix and viable bacteria when concentrations ≥100 µg/mL were incubated with 
planktonic bacteria during biofilm development, while neutral and anionic polymers did not. 
We propose that cationic polymers can sequester planktonic bacteria in solution through 
electrostatic interactions, preventing bacteria attachment and consequentially reducing biofilm 
formation. This method of biofilm prevention could be useful in clinical applications in 
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combination with existing antibiotics to reduce the necessary antibiotic load by suppressing 
biofilm development at early stages. Our findings provide a mechanistic link between the 
physical-interactions of planktonic bacteria and biofilm biological consequences, useful to 
develop versatile anti-biofilm polymers to modulate not only bacteria-material interactions, but 
also interfere bacteria-host interactions for infection prevention.
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Chapter 5 Membrane Targeting Cationic Polymers for Increased Tobramycin 
Susceptibility of Dormant Biofilm Bacteria  
Introduction 
Bacterial biofilms are a continuing problem in the healthcare community, and long-term 
effectiveness of current anti-biofilm methods has proven challenging. Bacterial biofilms can 
form on abiotic surface, such as implanted medical devices, as well as biotic surfaces, such as 
tissue.215 They are responsible for 65-80% of infections 23-24, and once established, are difficult 
to treat due to increased antibiotic tolerance.39 Specifically, Pseudomonas aeruginosa 
frequently develops into biofilms and consequently chronic infections of the respiratory system, 
especially in immunocompromised patients such as those with cystic fibrosis.184-186, 216  
P. aeruginosa biofilms in the respiratory system are typically treated by inhaled 
antibiotics, such as tobramycin. Combination therapies with multiple antibiotics have been 
explored, and while they may prove more effective to single-drug therapy, they also increase 
risk of multi-drug antibiotic resistance development due to biofilm hypermutability, which 
would hinder future treatment options.217-219  Enzymes that degrade the biofilm matrix have 
been shown to enhance antibiotic efficacy by improving antibiotic penetration.92-95 However, 
the degradation of the biofilm matrix promotes biofilm detachment, which allows portions of 
the biofilm to be disperses and potentially seed new biofilms throughout the body. Inhibition of 
quorum sensing has also been a target for enhanced antibiotic efficacy, due to its involvement 
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in multiple virulence factors such as the production of extracellular enzymes for antibiotic 
deactivation.220-222 Unfortunately, the quorum sensing pathways are highly complex and their 
effects and role in biofilms are not well defined.  
Metabolically inactive bacteria or dormant bacteria are another challenge to antibiotic 
treatment, especially in biofilms. Bacteria in biofilm have reduced rate of metabolism and cell 
division, but can revert to an metabolically active state even after extended period of times.223-
224   Dormancy occurs when the environment is not favorable, such as low nutrient or oxygen 
accessibility, as is the case for embedded biofilm bacteria.28, 142, 224-226 Because many antibiotics 
target pathways for cellular repair and/or division (i.e. cell wall synthesis inhibitors, protein 
synthesis inhibitors), dormancy related repressed cellular activity have been theorized to be a 
cause of reduced antibiotic efficacy.28, 149, 225  Additionally, has been proposed that dormant 
bacterial may also have reduced antibiotic uptake, because it is an energy-dependent 
process.227-228 Previous studies has investigated overcoming dormancy related antibiotic 
tolerance in P. aeruginosa biofilms229, such as through using molecules to generate a proton-
motive force to increase tobramycin uptake151, 230, stimulating bacterial to a higher metabolic 
state through motility150 or signaling molecules231, or  conjugation of antibiotics with 
antimicrobial peptides that disrupt the bacterial membrane for enhanced antibiotic 
penetration.232 
In our previous research (chapter 4), cationic poly[(3-methacryloylamino)propyl] 
trimethylammonium chloride bound to bacterial membranes to modulate physiochemical 
behavior during biofilm assembly.  In this study, we will explore the application of this cationic 
polymer for treatment of developed biofilms. Specifically, the aim of this study is to determine 
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if cationic polymers can be used to increase antimicrobial susceptibility of dormant bacterial 
cells through non-disruptive membrane binding. This study will extend the application of 
cationic polymers from use in preventative biofilm approaches to active treatment approaches, 
providing a multi-pronged strategy to combat biofilm infections.   
Methods 
Materials 
Tryptic Soy broth (TSB, Thermo Scientific Oxoid™), Mueller Hinton broth (MHB, BD and 
Company ©), and phosphate buffered saline (PBS, pH=7.4, Gibco®) were prepared according to 
manufacturer instructions and autoclave sterilized prior to use. SYTO 9 and propidium iodide 
(PI) nucleic acid stains (Molecular Probes, OR) were used as prescribed by the product manual 
at 1.5 µL/mL. Crystal violet (Sigma-Aldrich) was diluted in Millipore water to a working 
concentration of 0.01% (wt/vol). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolilum 
bromide, Thermo Scientific) was diluted in Millipore water to working concentration of 0.3% 
(wt/vol). Cyanin-5 NHS ester was purchased from Lumiprobe. Diisopropylethylamine, 
tobramycin and solvents were purchased from Fisher Scientific. 3-
(Methacrylamido)propyltrimethylammonium chloride (MAPTAC, 95%) from Wako Pure 
Chemical and Fluorescein o-acrylate (AAcF, 97％) from Sigma-Aldrich were used as received 
without further purification. 4-Cyanopentanoic acid dithiobenzoate (CPD), used as a chain 
transfer agent (CTA), was synthesized according to the method reported by Mitsukami and co-
workers.233 2,2’-Azobis(isobutyronitrile) (AIBN, 98%) was used as received. Water was purified 
with an ion-exchange system. 
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Poly[(3-methacryloylamino)propyl] trimethylammonium chloride (P-1) were synthesized 
by RAFT polymerization as described in Chapter 4 and characterized by 1H NMR and GPC 
(Appendix C). Stock solutions were prepared at 10 mg/mL in 0.01 % acetic acid). Further P-1 
stock solutions were prepared by ten-fold dilutions in PBS (1000, 100, 10 µg/mL). 
Pseudomonas aeruginosa (P. aeruginosa) PAO1 was received from Dr. Chuanwu Xi 
(Environmental Health Science, University of Michigan). P. aeruginosa cultures were prepared 
by suspension of a bacteria colony in TSB, collected from agar plate (<5 days old). Cultures were 
grown overnight (18 hours) at 37 °C at 180 rpm. Further preparations are as noted in 
subsequent methods. 
Cy5-tobramycin was synthesized by Dr. Rajani Bhat (University of Michigan) using the 
reaction of Cy5-NHS ester (10 mg, 1.62 x 10-2 mmol, 1 eq), Tobramycin (8 mg, 1.79 x10-2 mmol, 
1.1 eq) and N,N-diisopropylethylamine (10mg, 7.7 x10-2 mmol, 5 eq). Compounds were 
dissolved in DMSO (0.7 mL) and reacted in the absence of light for 20 hours. DMSO was 
evaporated by N2 gas.  The resultant solid was dissolved in minimum quantity of methanol and 
purified by flash column using DCM:Methanol:NH4OH (5:4:1) as the eluent. Refractive index (Rf) 
of dye-antibiotic conjugate was seen to be 0.4.   
Fluorescein labeled PMAPTAC was prepared by Yusa and colleagues (University of 
Hyogo). MAPTAC (1.81 g, 8.18 mmol), AAcF (32.6 mg, 0.0844 mmol), CPD (23.7 mg, 0.0846 
mmol), and AIBN (6.80 mg, 0.0414 mmol) were dissolved in methanol (5.20 g). The solution was 
heated at 60 °C for 8h under argon atmosphere. After the polymerization, 1H NMR was 
measured to determine the monomer conversion (= 41.1%). The polymerization mixture was 
dialyzed against pure water for one day. The polymer (P(MAPTAC/AAcF3)63) was recovered with 
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a freeze-drying technique (0.420 g, 22.5%). Degree of polymerization (DP) was 63 estimated by 
1H NMR (Appendix D). Number-average molecular weight (Mn) and molecular weight 
distribution (Mw/Mn) were estimated by gel-permeation chromatography (GPC) to be 1.40 × 104 
and 1.04, respectively (Appendix D). The AAcF content in the copolymer was 3 mol% estimated 
from UV-vis absorption spectra (Appendix D). 
Antimicrobial Activity: MIC Assay 
The minimum inhibitory concentration (MIC) of antibiotics against P. aeruginosa (PAO1) 
was determined in a modified microbroth dilution assay according to the Clinical and 
Laboratory Standards Institute guidelines with suggested modifications by R. E.W Hancock 
Laboratory (University of British Columbia, British Columbia, Canada)169 and Giacometti et al.170 
Bacteria was grown overnight (~18 hours) in TSB at 37 °C with orbital shaking (180 rpm), and 
regrown to the exponential phase (OD600= 0.5-0.7, 2 hours). Dilution with TSB resulted in a 
bacteria suspension with an OD600= 0.001, ~4 x 106 CFU/mL. Stock solutions of tobramycin (1 
mg/mL), ciprofloxacin (0.1 mg/mL), ceftazidime (1 mg/mL), and H2O2 (500 mM) were serially 
diluted to working concentrations in PBS and added to 96-well sterile round-bottom 
polypropylene plate wells (10 µL). PBS was used as a solvent control. A stock of dilute bacterial 
suspensions (OD600= 0.001) was divided (4.5 mL), to which half an aliquot (0.5 mL) of P-1 was 
added to achieve a concentration of 1000 µg/mL, and the remaining half an aliquot of PBS. 
Dilute suspensions were then added to the wells of plates (90 µL). Plates were incubated for 18 
hours at 37 °C. MIC was defined as the lowest concentration of antibiotics to completely inhibit 
bacterial growth. Assays were repeated a minimum of three times in triplicate on different 
days.  
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Biofilm Formation and Polymer Exposure for Total Biomass, Direct Enumeration and Metabolic 
Activity 
Biofilm growth was performed with modifications to previous literature methods.201-202 
12 mm diameter borosilicate glass coverslips (Fisherbrand™) were sterilized in 70 vol% ethanol 
for a minimum of 1 hour and allowed to air dry. A thin strip of label tape was placed on the 
bottom wells of a sterile 12-well polystyrene plates (Corning® Costar®) to facilitate coverslip 
retrieval, and the plate sprayed with 70 vol% ethanol and allowed to dry completely. Coverslips 
were placed 1 per well, with the entire coverslip being flush with the well bottom. P. 
aeruginosa overnight cultures were diluted in TSB to desired concentration of OD600= 0.001. 
Bacteria solution (900 µL) was added to each well to fully immerse the coverslip. PBS (100 µL) 
was then added to each well.  TSB with PBS (100 µL) was also assayed along with the test 
samples to confirm no bacterial contamination. Plates were wrapped in parafilm and incubated 
for 24 hours at 37 °C in the absence of shaking. 
To assess the effects of polymer exposure on biofilms, the culture medium was removed 
from the wells by micropipette following incubation. Wells were washed with excess PBS. 
Polymer stock solutions were added to biofilms to achieve final polymer concentrations 
between 1-1000 µg/mL and incubated at room temperature for 2 hours in the absence of 
shaking. Solution was then removed, and the biofilms washed with excess PBS. 
Evaluation of Total Biomass by Crystal Violet 
Biofilms were generated as described in the previous section. Crystal violet (CV, 0.01%, 
1000 µL) solution was introduced to wells by micropipette and used to stain the biofilm for 15 
minutes at room temperature without shaking. CV was removed from the wells by 
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micropipette, and wells were rinsed twice with PBS, and the solution discarded. In order to 
maintain a consistent biofilm area, coverslips (with adhered biofilms) were removed and 
transferred to a new sterile 12-well plate using forceps, by holding a coverslip edge carefully as 
to not disrupt the biofilm. Ethanol (100%, 1000 µL) was used to extract CV from the biofilms for 
10 minutes at room temperature and the biofilm manually disrupted by micropipette agitation 
of the solution and scraping. An aliquot of the solution (200 µL) was transferred to 96-well 
round-bottom plate, which was centrifuged at 1000 rmp for 5 minutes in order to reduce the 
impact of cellular debris in solution. Aliquots (25 µL) of solution were then transferred to 
untreated, sterile polystyrene 96-well flat-bottom plate containing ethanol (75 µL) to create 1:4 
solutions and the OD595 was obtained on a Varioskan Flash microplate reader (Thermo Fisher). 
Experiments were carried out in duplicate on three separate days. Daily averages were 
calculated from duplicates and used to determine a grand average and standard error of the 
mean (n=3). 
Evaluation of Viable Bacteria by Direct Enumeration  
Biofilms were generated as described in the previous section. Washed coverslips (with 
adhered biofilms) were removed and transferred to 15 mL conical tubes containing PBS (3 mL) 
using forceps, by holding a coverslip edge carefully as to not disrupt the biofilm. Coverslips in 
PBS were sonicated for 10 minutes to fully disrupt biofilms and dispersed bacteria in solution. 
10-fold serial dilutions were performed in PBS, and an aliquot of samples (100 µL) was plated 
on TSB agar plates. The agar plates were incubated overnight (~18 hours) at 37 °C, and the 
number of viable colonies was counted. An appropriate dilution was selected from agar plate 
contained 30-300 colonies, the accepted range of countable colonies.203  Experiments were 
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carried out in duplicate on three separate days. Daily averages were calculated from duplicates 
and used to determine a grand average and standard error of the mean (n=3).  
Evaluation of Metabolic Activity by MTT 
Biofilms were generated as described in section Chapter 0. To each well, a premixed 
solution of PBS (750 µL) and 0.3% MMT (250 µL) were added and allowed to incubate for 2 
hours at 37 °C in the absence of stirring. The solution as removed by micropipette and the wells 
washed with PBS. Washed coverslips were removed and transferred to a new 12-well plate. A 
solution of DMSO (750 µL) and glycine buffer solution (pH 10.5, 126 µL) was added to each well, 
the biofilms manually disrupted, and allowed to incubate at room temperature for 15 minutes. 
Aliquots (100 µL) of solution were then transferred to untreated, sterile polystyrene 96-well-
plate containing ethanol (75 µL) to create 1:4 solutions and the OD570 was obtained on a 
Varioskan Flash microplate reader (Thermo Fisher). Experiments were carried out in duplicate 
on three separate days. Daily averages were calculated from duplicates and used to determine 
a grand average and standard error of the mean (n=3). 
Biofilm Formation, Polymer Exposure and Cy5-Tobramycin Exposure for Confocal Microscopy 
An overnight culture of P. aeruginosa was diluted to 0.001 OD600 in TSB. Bacteria 
solution (OD600= 0.001, 2.7 mL) and PBS (0.3 mL) was added to a clear cell culture dish (FD35-
100, Fluorodish™) with glass window diameter of 23.5 mm. Dishes were wrapped in parafilm 
and incubated 24 hours at 37 °C in the absence of shaking.  Following incubation, the culture 
medium was removed from the dish by micropipette. Biofilms were washed twice with excess 
PBS. Polymer solutions (2 mL, 100 µg/mL) were added to biofilm dishes (or PBS for control 
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biofilms) and incubated for 2 hours at room temperature without shaking. Polymer solution 
was then removed, and the biofilms washed twice with excess PBS. Biofilms were stained by 
SYTO 9 (3.34 mM) and/or propidium iodide (20 mM) in 0.85% NaCl for 20 minutes at room 
temperature in the absence of light without shaking. SYTO 9-PI solution was then removed by 
micropipette and biofilms washed once with 0.85% NaCl solution. Biofilms were examined by 
inverted confocal microscope (Eclipse Ti-U, Nikon) using a 60x oil objective. 
Fluorescein labeled P-1 (F-P-1) was utilized to assess polymer penetration and location 
of P-1 within biofilms. F-P-1 was incubated with 24h biofilms for 2 hours at room temperature 
prior to biofilm washing and staining with PI as described above.  
Cy-5 labeled tobramycin (1 mg/mL, 2 mL) utilized to assess antibiotic penetration of 
natural biofilms and P-1 exposed biofilms.  Cy-5 tobramycin was incubated for 2 hours at room 
temperature prior to biofilm staining. Tobramycin solution was then removed, the biofilms 
washed with excess PBS, and the biofilm stained with SYTO 9 and imaged as described above. 
Membrane Potential Measurement by DisC3-(5) 
The effect of polymer binding on membrane potential was evaluated for stationary and 
exponential phase P. aeruginosa cultures by DiSC3-(5).78  An overnight culture of P. aeruginosa 
(~18 hours) grown in TSB. Overnight cultures were used as stationary phase bacteria as analogs 
for biofilm dormant cells. Exponential phase bacteria were used for comparison, which were 
achieved by using overnight culture inoculated diluted in TSB at 37 °C with orbital shaking (180 
rpm) for 2 hours (OD600 of 0.5-0.8). Bacterial solutions were centrifuged at 1,700 x g for 10 
minutes to yield bacterial pellets and the supernatant broth removed by pipette. Bacteria was 
washed by resuspended in HEPES buffer (5 mM, pH 7.2), centrifuging, removal of wash buffer, 
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and resuspension in HEPES buffer to an OD600 of 0.05. Bacteria suspensions (95.5 µL) were 
added to a sterile flat-bottom polystyrene-wells. A stock solution of DiSC3-(5) in DMSO (0.1 mM, 
0.5 µL) was transferred to the bacteria suspension and stirred for 180 seconds to reach stable 
fluorescence intensity due to accumulation of dye on the bacterial membranes, with a final 
DiSC3-(5) concentration of 0.5 µM. After 180 seconds, stock polymer solutions in PBS (or PBS for 
control) were added to the bacterial solutions (10 µL), to achieve final polymer concentrations 
of 1-1,000 µg/mL.  The fluorescence intensity was monitored using a Varioskan Flash microplate 
reader (Thermo Fisher) with an excitation and emission wavelengths of 622 nm and 670 nm, 
respectively. Experiment were carried out in quadruplicate on three separate days (n=3).  
Combination Treatment by P1 and Tobramycin 
Biofilms were generated as described in the previous section, with stock polymer stock 
incubation for 2 hours at room temperature to achieve polymer concentrations of 1-1,000 
µg/mL.  Following polymer incubation, supernatant was removed by pipette and the wells 
washed with excess PBS. Stock solution of tobramycin (100 µg/mL, 1 mL) were added to each 
well and incubated at room temperature for 2 hours in the absence of shaking.  Following 
tobramycin treatment, the solution was removed, and wells washed with excess PBS. Washed 
coverslips were removed and transferred to 15 mL conical tubes containing PBS (3 mL). 
Coverslips in PBS were sonicated for 10 minutes to fully disrupt biofilms and dispersed bacteria 
in solution. 10-fold serial dilutions were performed in PBS, and an aliquot of samples (100 µL) 
was plated on TSB agar plates. The agar plates were incubated overnight (~18 hours) at 37 °C, 
and the number of viable colonies was counted. An appropriate dilution was selected from agar 
plate contained 30-300 colonies, the accepted range of countable colonies.203  Experiments 
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were carried out in duplicate on three separate days. Daily averages were calculated from 
duplicates and used to determine a grand average and standard error of the mean (n=3).  
Results 
Polymer Post-Treatment Effect on Mature Biofilms 
In this study, naturally formed biofilms were challenged with cationic polymer P-1 
(Figure 5.1) to determine the penetration of the cationic polymer through the biofilm matrix 
and binding to bacteria, as well as the effect on bacterial cell viability and biofilm structure.  
 
 
Figure 5.1. Chemical structure and characterization of cationic poly[(3-methacryloylamino)propyl] trimethylammonium chloride 
(P-1).  
Polymer Penetration through Biofilm and binding to bacteria  
Biofilms are composed of bacteria embedded in an extracellular polymeric substance 
(EPS). Previous studies have demonstrated that cationic antibiotic molecules have difficulty 
penetrating through the biofilm to embedded bacteria due to the anionic nature of the EPS. 
Similarly, P-1 may also be trapped in the biofilm matrix due to the cationic property of polymer 
and large molecular size. In order to access if P-1 is able to penetration through the biofilm 
matrix, biofilms are treated with fluorescently labeled P-1, and the distribution of P-1 was 
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examined by confocal microscopy. The images indicated that the florescence from P-1 was 
observed through the entire biofilm (Figure 5.2), suggesting that P-1 could fully penetrates 
through the biofilm matrix to the bacteria attached at the glass surface. Furthermore, the 
fluorescence from P-1 also matched with those from bacteria embedded in the biofilm, 
suggesting that P-1 had access to bacteria.  
 
Figure 5.2. Representative three-dimensional renderings of P-1 (100 µg/mL) penetration into P. aeruginosa biofilms grown for 
24 hours.  
Biofilm removal and killing of bacteria 
Cationic polymers have been reported to remove biofilms to some extent. The 
interaction of cationic polymers with biofilms may change the biofilm matrix structures or 
solubilize the matrix biopolymers, resulting in removal of biofilms. In addition, cationic 
polymers have been reported to kill bacteria while P-1 did not show any growth inhibition 
(Chapter 4).  To examine these effects of P-1 on biofilms, the quantity of viable bacteria after 
polymer treatment was assessed. P. aeruginosa biofilms grown for 24 hours contained 2.15 
(±1.0) x 108 CFU/cm2 viable bacteria (Figure 5.3). After treatment by P-1, the biofilm contained 
1.99 (±0 .4) x 108 CFU/cm2 at 1 µg/mL, and higher concentrations of P-1 did not decrease viable 
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bacteria, for example 2.3 (±0.8) x 108 CFU/cm2 at 1000 µg/mL (Figure 5.3).  There is no 
difference in viable bacteria in biofilms treated with P-1 and control biofilms. This indicates that 
P-1 did not affect the biofilm and bacteria.  
 
Figure 5.3. Viable bacteria evaluation of polymer challenged P. aeruginosa biofilms. Viable bacteria dependence on polymer 
concentration after challenging 24-hour biofilms with of incubation in the presence of P-1 (2 hours). The experiment was 
performed in duplicate, and the absorbance was determined as the average of data for each experiment. The data points and 
error bars represent the average and s.d from data in three independent experiments (n = 3), with significance (**p< 0.01) 
indicated against control (PBS). 
Biofilm Structure  
The previous result suggests that there is no change in cell viability and biofilm when 
treated with P-1. We further probed into the biofilm structures after polymer treatment using 
confocal microscopy. The biofilms were scanned for a z-axis sections of biofilms, and stacks 
reassembled to form 3-dimensional renderings. The control biofilms had a dense homogeneous 
layer of bacteria attached to the glass surface, and bacteria were distributed throughout the 
biofilm matrix, giving approximately 75 µm thickness (Figure 5.4). The biofilm surface has a 
higher density of bacteria. We speculate this was artifact by compressing the top layer of 
biofilm during washing or planktonic bacteria loosely bound to the biofilm surface. While live 
bacteria were found throughout the biofilm, membrane compromised (dead) bacteria were 
C
on
tr
ol
 (P
B
S)
10
00
 µ
g/
m
L 
P-
1
10
0 
µg
/m
L 
P-
1
10
 µ
g/
m
L 
P-
1
1 
µg
/m
L 
P-
10
1×108
2×108
3×108
4×108
C
FU
/c
m
2
 129 
found primarily at the glass surface, which might reflect depletion of nutrient and oxygen at the 
bottom of biofilm. When the biofilm was challenged with cationic polymer P-1, no significant 
structural changes such as voids or significant reduction in biofilm thickness was observed 
(Figure 5.4). 
   
Figure 5.4. Representative three-dimensional renderings of naturally forming biofilms (control) and biofilms challenged with 
100 µg/mL P-1 for 2 hours.  
Metabolic Activity 
Bacteria in biofilms reduce their metabolic activity because of low nutrient and oxygen 
availability. Consequentially, they are tolerant to antibiotics because antibiotics target 
metabolically active bacteria. Here we examined the effect of P-1 on the metabolic activity of 
bacteria in biofilms. The metabolic activity of bacteria within P. aeruginosa biofilms were 
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assessed by MTT assay after challenged with P-1 at various concentrations. At low P-1 
concentrations, metabolic activity was similar to unchallenged control biofilms (Figure 5.5a). At 
the concentrations of 100 and 1000 µg/mL, metabolic activity of bacteria in the biofilm was 
enhanced by 40-50 % as compared to the control (Figure 5.5a). The direct enumeration data 
from this study indicated the same number of viable bacteria in biofilms with and without 
polymer treatment (Figure 5.3). Therefore, the result suggest that bacteria had increased 
metabolic activity, approximately 50% higher than the control (Figure 5.5b). To further examine 
this effect, increases to metabolic activity per bacteria was calculated by divining the OD 
reading with the number of viable bacteria (Figure 5.5c). There was a statically significant 
difference in the metabolic activity between biofilms treated by 1000 µg/mL of P-1 and control. 
This result suggests that P-1 might “awaken” the dormant bacteria in biofilms into metabolically 
active state.  
 
Figure 5.5. Metabolic activity of polymer challenged P. aeruginosa biofilms by MTT assays. A) Metabolic activity as indicated by 
the absorbance of solubilized formazan crystals formed by metabolic conversion of MTT. B) Metabolic activity normalized to 
control biofilms. C) Metabolic activity normalized to the average number of viable bacteria. The experiment was performed in 
duplicate, and the absorbance was determined as the average of data for each experiment. The data points and error bars 
represent the average and s.d from data in three independent experiments (n = 3), with significance (**p< 0.01) indicated 
against control (PBS).  
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Bacterial Membrane Potential 
Because the P-1 cationic polymer chains of are likely to bind to anionic bacterial cell 
membranes, we hypothesize that the cationic polymer acts on bacterial cell membranes to 
enhance the metabolic activity.  To test the hypothesis, we examined the effect of polymer on 
the membrane potential of bacteria. We used planktonic bacteria in the stationary phase as a 
model for dormant bacteria in biofilms. DiSC3-(5) is a fluoresce dye that are sensitive to 
membrane potential; this dye molecule binds to and accumulates on the bacterial membrane 
when the membrane is hyperpolarized, and as the membrane potential is increased, more dye 
molecules bind to membranes.  While the dye free in water is fluorescent, the high 
concentrations of dye molecules on membranes results in fluoresce quenching. Therefore, 
fluorescence from the dye reflect the membrane potential; where greater the membrane 
potential, lower fluorescence intensity from the dye. Alternatively, if membranes become 
compromised, membrane potential is reduced to zero, and the dye doesn’t bind to the 
membranes, resulting in no change in fluorescence.  The fluorescence of DiSC3-(5) in bacterial 
suspension was decreased immediately after addition of P-1 (Figure 5.6a), indicating an 
increase in membrane potential. The fluorescent intensity continued to decrease over time 
(Figure 5.6a), which may reflect the time necessarily for the polymer to bind to the membrane 
surface or for the bacteria to respond to the polymer binding. The DiSC3-(5) fluorescence was 
significantly decreased at 1 µg/mL (Figure 5.6b), indicating even low concentrations of P-1 are 
capable of increasing the membrane potential. Additionally, concentrations beyond 1 µg/mL do 
not decrease the fluorescence intensity (Figure 5.6b). In addition, P-1 also increased the 
membrane potential of bacteria in the exponential phase, indicating that the effect of polymer 
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is not specific to the bacteria in the stationary phase (Figure 5.6b). These results suggest that 
the binding of polymer chains to bacterial cell membranes may directly cause enhancement of 
membrane potential. It has been reported that the uptake of tobramycin is dependent on the 
membrane potential; as the membrane potential is increased, the uptake is increased.227, 230, 234 
In combined with the result of enhanced metabolic activity (Figure 5.5), it may be possible that 
P-1 increase the susceptibility of bacteria in biofilms against tobramycin. We will first examine 
the penetration of tobramycin into biofilm and determine the efficacy of tobramycin in 
combination with P-1 to test this hypothesis.  
 
Figure 5.6. Membrane potential of planktonic P. aeruginosa measured by DiSC3-(5). (a) Fluorescence intensity after the 
introduction of P-1 to stationary phase bacteria. (b) Fluorescence intensity of stationary phase bacteria after 30 minutes of 
binding to P-1 at varying concentrations. The experiment was performed in quadruplicate, and the fluorescence was 
determined as the average of data for each experiment. The data points and error bars represent the average and s.d from data 
in three independent experiments (n = 3), with significance (**p< 0.01) indicated against control (PBS). 
Tobramycin Penetration through Mature Biofilms 
A commonly cited challenge of anti-biofilm treatment is the penetration of antibiotics 
through the matrix in order to access interior bacteria.28, 32, 235 This may be true in the case of 
cationic antibiotics such as tobramycin, which may be sequestered in the anionic matrix away 
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from bacteria. First, we investigated the penetration of tobramycin though the biofilm matrix 
using Cy5-labeled tobramycin. The fluorescence image showed that the fluoresce from Cy5 
were observed though the entire biofilm structure, tobramycin molecules were able to fully 
penetrate to the biofilm to the bacteria attached at the substrate (Figure 5.7). This result is 
inconstant with the previous reports in literature, showing incomplete dye penetration. We 
speculate that this inconstancy is due to the use of static biofilms as opposed to flow-cell 
biofilms which are more physically robust and have different matrix structures, or a factor of 
long exposure times that overcome retarded penetration. P-1 challenged biofilms treated with 
tobramycin also indicated the penetration of antibiotic was not hindered (Figure 5.7), 
suggesting that P-1 will not affect the penetration of tobramycin in biofilm bacteria.  
 
Figure 5.7. Representative three-dimensional renderings of Cy5-labeled tobramycin penetration through P. aeruginosa biofilms. 
Tobramycin is able to fully penetrate through the anionic matrix to access the inner-most cells bound to the substrate. 
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Cationic Polymer-Tobramycin Combined Treatment Efficacy 
P. aeruginosa biofilms are highly resistant against antimicrobial agents, which is one of 
the primary challenges to the treatment of biofilm associated infections. Due to the increase in 
metabolic activity and membrane potential of bacteria when challenged with P-1, we 
hypothesized that a combination treatment of P-1 followed by tobramycin may increase the 
efficacy of tobramycin treatment. Despite tobramycin having an MIC of 0.3 µg/mL, treatment of 
control biofilms with 100 µg/mL tobramycin (>100x MIC) resulted in an 82% reduction of 
bacteria (Figure 5.8) compared to pre-treatment viability studies (Figure 5.3), less than a 1 log 
reduction in viable bacteria. This indicates that the static biofilms are a good representation of 
the antibiotic tolerant systems seen in clinical applications. When pre-treated with P-1, 
bacterial load was reduced by 71-82% (Figure 5.8). This reduction is comparable to the control, 
and therefore suggests no change in the efficacy of tobramycin on biofilms pre-treated with P-
1. The lack of efficacy change suggests that despite change in membrane potential and 
metabolic activity as suggested by MTT (Figure 5.5), dormant bacteria in biofilms maintain 
additional tolerance mechanisms that cannot be overcome with cationic polymers alone. 
Alternatively, the efficacy of tobramycin was already saturated under this condition, and the 
effect of P-1 did not enhance the efficacy anymore.  
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Figure 5.8. Combination therapy of P-1 challenged P. aeruginosa biofilms followed by treatment by tobramycin (100 µg/mL). 
The experiment was performed in duplicate, and the absorbance was determined as the average of data for each experiment. 
The data points and error bars represent the average and s.d from data in three independent experiments (n = 3), with no 
significance indicated against control (PBS). 
Proposed Mechanism: Awakened Bacteria  
The results suggest that P-1 increase the membrane potential and metabolic activity in 
P. aeruginosa. When cationic polymers have bind to the bacterial membranes, there is an 
increase in metabolic activity as indicated by MTT assay. This enhanced metabolic activity 
occurs at P-1 concentrations >1000 µg/mL, whereas increased membrane potential occurs at >1 
µg/mL P-1, suggesting that the enhancement of metabolic activity is not reliant on membrane 
potential. While it is possible that enhanced metabolic activity measured by MTT assay could be 
the result of increased uptake of MTT, and that uptake is the rate limiting step of the MTT to 
formazan conversion. If this was the case, we hypothesize that all concentrations of P-1 would 
show enhanced metabolic activity, as they have similar membrane potentials. The exact 
mechanism of enhanced cellular activity by cationic polymer binding is an area for further 
examination but may be related to an increase in nutrient uptake due to increased PMF, as 
conversely PMF decreases in nutrient limited conditions.  
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The challenge of antibiotic treatment of dormant bacteria is due to multiple factors. For 
the purposes of this study, we will limit the discussion to the challenges of tobramycin, a 
clinically relevant antibiotic for the treatment of P. aeruginosa biofilms, particularly in cystic 
fibrosis patients. Antibiotics must have access to the target area of the cell, through cellular 
uptake. For tobramycin, this involves crossing the membrane barrier and binding to the 
ribosome. Once the antibiotic has entered the cell, cellular activity determines the internal 
effectiveness of the antibiotic. Once tobramycin has bound to the ribosome, its role is to inhibit 
the initiation of protein synthesis, thus it is only effective when cells are attempting to initiate 
protein synthesis. A final barrier to antibiotic efficacy, especially in the case of P. aeruginosa, 
are bacterial efflux systems that actively expel the antibiotic from the cell.236-238 Therefore, in 
totality, the effectiveness of antibiotics is dependent on 1) the uptake of the antibiotic, 2) 
cellular activity of the bacteria, and 3) retention of the antibiotic at the target site. 
In order to explain the results of this study, we propose the following reasons why the 
copolymers did not enhance the susceptibility of P. aeruginosa in biofilm to tobramycin.  
(1) No increase in tobramycin uptake. The uptake of tobramycin by P. aeruginosa has been 
reportedly liked to membrane potential.227, 230, 234 In dormant biofilm bacteria, the membrane 
potential of P. aeruginosa is reduced due to environmental conditions of pH an oxygen 
accessibility 239-240, which consequentially reduces the uptake of tobramycin into cells. Our 
result indicated that the binding of cationic polymers to the bacterial membrane increases 
membrane potential (Figure 5.6) Because the membrane potential has been previously linked 
to tobramycin uptake, we postulated cationic polymers could consequentially increase 
tobramycin uptake into the cells, resulting in increased susceptibility to tobramycin. However, 
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the lack of the enhanced activity may result from no enhancement in tobramycin update. It is 
necessary to determine absolute tobramycin uptake by control and P-1 bound bacteria to 
determine if tobramycin uptake is affected by P-1 increased membrane potential. 
(2)  Efflux pumps. We propose the lack of enhancement is related to the role of effective efflux 
pumps in P. aeruginosa bacteria, which can quickly remove harmful antibiotics from cells.26, 40, 
241-242 Efflux pumps are energy dependent, thus if metabolic activity is increased as this study 
suggests, efflux pumps may also work more effectively to remove antibiotics.236, 242-243 Thus, as 
there is no increase in antibiotic susceptibility, this suggests that the rate of efflux is greater 
than either the rates of tobramycin uptake or cellular activity necessary for antibiotic activity. 
 
 
Figure 5.9. Proposed mechanism of cationic polymer “awakening” of dormant bacteria, where tobramycin uptake and cellular 
activity are enhanced, but bacterial susceptibility is not enhanced, proposed to due to enhanced efflux systems. 
Conclusions 
In summary, cationic poly[(3-methacryloylamino)propyl] trimethylammonium chloride 
(P-1) is capable of modulating the behavior of dormant bacteria behavior through electrostatic 
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binding. Specifically, P-1 has been shown to increase the membrane potential of stationary 
phase bacteria, where reduction in membrane potential has previously been linked to 
decreased antibiotic uptake. Additionally, P-1 interaction with dormant biofilm bacteria 
increases their metabolic activity ~50% at concentrations >1000 µg/mL. However, despite 
indications that antibiotics would have increased susceptibility due to increased uptake and 
increased cellular activity, there was no synergistic effect of P-1 and tobramycin in combination 
treatments. We propose that this is due to simultaneous stimulation of efflux systems in P. 
aeruginosa bacteria, which remove tobramycin at a greater rate than can be overcome by 
increased uptake or increased cellular activity. This approach to “awaken” dormant bacteria 
provides new insight into mechanism of biofilm tolerance. Future studies that combine this 
“awakening” approach with approaches that enhance metabolic activity may be effective at 
overcoming efflux dominance. The findings here provide a potential new route to enhance the 
treatment of biofilm infections through bacteria behavior modulation that is applicable for 
difficult to access biofilms, including those on tissue surfaces such as those in cystic fibrosis 
patients.
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Chapter 6 Conclusions and Future Directions 
In this dissertation, two different approaches have been explored to combat bacterial 
infections. New therapeutic agents were synthesized using random amphiphilic methacrylate 
copolymer design, with multi-armed architectures designed to mimic the multi-polymer 
mechanism of membrane disruption for antimicrobial activity. Additionally, cationic polymers 
were utilized to modulate the formation and behavior of P. aeruginosa biofilms.  
Hyperbranched and 4-arm Star-Shaped Polymers as Antimicrobial Agents 
One goal of work in this dissertation was to design cationic amphiphilic copolymers with 
potent antimicrobial activity and selective activity towards bacterial cells over mammalian cells, 
for applications as alternative antibiotics. In order to accomplish that, this work specifically 
focused on the use of architecture as a new tunable factor for polymer design. The hypothesis 
of this work was the macromolecules presenting multiple antimicrobial polymer chains would 
show improved antimicrobial activity and membrane selectivity. This hypothesis was based on 
the need for collective action of multiple polymers for membrane disruption (antimicrobial 
activity), and the localization of cationic charge for improved electrostatic interactions. In 
chapter 2, randomly branched copolymers synthesis was attempted through incorporation of a 
crosslinking monomer by free radical polymerization in the presence of chain transfer agent. 
However, the polymers were synthesized by this approach were not hyperbranched, but lightly 
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crosslinked high MW polymers. The finding of this study indicates that the resulting polymer 
structures were not branched, and high molecular weight polymers were responsible for their 
apparent increase in antimicrobial and hemolytic activities compared to linear polymers with 
comparable molecular weights. In chapter 3, 4-armed star-shaped polymers were synthesized 
by ATRP using a core molecule functionalized with 4 initiators. Compared to linear polymers 
with the molecular weight comparable to the whole star-shaped molecule or arm polymer 
chain, the antimicrobial activity of 4-armed star-shaped polymers was not affected by the 
polymer shape. However, the hemolytic activity of 4-armed star-shaped polymers was 
increased compared to linear polymer counterparts. Therefore, we conclude that the 
enhancement of hemolytic activity is due to the polymer architecture. 
In conclusion, we successfully synthesized polymers presenting macromolecules with 4-
arms of amphiphilic polymer chains. While we hypothesized this architecture would improve 
antimicrobial activity and selectivity, the results appeared not to support this hypothesis, 
instead not affecting antimicrobial activity and reducing selectivity. A potential problem with 
this approach may be that the number of arms is too low to successfully mimic the collection of 
multiple polymer chains at bacterial membranes. Experimentally, the formation of pores in lipid 
bilayers has been observed as a result of AMPs and is related to AMP concentration. Based on 
the size of the observed pores, calculation of the number of AMPs necessary for pore formation 
have been calculated to be between 4-11166-167, depending on the pore formation model and 
AMP. Because it is not possible for a single AMP to form a pore, it has been experimentally 
determined that multiple AMPs are necessary for membrane disruption. Therefore, future 
studies should pursue examining multi-armed polymers with greater than 4 arms (i.e. 6, 8, 10) 
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with the hypothesis that at a critical number of arms, antimicrobial activity will improve beyond 
the linear polymer design. However, we suspect that multi-armed architecture will still induce 
increased hemolysis compared to linear polymers, as seen in this study because they will 
maintain the multi-armed architecture observed to be harmful to RBCs. Another possibility is 
exploration of a different shape of polymers, such as cyclic polymer structures. While no studies 
have explored cyclic antimicrobial polymers, research performed on cyclic antimicrobial peptide 
analogs of α-helix indicate cyclization reduces hemolytic activity.244-247  This may indicate that 
the constrained cyclic structure restricted the peptide to adapt an amphiphilic conformation in 
cell membranes. This in turn disfavors the insertion of peptide chain into human cell 
membranes in which the lipids are generally packed while bacterial cell membranes can 
accommodate the distorted peptide conformation. This effect results in reduced hemolytic 
activity. Our laboratory has demonstrated that random copolymers also adopt an amphiphilic 
conformation in which the cationic and hydrophobic side chains are segregated into the 
opposite side of polymer backbone.80  Therefore, cyclic polymer structures may also provide 
distorted amphiphilic conformations of polymer chains capable of selectively disrupt bacterial 
cell membranes over human cell membranes.  
Cationic Polymers for Biofilm Mitigation 
 The second goal of this dissertation was to utilize cationic polymers to modulate biofilm 
behavior, through formation and increased sensitivity against antibiotics. Specifically, we 
hypothesized that disrupting the natural behavior of planktonic bacteria may cause sub-optimal 
changes in the biofilm development process, leading to decreased biofilm accumulation. 
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Furthermore, we hypothesized that treatment of cationic polymers to existing biofilms may 
sensitize them to traditional antibiotics.  
 In chapter 4, we found that the incubation of planktonic bacteria with a cationic 
polymer reduced biofilm formation through both biomass and viable bacteria. We proposed a 
new mechanism of biofilm prevention, specifically that cationic polymers sequester bacteria in 
solution and prevent attachment to the surface.  Therefore, this study supported our 
hypothesis that targeting planktonic bacteria behavior could result in sub-optimal biofilm 
development. The next step to further this approach for clinical application would be an 
evaluation of toxicity against mammalian cells. Previous studies have reported cationic polymer 
toxicity to mammalian cells.248 Future studies should be conducted to reduce the cationic 
functionalities by for example, reducing polymer size and designing cationic copolymers with 
neutral side chains. 
 In chapter 5, the hypothesis was that cationic polymers could be used to increase 
antimicrobial susceptibility of dormant bacterial cells through non-disruptive membrane 
binding. The finding of this study was that the treatment of developed biofilms with a cationic 
polymer increased the metabolic activity of embedded bacteria but did not sensitize the 
bacteria to tobramycin. While this finding did not agree with our hypothesis of increased 
sensitization by the interactions between the cationic polymers and bacteria, the finding that a 
change in bacteria metabolic activity offers a promising avenue for future research. A problem 
with this approach is the potential pitfalls for antibiotic failures; antibiotic efficacy is dependent 
on uptake, cellular activity and retention of the antibiotic in the cell, and cationic polymer 
binding may only promote uptake based on changes in proton motive force. If any of these 
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steps is hampered, the antibiotic would fail. Based on the finding that cationic polymers can 
increased bacterial proton motive force, our new hypothesis is that cationic polymers can 
increase antibiotic uptake, based on the observation of increased membrane potential.  
Additional approaches must be used in combination with cationic polymers to improve 
antibiotic sensitivity, such as efflux pump inhibiting molecules or metabolites that increased 
cellular activity to a rate beyond efflux activity. In this way, systematic studies may be 
conducted that control barriers to antibiotic efficacy in order to identify the effect of cationic 
polymers on dormant bacteria behavior. Characterizing antibiotic concentration in bacteria, and 
the use of antibiotics with external or internal cellular targets, would be essential studies to 
confirm the role of cationic polymers in antibiotic uptake. 
Future Prospective of Cationic Polymers for Infection Prevention 
 Synthetic cationic polymers offer a potential platform for bacterial infection prevention. 
If the challenges of adequate antimicrobial efficacy with selectivity towards bacterial cells can 
be overcome, random amphiphilic methacrylate polymers have promising applications as 
topical therapeutic agents at infection sites, such as in creams or integrated into wound 
dressings. These would be a significant new contribution to the field of medicine, providing not 
only a new kind of therapeutic, but agents that have low chance of resistance development and 
can overcome current resistances against a broad spectrum of bacteria. Once the mechanism of 
cationic polymer related biofilm prevention and sensitization are addressed, there are many 
potential applications both alone and with traditional antibiotics. Alone they could be 
incorporated as anti-biofilm agents in products such as mouth wash to prevent oral biofilms 
associated with dental carries, where the agent could be delivered in high concentrations at 
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regular dosages and limited exposure to mammalian cells for long term biofilm prevention. In 
combination with traditional antibiotics, they could be used in the treatment of P. aeruginosa 
biofilms in cystic fibrosis lungs, simultaneously sensitizing existing biofilms to co-administered 
therapeutics and preventing new biofilm growth from developing. The future of these synthetic 
cationic polymers relies on 1) identifying new polymer designs for targeted application and 2) 
delineating the mechanisms of polymer activity for effective biofilm infection mitigation and 
treatment.
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Appendices
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Appendix A. Characterization of Chapter 2 Crosslinked Copolymers 
1H NMR spectra of Series a polymer 
  
Figure A.1. 1H NMR spectra of Pa1 
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Figure A.2. 1H NMR spectra of Pa2 
 
Figure A.3. 1H NMR spectra of Pa5 
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Figure A.4. 1H NMR spectra of Pa6 
 
Figure A.5. 1H NMR spectra of Pa9 
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Figure A.6. 1H NMR spectra of Pa10 
 
Figure A.7. 1H NMR spectra of Pa11 
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Figure A.8. 1H NMR spectra of Pa12 
 
Figure A.9. 1H NMR spectra of Pa13 
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Figure A.10. 1H NMR spectra of Pa14 
 
Figure A.11. 1H NMR spectra of Pa15 
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Figure A.12. 1H NMR spectra of Pa16 
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A.A.2. 1H NMR spectra of Series b copolymers 
 
 
Figure A.13. 1H NMR spectra of Pb17 
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Figure A.14. 1H NMR spectra of Pb21 
 
Figure A.15. 1H NMR spectra of Pb22 
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Figure A.16. 1H NMR spectra of Pb25 
 
Figure A.17. 1H NMR spectra of Pb26 
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Figure A.18. 1H NMR spectra of Pb27 
 
Figure A.19. 1H NMR spectra of Pb28 
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Figure A.20. 1H NMR spectra of Pb29 
 
Figure A.21. 1H NMR spectra of Pb30 
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Figure A.22. 1H NMR spectra of Pb31 
 
Figure A.23. 1H NMR spectra of Pb32 
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A.A.3. 1H NMR spectra of Series c copolymers 
 
 
Figure A.24. 1H NMR spectra of Pc33 
 
Figure A.25. 1H NMR spectra of Pc37 
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Figure A.26. 1H NMR spectra of Pc38 
 
Figure A.27. 1H NMR spectra of Pc39 
ppm0.51.01.52.02.53.03.54.04.55.0
5 9
. 5
7
4 .
9 4
3 .
0 0
3 0
. 4
3
7 .
3 7
5 5
. 8
9
8 .
8 9
1 3
3 .
8 6
1D
."&."
&(%."
..1
B
I
J
HL
%0
CDEhG
E
KFFh
ppm0.51.01.52.02.53.03.54.04.55.0
3 9
. 7
7
3 .
0 0
2 1
. 3
5
5 .
6 5
3 3
. 0
1
1 0
8 .
6 8
1D
."&."
&(%."
..1
B
I
J
HL
%0
CDEhG
E
KFFh
 161 
 
Figure A.28. 1H NMR spectra of Pc41 
 
Figure A.29. 1H NMR spectra of Pc42 
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Figure A.30. 1H NMR spectra of Pc43 
 
Figure A.31. 1H NMR spectra of Pc44 
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Figure A.32. 1H NMR spectra of Pc45 
 
Figure A.33. 1H NMR spectra of Pc46 
 
ppm0.51.01.52.02.53.03.54.04.55.0
4 0
. 8
6
3 .
0 0
2 1
. 3
0
6 .
9 3
3 5
. 0
0
9 6
. 9
4
1D
."&."
&(%."
..1
B
I
J
H
%0
CDEhG
E
KFFh
ppm0.51.01.52.02.53.03.54.04.55.0
3 6
. 8
8
3 .
0 0
1 9
. 4
5
6 .
5 3
3 1
. 5
2
8 6
. 7
4
1D
."&."
&(%."
..1
B
I
J
HL
%0
CDEhG
E
KFFh
 164 
 
Figure A.34. 1H NMR spectra of Pc47 
  
Figure A.35. 1H NMR spectra of Pc48 
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A.A.4 1H NMR spectra of Series d copolymers 
 
Figure A.36. 1H NMR spectra of Pd49 
 
Figure A.37. 1H NMR spectra of Pd50 
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Figure A.38. 1H NMR spectra of Pd51 
 
Figure A.39. 1H NMR spectra of Pd52 
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A.A.5. Sample calculations of monomer conversion and monomer composition 
 
Calculation of Conversion Rate 
Calculated from crude polymer 1H NMR 
%𝐶𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 = 1 − 1-∫ 𝑑2 1 
Calculation of molar composition of final polymer products 
 
𝐹345 = 6 𝐻8𝐻8 + 𝐻:;<=𝑔 + 𝑘 + 𝑖 
𝐹3@A45 = 6B 𝐻:;𝐻8 + 𝐻:;C ∫𝑔 + 𝑘 + 𝑖< − ∫ℎ∫𝑔 + 𝑘 + 𝑖  𝐹45 = 1 − 𝐹345 −	𝐹3@A45 
 𝐻8= height of peak i integration  𝐻:;= height of peak g + k integration 𝐹45= mol fraction of MA  𝐹345= mol fraction of EMA 𝐹3@A45= mol fraction of EGDMA  
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Figure A.40. Sample H NMR of calculation of molar composition of polymer Pb30  
Calculation of Apparent Degree of Polymerization (DP) 
 
𝐷𝑃 = ∫ (𝑔 + 𝑘 + 𝑖)(2𝑓45 + 2𝑓345 + 4𝑓3@A45) 
 𝑓45= mol fraction of MA 𝑓345  = mol fraction of EMA 𝑓3@A45  = mol fraction of EGDMA 
 
Where the multiplier is the number of protons (2 or 4) on the associated carbon in MA, 
EMA or EDMA 
 
ppm0.51.01.52.02.53.03.54.04.55.0
3 6
. 3
2
3 .
0 0
2 6
. 4
4
7 .
6 0
3 0
. 3
7
7 3
. 9
7
1C
."&."
&(%."
..1
B
I
J
HL
%0
CDEhG
E
KFFh
@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@

@@@@@@@@
)HL
)J
 169 
A.A.6. Characterization Series a, Series c, and Series d polymers  
 
Table A.1. Comparison of monomer feed composition to polymer composition calculated by H-NMR for Series a.  
  Monomer Feed Composition (%) Polymer Composition, H-NMR (%) 
  AEMA EMA EGDMA MA EMA EGDMA 
Se
rie
s a
 
Pa1 100.0 0.0 0.0 100 0 0 
Pa2 99.0  0.0 1.0 99 0 1 
Pa3 95.2 0.0 4.8  Gel Gel Gel 
Pa4 90.9 0.0 9.1  Gel Gel Gel 
Pa5 100.0 0.0 0.0 100 0 0 
Pa6 99.0 0.0 1.0 99 0 1 
Pa7 95.2 0.0 4.8  Gel Gel Gel 
Pa8 90.9 0.0 9.1  Gel Gel Gel 
Pa9 100.0 0.0 0.0 100 0 0 
Pa10 99.0 0.0 1.0 98 0 2 
Pa11 95.2 0.0 4.8 94 0 6 
Pa12 90.9 0.0 9.1 96 0 4 
Pa13 100.0 0.0 0.0 100 0 0 
Pa14 99.0 0.0 1.0 98 0 2 
Pa15 95.2 0.0 4.8 90 0 10 
Pa16 90.9 0.0 9.1 87 0 13 
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Table A.2. Comparison of monomer feed composition to polymer composition calculated by H-NMR for Series c.  
  Monomer Feed Composition (%) Polymer Composition, H-NMR (%) 
  MA EMA EGDMA MA EMA EGDMA 
Se
rie
s c
 
Pc33 50.0 50.0 0.0 53 47 0 
Pc34 49.5 49.5 1.0  Gel Gel Gel 
Pc35 47.6 47.6 4.8  Gel Gel Gel 
Pc36 45.5 45.5 9.1  Gel Gel Gel 
Pc37 50.0 50.0 0.0 59 41 0 
Pc38 49.5 49.5 1.0 51 50 1 
Pc39 47.6 47.6 4.8 54 45 1 
Pc40 45.5 45.5 9.1  Gel Gel Gel 
Pc41 50.0 50.0 0.0 60 40 0 
Pc42 49.5 49.5 1.0 52 44 4 
Pc43 47.6 47.6 4.8 48 43 9 
Pc44 45.5 45.5 9.1 52 42 6 
Pc45 50.0 50.0 0.0 53 47 0 
Pc46 49.5 49.5 1.0 53 41 6 
Pc47 47.6 47.6 4.8 50 40 10 
Pc48 45.5 45.5 9.1 47 42 11 
 
Table A.3. Comparison of monomer feed composition to polymer composition calculated by H-NMR for Series d.  
  Monomer Feed Composition (%) Polymer Composition, H-NMR (%) 
  MA EMA EGDMA MA EMA EGDMA 
Se
rie
s d
 Pd49 
63.6 
 
 
27.3 
 
 
9.1 
 
 
 69 26 5 
Pd50  58 32  10 
Pd51  63 34  3 
Pd52 57 29  14 
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Table A.4. Polymerization conversion and yield of Series a homopolymer.  
      Boc-Protected Deprotected 
    State % Conversion % Yield % Yield 
Se
rie
s a
 
Pa1 
0% MMP 
 
 
0% EGDMA Liquid 96 89 86 
Pa2 1% EGDMA Liquid 95 93 71 
Pa3 5% EGDMA Gel  Gel Gel Gel 
Pa4 10% EGDMA Gel  Gel Gel Gel 
Pa5 
1% MMP 
 
 
0% EGDMA Liquid 96 100 100 
Pa6 1% EGDMA Liquid 95 99 80 
Pa7 5% EGDMA Gel  Gel Gel Gel 
Pa8 10% EGDMA Gel  Gel Gel Gel 
Pa9 
5% MMP 
 
 
0% EGDMA Liquid 94 100 100 
Pa10 1% EGDMA Liquid 92 100 80 
Pa11 5% EGDMA Liquid 89 100 96 
Pa12 10% EGDMA Liquid 94 93 86 
Pa13 
10 %MMP 
 
 
0% EGDMA Liquid 92 97 100 
Pa14 1% EGDMA Liquid 85 86 98 
Pa15 5% EGDMA Liquid 88 95 88 
Pa16 10% EGDMA Liquid 98 99 84 
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Table A.5. Polymerization conversion and yield of Series c copolymer.  
      Boc-Protected Deprotected 
    State % Conversion % Yield % Yield 
Se
rie
s c
 
Pc33 
0% MMP 
 
 
0% EGDMA Liquid 98 100 100 
Pc34 1% EGDMA Gel  Gel Gel Gel 
Pc35 5% EGDMA Gel  Gel Gel Gel 
Pc36 10% EGDMA Gel  Gel Gel Gel 
Pc37 
1% MMP 
 
 
0% EGDMA Liquid 99 100 100 
Pc38 1% EGDMA Liquid 97 100 84 
Pc39 5% EGDMA Liquid 96 100 92 
Pc40 10% EGDMA Gel  Gel Gel Gel 
Pc41 
5% MMP 
 
 
0% EGDMA Liquid 98 100 100 
Pc42 1% EGDMA Liquid 96 91 99 
Pc43 5% EGDMA Liquid 96 87 100 
Pc44 10% EGDMA Liquid 97 86 100 
Pc45 
10 %MMP 
 
 
0% EGDMA Liquid 98 86 100 
Pc46 1% EGDMA Liquid 99 76 100 
Pc47 5% EGDMA Liquid 99 95 90 
Pc48 10% EGDMA Liquid 99 82 90 
 
Table A.6. Polymerization conversion and yield of Series d copolymer.  
      Boc-Protected Deprotected 
    State % Conversion % Yield % Yield 
Se
rie
s d
 Pd49 0% MMP   
10% EGDMA 
 
 
Liquid 90 82 97 
Pd50 1% MMP Liquid 87 72 100 
Pd51 5% MMP Liquid 90 76 100 
Pd52 10% MMP Liquid 87 76 97 
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Table A.7. Characterization by GPC of Series a homopolymers 
 
 
MW (g/mol) 
 (1H NMR) 
Mn (g/mol) 
(GPC) 
Mw (g/mol) 
(GPC) 
Đ 
(GPC) 
Se
rie
s a
 
Pa1 No CTA  32595 129391 3.97 
Pa2  No CTA 65237 371016 5.69 
Pa5 14369.1779 13399 29018 2.17 
Pa6 10759.748 14299 41408 2.90 
Pa9 6067.52586 4500 7410 1.65 
Pa10 5812.64805 4249 7586 1.79 
Pa11 4686.74156 7357 22638 3.08 
Pa12 3379.1705 9376 61641 6.57 
Pa13 4758.5037 3419 5042 1.47 
Pa14 3195.16916 2837 4087 1.44 
Pa15 3020.6078 3588 6304 1.76 
Pa16 2887.16932 4594 12715 2.77 
 
 
Table A.8. Characterization by GPC of Series c copolymers 
 
 
MW (g/mol) 
 (1H NMR) 
Mn (g/mol) 
(GPC) 
Mw (g/mol) 
(GPC) 
Đ 
(GPC) 
Se
rie
s c
 
Pc33 No CTA 15772 51085 3.23896779 
Pc37 10104.5087 6125 20924 3.41616327 
Pc38 5272.09273 6680 17002 2.54520958 
Pc39 3544.22366 6270 78854 12.5763955 
Pc41 5744.78268 3373 5137 1.52297658 
Pc42 4144.59625 2877 4550 1.58150852 
Pc43 3402.1019 6108 21784 3.5664702 
Pc44 2072.01829 10252 256014 24.972103 
Pc45 3600.2555 2537 3443 1.3571147 
Pc46 3342.59151 2961 5082 1.71631206 
Pc47 2417.91996 5332 15679 2.94054764 
Pc48 2139.54836 15772 51085 3.23896779 
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Table A.9. Characterization by GPC of Series d copolymers 
 
 
MW (g/mol) 
 (1H NMR) Mn (g/mol) Mw (g/mol) Đ 
Se
rie
s d
 Pd49 No CTA 7299 63064 8.64 
Pd50 6869.00305 12926 44294 3.43 
Pd51 4780.53194 7214 18491 2.56 
Pd52 2441.55405 4826 8697 1.80 
 
Table A.10. Degree of polymerization and average crosslink density as determined by 1H-NMR for Series a homopolymer. 
Average crosslink/CTA ratio denoted by * are theoretical calculations of gelled polymers based on linear comparable 
compositions.  
 
 
Apparent 
DP 
Average 
#Crosslink/CTA Ratio 
Se
rie
s a
 
Pa1 No CTA No CTA 
Pa2 No CTA No CTA 
Pa3 Gel No CTA 
Pa4 Gel No CTA 
Pa5 62 No EGDMA 
Pa6 46 0.5 
Pa7 Gel 3.1* 
Pa8 Gel 6.2* 
Pa9 26 No EGDMA 
Pa10 25 0.5 
Pa11 19 1.1 
Pa12 14 0.6 
Pa13 21 No EGDMA 
Pa14 14 0.3 
Pa15 12 1.3 
Pa16 11 1.7 
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Table A.11. Degree of polymerization and average crosslink density as determined by 1H-NMR for Series c copolymers. Average 
crosslink/CTA ratio denoted by * are theoretical calculations of gelled polymers based on linear comparable compositions.  
 
 
Apparent 
DP 
Average 
#Crosslink/CTA Ratio 
Se
rie
s c
 
Pc33 No CTA No CTA 
Pc34 Gel  No CTA 
Pc35 Gel  No CTA 
Pc36 Gel  No CTA 
Pc37 55 No EGDMA 
Pc38 29 0.3 
Pc39 20 0.2 
Pc40 Gel 11.0* 
Pc41 31 No EGDMA 
Pc42 22 0.9 
Pc43 18 1.7 
Pc44 11 0.7 
Pc45 20 No EGDMA 
Pc46 17 1.1 
Pc47 12 1.4 
Pc48 11 1.3 
 
Table A.12. Degree of polymerization and average crosslink density as determined by 1H-NMR for Series d copolymers. Average 
crosslink/CTA ratio denoted by * are theoretical calculations of gelled polymers based on linear comparable compositions.  
 
 
Apparent 
DP 
Average 
#Crosslinks/CTA Ratio 
Se
rie
s d
 Pd49 No CTA No CTA 
Pd50 33 3.6 
Pd51 24 0.8 
Pd52 14 1.6 
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A.A.7. Antimicrobial activity of Series a, Series c, and Series d polymers 
 
Table A.13. Antimicrobial activity (MIC) and hemotoxicity (HC50) of Series a polymer 
 
 
MIC (µg/mL) 
 
HC50 
(µg/mL) 
%Hemolysis 
at 1000 
µg/mL 
Selectivity Index 
(HC50/MIC E. 
coli) 
  E. coli S. aureus    
Se
rie
s a
 
Pa1 208 (±72) 83 (±36) N/A 8 (±2)%* No HC50 
Pa2 208 (±72) 62.5 N/A 3 (±2)%* No HC50 
Pa5 167 (±72) 42 (±18) N/A 12 (±2)% No HC50 
Pa6 417 (±144) 62.5 N/A 11 (±3)%* No HC50 
Pa9 208 (±72) 83 (±36) N/A 1 (±1)% No HC50 
Pa10 >1000 83 (±36) N/A 0% No HC50 
Pa11 >1000 83 (±36) N/A 4 (±1)%* No HC50 
Pa12 >1000 104 (±36) N/A 2 (±1)%* No HC50 
Pa13 208 (±72) 104 (±36) N/A 0% No HC50 
Pa14 >1000 167 (±72) N/A 0% No HC50 
Pa15 >1000 167 (±72) N/A 0% No HC50 
Pa16 >1000 104 (±36) N/A 2 (±1)% No HC50 
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Table A.14. Antimicrobial activity (MIC) and hemotoxicity (HC50) of Series c copolymer 
 
 
MIC (µg/mL) 
 
HC50 
(µg/mL) 
Selectivity Index 
(HC50/MIC E. 
coli) 
  E. coli S. aureus   
Se
rie
s c
 
Pc33 31 167 (±72) 6  0.19 
Pc37 16 104 (±36) 8 (±1) 0.50 
Pc38 16 125 9 (±2) 0.56 
Pc39 42 (±18) 167 (±72) 9 (±2) 0.21 
Pc41 16 42 (±18) 13 (±2) 0.81 
Pc42 13 (±5) 52 (±18) 9 (±2) 0.69 
Pc43 8 83 (±36) 9 (±2) 1.13 
Pc44 26 (±9) 167 (±72) 9 (±2) 0.35 
Pc45 10 (±5) 26 (±9) 27 (±4) 2.70 
Pc46 13 (5)  52 (18) 17 (1) 1.31 
Pc47 8 63 16 (1) 2.00 
Pc48 16 125 12 (1) 0.75 
 
Table A.15. Antimicrobial activity (MIC) and hemotoxicity (HC50) of Series d copolymer 
 
 
MIC (µg/mL) 
 
HC50 
(µg/mL) 
Selectivity Index 
(HC50/MIC E. 
coli) 
  E. coli S. aureus   
Se
rie
s d
 Pd49 62.5 125 5 (±1) 0.08 
Pd50 62.5 125 7 (±1) 0.11 
Pd51 62.5 125 11(±3) 0.18 
Pd52 62.5 125 25 (±3) 0.40 
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Appendix B. Characterization of Chapter 3 Copolymers 
 
 
Figure B.41. 1H NMR spectra of boc-protected PL1 
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Figure B.42. 1H NMR spectra of boc-protected PL2 
 
Figure B.43. 1H NMR spectra of boc-protected PL3 
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Figure B.44. 1H NMR spectra of boc-protected PL4 
 
Figure B.45. 1H NMR spectra of boc-protected PL5 
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Figure B.46. 1H NMR spectra of boc-protected PL6 
 
Figure B.47. 1H NMR spectra of boc-protected PL7 
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Figure B.48. 1H NMR spectra of boc-protected PL8 
 
Figure B.49. 1H NMR spectra of boc-protected PL9 
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Figure B.50. 1H NMR spectra of boc-protected PS10  
 
Figure B.51. 1H NMR spectra of boc-protected PS11 
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Figure B.52. 1H NMR spectra of boc-protected PS12 
  
 
Figure B.53. 1H NMR spectra of boc-protected PS13  
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Figure B.54. 1H NMR spectra of boc-protected PS14  
 
Figure B.55. 1H NMR spectra of boc-protected PS15 
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Figure B.56. 1H NMR spectra of boc-protected PS16 
 
Figure B.57. 1H NMR spectra of boc-protected PS17 
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Figure B.58. 1H NMR spectra of boc-protected PS18 
A.B.2. 1H NMR spectra of deprotected AEMA-EMA copolymers 
 
Figure B.59. 1H NMR spectra of PL1 
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Figure B.60. 1H NMR spectra of PL2 
 
Figure B.61. 1H NMR spectra of PL3 
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Figure B.62. 1H NMR spectra of PL4 
 
Figure B.63. 1H NMR spectra of PL5 
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Figure B.64. 1H NMR spectra of PL6 
 
 
Figure B.65. 1H NMR spectra of PL7 
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Figure B.66. 1H NMR spectra of PL8 
 
Figure B.67. 1H NMR spectra of PL9 
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Figure B.68. 1H NMR spectra of PS10 
 
Figure B.69. 1H NMR spectra of PS11 
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Figure B.70. 1H NMR spectra of PS12 
 
Figure B.71. 1H NMR spectra of PS13 
ppm0.51.01.52.02.53.03.54.04.55.0
1 0
0 .
0 0
1 0
2 .
1 9
8 8
. 5
1
1 2
. 1
4
1 0
. 1
7
7 2
. 4
3
8 5
. 0
7
14
&"
'
$
#%
%.40
9
ppm0.51.01.52.02.53.03.54.04.55.0
5 .
2 6
5 .
2 9
7 0
. 4
1
3 1
. 3
0
6 6
. 8
7
9 7
. 2
4
1 5
. 1
4
5 9
. 3
2
2 4
. 0
0
6 7
. 1
4
6 7
. 9
9
14
&"
'
$
#%
*
 194 
 
Figure B.72. 1H NMR spectra of PS14 
 
Figure B.73. 1H NMR spectra of PS15 
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Figure B.74. 1H NMR spectra of PS16 
 
Figure B.75. 1H NMR spectra of PS17 
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Figure B.76. 1H NMR spectra of PS18
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Appendix C. Characterization of P-1 and P-2 polymers by 1H NMR and GPC 
 
Figure C.77. 1H NMR spectra for (a) P-1 and (b) P-2 in D2O. 
 
Figure C.78.  GPC elution curves for (a) P-1 using two Shodex Ohpak SB-804 HQ columns and a 0.3 M Na2SO4 aqueous solution 
containing 0.5 M acetic acid as an eluent and (b) P-2 using a Shodex Asahipak GF-7M HQ column and a phosphate buffer (pH 9) 
containing 10 vol% acetonitrile as an eluent
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Appendix D. Characterization of fluorescein labeled P-1 (F-P-1) 
 
1H NMR was measured with a Bruker DRX-500. Gel-permeation chromatography (GPC) was 
performed using a pump of Jasco PU-2080, refractive index (RI) detector of Jasco RI-2031 Plus 
and Shodex Ohpak SB-G guard column and 10 μm bead size SB-804 HQ column working at 40 °C 
under a flow rate of 0.6 mL/min. A 0.3 M Na2SO4 aqueous solution containing 0.5 M acetic acid 
was used as an eluent. The values of Mn and Mw/Mn were calibrated with standard poly(2-
vinylpyridine) samples. UV-vis absorption spectra were obtained with a Jasco V-630 
spectrometer using a quartz cell with an optical path length of 1.0 cm. Fluorescence 
measurements were performed using a Hitachi High Technologies F-2500 fluorescence 
spectrophotometer. Dynamic light scattering (DLS) measurements were performed using a 
Malvern Zetasizer nano ZS equipped with a He-Ne laser (4 mW at 632.8 nm) at 25 °C. 
 
Figure D.79. 1H NMR spectrum of F-P-1 in D2O. 
 199 
 
Figure D.80. GPC chart of F-P-1 using A 0.3 M Na2SO4 aqueous solution containing 0.5 M acetic acid as an eluent at 40 °C. 
 
Figure D.81. UV-vis absorption spectrum of F-P-1in PBS at Cp = 0.05 g/L. F-P-1 was dissolved in PBS at polymer concentration 
(Cp) = 0.05 g/L. The maximum absorption can be observed at 489 nm. Fluorescence measurement was performed for F-P-1 in 
PBS at Cp = 0.05 g/L. The excitation wavelength was 489 nm. The slit widths of excitation and emission were 20 and 2.5 nm, 
respectively. The maximum fluorescence wavelength was 513 nm. 
 
 
Figure D.82. Fluorescence emission spectrum for F-P-1in PBS at Cp = 0.05 g/L. F-P-1 was dissolved in PBS at Cp = 5.25 g/L. The 
solution was filtrated using membrane filter with 0.2 μm pore size. DLS measurement was performed at 25 °C (Figure 5). 
Bimodal hydrodynamic radius (Rh) distribution was observed.  
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Figure D.83. Hydrodynamic radius (Rh) distribution for P(MAPTAC/AAcF3)63 in PBS at Cp = 5.25 g/L at 25 °C.
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